curriculum vitae of mark w. dewhirst, dvm, phd … · 2015-01-30 · 1 curriculum vitae of mark w....
TRANSCRIPT
1
CURRICULUM VITAE of
MARK W. DEWHIRST, DVM, PhD
PERSONAL DATA Date of Birth May 20, 1949 Place Manhattan, Kansas Citizen of U.S.A. EDUCATION High School Catalina High School, Tucson Arizona 1967 Diploma College Northern Arizona University 1968 University of Arizona 1971 B.S., Chemistry - With Distinction Professional Colorado State University 1975 DVM Graduate School Colorado State University 1979 Ph.D., Radiation Biology PROFESSIONAL Primary Academic Appointment Duke University Radiation Oncology First Duke Faculty Appointment Duke University Assistant Professor (August 1984)
Present Academic Rank Gustavo S. Montana Professor of Radiation Oncology (2002) Department of Radiation Oncology Associate Dean, Faculty Mentoring (2011) School of Medicine Duke University Durham, North Carolina
PROFESSIONAL TRAINING
2
AND ACADEMIC CAREER July 1979 - December 1979 Research Associate Department of Radiology Division of Radiation Oncology University of Arizona, Tucson Arizona
January 1979 - July 1984 Adjunct Assistant Professor Department of Radiology Division of Radiation Oncology University of Arizona, Tucson Arizona October 1982 - July 1984 Adjunct Assistant Professor Department of Veterinary Sciences University of Arizona, Tucson Arizona August 1984 - July 1988 Assistant Professor Department of Radiology / Radiation Oncology Duke University Medical Center October 1984 - June 1994 Adjunct Assistant Professor Department of Anatomy, Physiology, and Radiology School of Veterinary Medicine North Carolina State University Raleigh North Carolina July 1988 - June 1993 Associate Professor (with tenure) Department of Radiation Oncology Duke University Medical Center July 1993-June 2002 Professor (with tenure) Department of Radiation Oncology Duke University Medical Center May 1989 - 1999 Assistant Professor Department of Pathology Duke University Medical Center
Durham North Carolina July 1994 - Present Adjunct Professor of Radiology
Department of Anatomy, Physiological Sciences and Radiology School of Veterinary Medicine North Carolina State University Raleigh North Carolina
September 1999 - Present Professor (Joint appointment) Department of Biomedical Engineering
Duke University Medical Center Durham North Carolina October 1999 - Present
3
Professor (Joint appointment) Department of Pathology Duke University Medical Center Durham North Carolina
SCHOLARLY SOCIETIES Sigma Xi Phi Lambda Upsilon PUBLICATIONS (478 Refereed Publications) Refereed Journals 1. DEWHIRST MW, Stamp GL, Hurvitz AI, Idiopathic monoclonal (IgA) gammopathy in a
dog. J Am Vet Med Assoc 170:1313-1316, 1977. 2. Phillips RK, DEWHIRST MW, Electrophoretic evaluation of sera from canine cancer
patients. Am J Vet Res 39:1482, 1978. 3. DEWHIRST MW, Ozimek EJ, Gross J, Cetas TC, Will hyperthermia conquer the elusive
hypoxic cell: Implications of heat effects on tumor and normal tissue microcirculation. Radiology 137:811-817, 1980.
4. Gross JF, Roemer R, DEWHIRST MW, Meyer T, A uniform thermal field in a
hyperthermia chamber for microvascular studies. Int J Heat Mass Transfer 25:1313-1320, 1982.
5. DEWHIRST MW, Connor WG, Sim DA, Preliminary results of a phase III trial of
spontaneous animal tumors to heat and/or radiation: Early normal tissue response and tumor volume influence on initial response. Int J Radiat Oncol Biol Phys 8:1951-1961, 1982.
6. Fletcher AM, Cetas TC, DEWHIRST MW, Wilson SE, Liver temperatures in rats
subjected to whole body hyperthermia, evidence for congestion and lymphocyte damage. J Natl Cancer Inst Monogr 61:321-323, 1982.
7. DEWHIRST MW, Connor WG, Moon TE, Roth HB, Response of spontaneous animal
tumors to heat and/or radiation: Preliminary results of a Phase III trial. J Natl Cancer Inst Monogr 61:395-397, 1982.
8. Nasoni RL, Bowen T, DEWHIRST MW, Roth H, In vivo temperature dependence of the
speed of sound in mammalian tissue and its possible use in hyperthermia. J Natl Cancer Inst Monogr 61:501-504, 1982
9. DEWHIRST MW, Sim DA, Wilson S, DeYoung D, Parsells JL, Correlation between initial
and long term responses of spontaneous pet animal tumors to heat and radiation or radiation alone. Cancer Res 43:5735-5741, 1983.
10. DEWHIRST MW, Gross JF, Sim D, Arnold P, Boyer D, The effect of rate of heating and
cooling prior to heating on tumor and normal tissue microcirculatory blood flow. Biorheology 21:539-558, 1984.
4
11. DEWHIRST MW, Sim, DA, Analysis of prognostic variables which influence early and long-term response of pet animal tumors to radiation alone and radiation plus heat. Front Radiat Ther Oncol 18: 47-55, 1984.
12. DEWHIRST MW, Sim D, Sapareto S, Connor WG, Importance of minimum tumor
temperature in determining early and long-term responses of spontaneous canine and feline tumors to heat and radiation. Cancer Res 44:43-50, 1984.
13. DEWHIRST MW, Sim DA, The utility of thermal dose as a predictor of tumor and normal
tissue responses to combined radiation and hyperthermia. Cancer Res 44:4772-4780, 1984.
14. Stauffer PR, Cetas TC, Fletcher AM, DeYoung DW, DEWHIRST MW, Oleson JR,
Roemer RB, Observations on the use of ferromagnetic implants for inducing hyperthermia. IEEE Trans Biomed Eng 31:76-90, 1984.
15. Oleson JR, Assaad A, DEWHIRST MW, DeYoung DW, Grochowski KJ, Sim DA,
Regional hyperthermia by magnetic induction in a beagle dog model: Analysis of thermal dosimetry. Radiat Res 98:445-455, 1984
16. DEWHIRST MW, Sim DA, Forsyth KS, Grochowski KJ, Wilson S, Bicknell E, Local
control and distant metastases in primary canine malignant melanomas treated with hyperthermia and/or radiotherapy. Int J Hyperthermia 1:219-234, 1985.
17. Thrall DE, DEWHIRST MW, Use of radiation and/or hyperthermia for treatment of mast
cell tumors and lymphosarcoma in dogs. Vet Clin North Am Small Anim Pract 15: 835-43, 1985.
18. DEWHIRST MW, Sim DA, Gross JF, Kundrat MA, Effects of heating rate on normal and
tumor microcirculatory function. In: KR Diller and RB Roemer (eds.), Heat and Mass Transfer in the Microcirculation of Thermally Significant Vessels. ASME, 1986. Pp. 75-80.
19. Meyer RE, Page RL, Thrall DE, DEWHIRST MW, Vose DL, Determination of continuous
atracurium infusion rate in dogs undergoing whole body hyperthermia. Cancer Res 46:5599-5601, 1986.
20. Thrall DE, Page RL, DEWHIRST MW, Meyer RE, Hoopes PJ, Kornegay JN,
Temperature measurements in normal and tumor tissue of dogs undergoing whole body hyperthermia. Cancer Res 46:6229-6235, 1986.
21. DEWHIRST MW, Sim DA, Estimation of therapeutic gain in clinical trials involving
hyperthermia and radiotherapy. Int J Hyperthermia 2:165-178, 1986. 22. Riviere JE, Page RL, DEWHIRST MW, Tyczkowska K, Thrall DE, Effect of hyperthermia
on cisplatin pharmocokinetics in normal dogs. Int J Hyperthermia 2:351-358, 1986. 23. McChesney SL, Gillette EL, DEWHIRST MW, Withrow SJ, Influence of WR 2721 on
radiation response of canine soft tissue sarcomas. Int J Radiat Oncol Biol Phys 12:1957-1963, 1986.
24. Page RL, Thrall DE, DEWHIRST MW, Meyer RE, Whole body hyperthermia: Rationale
and potential use for cancer treatment. Am J Vet Int Med 1:110-120, 1987.
5
25. Klein MK, DEWHIRST MW, Fuller DJM, Whole body hyperthermia and heat sensitizing drugs: A pilot study in canine lymphoproliferative disease. Int J Hyperthermia 3:187-198, 1987.
26. DEWHIRST MW, Winget JM, Edelstein-Keshet L, Sylvester J, Engler M, Thrall DE,
Page RL, Oleson JR, Clinical application of thermal isoeffect dose. Int J Hyperthermia 3:307-318, 1987.
27. Page RL, Meyer RE, Thrall DE, DEWHIRST MW, Cardiovascular and metabolic
response of tumour-bearing dogs to whole body hyperthermia. Int J Hyperthermia 3:513-525,1987.
28. Engler MJ, DEWHIRST MW, Winget JM, Oleson JR, Automated temperature scanning
for hyperthermia treatment monitoring. Int J Radiat Oncol Biol Phys 13:1377-1382, 1987.
29. Gillette EL, McChesney SL, DEWHIRST MW, Scott RJ, Response of canine oral
carcinomas to heat and radiation. Int J Radiat Oncol Biol Phys 13:1861-1867, 1987. 30. Zakris EL, DEWHIRST MW, Riviere JE, Hoopes PJ, Page RL, Oleson JR,
Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia. J Clin Oncol 5:1613-1620, 1987.
31. DEWHIRST MW, Gustafson C, Gross JF, Tso CY, Temporal effects of 5.0 Gy radiation
in healing subcutaneous microvasculature of a dorsal flap window chamber, Radiat Res 112:581-591, 1987.
32. Oleson JR, Calderwood SK, Coughlin CT, DEWHIRST MW, Gerweck LE, Gibbs FA Jr,
Kapp DS, Biological and clinical aspects of hyperthermia in cancer therapy. Am J Clin Oncol 11:368-380, 1988.
33. Page RL, Macy DW, Allen SA, DEWHIRST MW, Thrall DE, Gillette EL, Unexpected
toxicity associated with use of body surface area for dosing melphalan in the dog. Cancer Res 48:288-290, 1988.
34. Engler MJ, DEWHIRST MW, Oleson JR, Stability of temperatures during hyperthermia
treatments. Int J Hyperthermia 5:59-67, 1989. 35. Thrall DE, Page RL, DEWHIRST MW, Macy DW, McLeod DA, Scott RJ, Allen S, Gillette
EL, Whole body hyperthermia in dogs using a radiant heating device: Effect of surface cooling on temperature uniformity. Int J Hyperthermia 5:137-143, 1989.
36. Edelstein-Keshet L, DEWHIRST MW, Oleson JR, Samulski TV, Characterization of
tumour temperature distributions in hyperthermia based on assumed mathematical forms. Int J Hyperthermia 5:757-777, 1989.
37. Leopold KA, Harrelson J, Prosnitz L, Samulski TV, DEWHIRST MW, Oleson JR,
Preoperative hyperthermia and radiation for soft tissue sarcomas: Advantage of two vs. one hyperthermia treatments per week. Int J Radiat Oncol Biol Phys 16:107-115, 1989.
38. Oleson JR, DEWHIRST MW, Harrelson JM, Leopold KA, Samulski TV, Tso CY, Tumor
temperature distributions predict hyperthermia effect. Int J Radiat Oncol Biol Phys 16:559-570, 1989.
6
39. Shrivastava P, Luk K, Oleson J, DEWHIRST MW, Pajak T, Paliwal B, Perez C, Sapareto S, Saylor T, Steeves R, Hyperthermia quality assurance guidelines. Int J Radiat Oncol Biol Phys 16:571-587, 1989.
40. DEWHIRST MW, Animal modeling and thermal dose. Radiol Clin North Am 27:509-518,
1989. 41. DEWHIRST MW, Tso CY, Oliver R, Gustafson CS, Secomb TW, Gross JF, Morphologic
and hemodynamic comparison of tumor and healing normal tissue microvasculature. Int J Radiat Oncol Biol Phys 17:91-99, 1989.
42. McChesney SL, Withrow SJ, Gillette EL, Powers BE, DEWHIRST MW, Radiotherapy of
soft tissue sarcomas in dogs. J Am Vet Med Assoc 194:60-63,1989. 43. Thrall DE, McLeod DA, Bentel GC, DEWHIRST MW, A review of treatment planning and
dose calculation in veterinary radiation oncology. Vet Radiol 30:194-221, 1989. 44. Cope DA, DEWHIRST MW, Friedman HS, Bigner DD, Zalutsky MR, Enhanced delivery
of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia. Cancer Res 50:1803-1809, 1990.
45. Riviere JE, Page RL, Rogers RA, Chang SK, DEWHIRST MW, Thrall DE, Nonuniform
alteration of cis-diamminedichloroplatinum (II) tissue distribution in dogs with whole body hyperthermia. Cancer Res 50:2075-2080, 1990.
46. Acker JC, DEWHIRST MW, Honoré GM, Samulski TV, Tucker JA, Oleson JR, Blood
perfusion measurements in human tumours: Evaluation of laser Doppler methods. Int J Hyperthermia 6:287-304, 1990.
47. Thrall DE, DEWHIRST MW, Page RL, Samulski TV, McLeod DA, Oleson JR, A
comparison of temperatures in canine solid tumours during local and whole-body hyperthermia administered alone and simultaneously. Int J Hyperthermia 6:305-317, 1990.
48. Samulski TV, Grant WJ, Oleson JR, Leopold KA, DEWHIRST MW, Vallario P, Blivin J,
Clinical experience with multi-element ultrasonic hyperthermia system: Analysis of treatment temperatures. Int J Hyperthermia 6:909-922, 1990.
49. DEWHIRST MW, Prescott DA, Clegg S, Samulski TV, Page RL, Thrall DE, Leopold K,
Rosner G, Oleson JR, The use of hydralazine to manipulate tumor temperatures during hyperthermia. Int J Hyperthermia 6:971-983, 1990.
50. DEWHIRST MW, Oliver R, Tso CY, Gustafson C, Secomb T, Gross JF, Heterogeneity
in tumor microvascular response to radiation. Int J Radiat Oncol Biol Phys 18:559-568, 1990.
51. DEWHIRST MW, Phillips TL, Samulski TV, Stauffer P, Shrivastava P, Paliwal B, Pajak
T, Gillim M, Sapozink M, Myerson R, Waterman FM, Sapareto SA, Corry P, Cetas TC, Leeper DB, Fessenden P, Kapp D, Oleson JR, Emami B, RTOG quality assurance guidelines for clinical trials using hyperthermia. Int J Radiat Oncol Biol Phys 18:1249-1259, 1990.
7
52. Sostman HD, Charles HC, Rockwell S, Leopold K, Beam C, Madwed D, DEWHIRST MW, Cofer G, Moore D, Burn R, Oleson JR, Soft tissue sarcomas: Detection of metabolic heterogeneity with P-31 MR spectroscopy. Radiology 176:837-843, 1990.
53. DEWHIRST MW, Sostman HD, Leopold KA, Charles HC, Moore D, Burn RA, Tucker JA,
Harrelson JM, Oleson JR, Soft-tissue sarcomas: MR imaging and MR spectroscopy for prognosis and therapy monitoring, Work in progress. Radiology 174:847-853, 1990.
54. Lilley ER, Elion GB, DEWHIRST MW, Schold SC, Blum MR, Savina PM, Laskowitz DT,
Bigner DD, Friedman HS, Therapeutic analysis of melphalan-resistant human rhabdomyosarcoma xenograft TE-671MR. Cancer Res 51:3906-3909 1991.
55. Page RL, Thrall DE, DEWHIRST MW, Macy DW, George SL, McEntee MC, Heidner GL,
Novotney CA, Allen SA, Withrow SJ, Ogilvie GK, Gillette EL, Phase I study of melphalan alone and melphalan plus whole body hyperthermia in dogs with malignant melanoma. Int J Hyperthermia 7:559-566, 1991.
56. Waterman FW, DEWHIRST MW, Fessenden P, Samulski TV, Stauffer P, Emami B,
Corry P, Prionas SD, Sapozink M, Herman T, Kapp D, Myerson R, Ryan T, Sapareto SA, Shrivastava P, Cetas TC, Gillin M, Leeper DB, Oleson JR, Paliwal B, Pajak T, Phillips TL, RTOG quality assurance guidelines for clinical trials using hyperthermia administered by ultrasound. Int J Radiat Oncol Biol Phys 20:1099-1107, 1991.
57. Sapozink MD, Corry PM, Kapp DS, Myerson RJ, DEWHIRST MW, Emami B, Herman T,
Prionas S, Ryan T, Samulski T, Sapareto S, Shrivastava P, Stauffer P Waterman F, RTOG quality assurance guidelines for clinical trials using hyperthermia for deep seated malignancy. Int J Radiat Oncol Biol Phys 20:1109-1115, 1991.
58. Emami B, Stauffer P, DEWHIRST MW, Prionas S, Ryan T, Corry P, Herman T, Kapp
DS, Myerson RJ, Samulski TV, Sapareto S, Sapozink M, Shrivastava P, Waterman F, RTOG quality assurance guidelines for interstitial hyperthermia. Int J Radiat Oncol Biol Phys 20:1117-1124, 1991.
59. Marks LB, DEWHIRST MW, Accelerated repopulation: Friend or foe? Exploiting
changes in tumor growth characteristics to improve the 'efficiency' of radiotherapy. Int J Radiat Oncol Biol Phys 21:1377-1383, 1991.
60. Wu NZ, Klitzman B, Dodge R, DEWHIRST MW, Diminished leukocyte-endothelium
interaction in tumor microvessels. Cancer Res 52:4265-4268, 1992. 61. Thrall DE, Prescott DM, Samulski TV, DEWHIRST MW, Cline JM, Lee J, Page RL,
Oleson JR, Serious toxicity associated with annular microwave array induction of whole-body hyperthermia in normal dogs. Int J Hyperthermia 8:23-32, 1992.
62. Laskowitz DT, Elion GB, DEWHIRST MW, Griffith OW, Cattley RC, Bigner DD,
FriedmanHS, Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion. Int J Hyperthermia 8:111-120, 1992.
63. Page RL, Macy DW, Ogilvie GK, Rosner GL, DEWHIRST MW, Thrall DE, Withrow SJ,
McEntee MC, Cline JM, Heidner GL, Novotney CA, Gillette EL, Phase III evaluation of doxorubicin and whole body hyperthermia in dogs with lymphoma. Int J Hyperthermia 8:187-197, 1992.
8
64. Laskowitz DT, Elion GB, DEWHIRST MW, Griffith OW, Casero R, Scott PA, Bigner DD, Friedman HS, Effects of glutathione or polyamine depletion on in vivo thermosensitization. Int J Hyperthermia 8:199-208, 1992.
65. Gillette SM, DEWHIRST MW, Gillette EL, Thrall DE, Page RL, Powers BE, Withrow SJ,
Rosner G, Wong C, Sim DA, Response of canine soft tissue sarcomas to radiation or radiation plus hyperthermia: A randomized phase II study. Int J Hyperthermia 8:309-320, 1992.
66. Page RL, Thrall DE, George SL, Price GS, Heidner GL, McEntee MC, Novotney CA,
Hauck ML, DEWHIRST MW, Quantitative estimation of the thermal dose-modifying factor for cis-diamminedichloroplatinum (CDDP) in tumor-bearing dogs. Int J Hyperthermia 8:761-769, 1992.
67. Leopold KA, DEWHIRST MW, Samulski TV, Harrelson J, Tucker JA, George SL, Dodge
RK, Grant W, Clegg S, Prosnitz LR, Oleson JR, Relationships among tumor temperature, treatment time and histopathological outcome using preoperative hyperthermia with radiation in soft tissue sarcomas. Int J Radiat Oncol Biol Phys 22:989-998, 1992.
68. Prescott DM, Samulski TV, DEWHIRST MW, Page RL, Thrall DE, Dodge RK, Oleson
JR, Use of nitroprusside to increase tissue temperature during local hyperthermia in normal and tumor-bearing dogs. Int J Radiat Oncol Biol Phys 23:377-385, 1992.
69. Rine GP, DEWHIRST MW, Cobb ED, Samulski TV, Coleman EN, Clegg ST, Wallen CA,
Feasibility of estimating the temperature distribution in a tumor heated by a waveguide applicator. Int J Radiat Oncol Biol Phys 23:1009-1019, 1992.
70. Needham D, Hristova K, McIntosh TJ, DEWHIRST MW, Wu N, Lasic DD, Polymer-
grafted liposomes: Physical basis for the 'Stealth' Property. J Liposome Res 2:411-430, 1992.
71. Novotney CA, Page RL, Macy DW, DEWHIRST MW, Ogilvie GK, Withrow SL, McEntee
MC, Heidner GL, Allen SA, Thrall DE, Gillette EL, Phase I evaluation of doxorubicin and whole body hyperthermia in dogs with lymphoma. J Vet Int Med 6:245-249, 1992.
72. DEWHIRST MW, Combining hyperthermia and radiation: How beneficial? Oncology
5:110-112, 1992. 73. Laskowitz DT, Elion GB, DEWHIRST MW, Griffith OW, Savina PM, Blum MR, Prescott
DM, Bigner DD, Friedman HS, Hyperthermia-induced enhancement of melphalan activity against a melphalan resistant human rhabdomyosarcoma xenograft. Radiat Res 129:218-223, 1992.
74. DEWHIRST MW, Ong ET, Klitzman B, Secomb TW, Vinuya RZ, Dodge R, Brizel D,
Gross JF, Perivascular oxygen tensions in a transplantable mammary tumor growing in a dorsal flap window chamber. Radiat Res 130:171-182 1992.
75. DEWHIRST MW, Vinuya RZ, Ong ET, Klitzman B, Rosner G, Secomb T, Gross JF,
Effects of bradykinin on the hemodynamics of tumor and granulating normal tissue microvasculature. Radiat Res 130:345-354, 1992.
76. DEWHIRST MW, Ong ET, Madwed D, Klitzman B, Secomb T, Brizel D, Bonaventura J,
Rosner G, Kavanagh B, Edwards J, Gross J, Effects of the calcium channel blocker
9
flunarizine on the hemodynamics and oxygenation of tumor microvasculature. Radiat Res 132:61-68, 1992.
77. Kavanagh BD, Coffey BE, Needham D, Hochmuth RM, DEWHIRST MW, The effect of
flunarizine on erythrocyte suspension viscosity under conditions of extreme hypoxia, low pH, and lactate treatment. Br J Cancer 67(4):734-741, 1993. PMCID: PMC1968366.
78. Castellino S, Elion GB, Griffith OW, DEWHIRST M, Kurtzberg J, Cattley RC, Scott P,
Bigner DD, Friedman HS, Development of a model of melphalan-induced gastrointestinal toxicity in mice. Cancer Chemother Pharmacol 31:376-380, 1993.
79. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, DEWHIRST MW, Increased
microvascular permeability contributes to preferential accumulation of Stealth™ liposomes in tumor tissue. Cancer Res 53:3765-3770, 1993.
80. Prescott DM, Charles HC, Sostman HD, Page RL, Thrall DE, Moore D, Oleson JR,
DEWHIRST MW, Manipulation of intra- and extracellular pH in spontaneous canine tumours by use of hyperglycaemia. Int J Hyperthermia 9:745-754, 1993.
81. Anscher MS, Montana GS, Dodge R, Gaydica E, DEWHIRST MW, Prosnitz LR, The
lack of impact of treatment time on the outcome of definitive radiotherapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 3:707-711, 1993.
82. Brizel DM, Klitzman B, Cook JM, Edwards J, Rosner G, DEWHIRST MW, A comparison
of tumor and normal tissue microvascular hematocrits and red cell fluxes in a rat window chamber model. Int J Radiat Oncol Biol Phys 25:269-276, 1993.
83. Oleson JR, Samulski TV, Leopold KA, Clegg ST, DEWHIRST MW, Dodge RK, George
SL, Sensitivity of hyperthermia trial outcomes to temperature and time: Implications for thermal goals of treatment. Int J Radiat Oncol Biol Phys 25:289-297, 1993.
84. Secomb TW, Hsu R, DEWHIRST MW, Klitzman B, Gross JF, Analysis of oxygen
transport to tumor tissue by microvascular networks. Int J Radiat Oncol Biol Phys 25:481-489, 1993.
85. DEWHIRST MW, Factors influencing hyperthermic enhancement of drug cytotoxicity.
Editorial, Int J Radiat Oncol Biol Phys 25:569-570, 1993. 86. Leopold KA, DEWHIRST MW, Samulski TV, Dodge RK, George SL, Blivin JL, Prosnitz
LR, Oleson JR, Cumulative minutes with T90 greater than TEMP index is predictive of response of superficial malignancies to hyperthermia and radiation. Int J Radiat Oncol Biol Phys 25:841-847, 1993.
87. Teicher BA, Holden SA, Northey D, DEWHIRST MW, Herman TS, Therapeutic effect of
infused fluosol-DA/carbogen with ephendrine, flunarizine or nitroprusside. Int J Radiat Oncol Biol Phys 26:103-109, 1993.
88. Leopold KA, Oleson JR, Clarke-Pearson D, Soper J, Berchuck A, Samulski TV, Page
RL, Blivin J, Tomberlin JK, DEWHIRST MW, Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma. Int J Radiat Oncol Biol Phys 27:1245-1251, 1993.
89. DEWHIRST MW, Griffin TW, Smith AR, Parker RG, Hanks GE, Brady LW, Intersociety
Council on Radiation Oncology essay on the introduction of new medical treatments into practice. J Nat Cancer Inst 85:951-957, 1993.
10
90. Wu NZ, Klitzman B, Rosner G, Needham D, DEWHIRST MW, Measurement of material
extravasation in microvascular networks using fluorescence video-microscopy. Microvasc Res 46:231-253, 1993.
91. Page RL, McEntee MC, George SL, Williams PL, Heidner GL, Novotney CA, Riviere JE,
DEWHIRST MW, Thrall DE. Pharmacokinetic and phase I evaluation of carboplatin in dogs, J Vet Intern Med 7: 235-240, 1993
92. Wu NZ, Ross BA, Gulledge C, Klitzman B, Dodge R, DEWHIRST MW, Differences in
leucocyte-endothelium interactions between normal and adenocarcinoma bearing tissues in response to radiation. Br J Cancer 69(5):883-889, 1994. PMCID: PMC1968894.
93. DEWHIRST MW, Secomb TW, Ong ET, Hsu R, Gross JF, Determination of local
oxygen consumption rates in tumors. Cancer Res 54:3333-3336, 1994. 94. Clegg ST, Samulski TV, Murphy KA, Rosner GL, DEWHIRST MW, Inverse techniques
in hyperthermia: A sensitivity study. IEEE Trans Biomed Eng 41:373-382, 1994. 95. Krishna MC, DEWHIRST MW, Friedman HS, Cook JA, DeGraff W, Samuni A, Mitchell
JB, Hyperthermic sensitization by the radial initiator 2,2’-azobis (2-amidinopropane) dihydrochloride (AAPH): I. In vitro studies, Int J Hyperthermia 10:271-281, 1994.
96. DEWHIRST MW, Future directions in hyperthermia biology. Int J Hyperthermia 10:339
345, 1994. 97. Page RL, McEntee MC, Williams PL, George SL, Price GS, Novotney CA, Hauck ML,
Riviere JE, DEWHIRST MW, Thrall DE, Effect of whole-body hyperthermia on carboplatin disposition and toxicity in dogs. Int J Hyperthermia 10:807-816, 1994.
98. Prescott DM, Charles HC, Sostman HD, Dodge RK, Thrall DE, Page RL, Tucker JA,
Harrelson JM, Leopold KA, Oleson JR, DEWHIRST MW, Therapy monitoring in human and canine soft tissue sarcomas using magnetic resonance imaging and spectroscopy. Int J Radiat Oncol Biol Phys 28:415-423, 1994.
99. Brizel DM, Rosner G, Harrelson J, Prosnitz LR, DEWHIRST MW, Pretreatment
oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 30:635-642, 1994.
100. DEWHIRST MW, Madwed D, Meyer RE, Ong, ET, Klitzman B, Rosner GL, Dodge R,
Reduction in tumor blood flow in skin flap tumor after hydralazine is not due to a vascular steal phenomenon. Radiat Oncol Invest 1:270-278, 1994.
101. Sostman HD, Prescott DM, DEWHIRST MW, Dodge RK, Thrall DE, Page RL, Tucker
JA, Harrelson JM, Reece G, Leopold KA, Oleson JR, Charles HC, MR imaging and spectroscopy for prognostic evaluation in soft-tissue sarcomas. Radiology 190:269-275, 1994.
102. Brizel DM, Dodge R, DEWHIRST MW, The effect of the perflubron emulsion Oxygent™
on the calibration characteristics of polarographic oxygen electrodes. Radiat Oncol 33:262-265, 1994.
11
103. Secomb TW, Hsu R, Ong ET, Gross JF, DEWHIRST MW, Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncologica 34:313-316, 1995.
104. Meyer RE, Shan S, DeAngelo J, Dodge RK, Bonaventura J, Ong ET, DEWHIRST MW,
Nitric oxide synthase inhibition irreversibly decreases perfusion in the R3230Ac rat mammary adenocarcinoma. Br J Cancer 71(6):1169-1174, 1995. PMCID: PMC2033822.
105. Castellino SM, Friedman HS, Elion GB, Ong ET, Marcelli SL, Page R, Bigner DD,
DEWHIRST MW, Flunarizine enhancement of melphalan activity against drug sensitive/resistant rhabdomyosarcoma. Br J Cancer 71(6):1181-1187, 1995. PMCID: PMC2033851.
106. Brizel DM, Lin S, Johnson JL, Brooks J, DEWHIRST MW, Piantadosi CA, The
mechanisms by which hyperbaric oxygen and carbogen improve tumor oxygenation. Br J Cancer 72:1120-1124, 1995.
107. Schuster JM, Zalutsky MR, Noska MA, Dodge R, Friedman HS, Bigner DD, DEWHIRST
MW, Hyperthermic modulation of radiolabeled antibody uptake in a human glioma xenograft and normal tissues. Int J Hyperthermia 11:59-72, 1995.
108. Prosnitz LR, DEWHIRST MW, Progress toward a thermal dosimetry system [editorial
comment]. Int J Radiat Oncol Biol Phys 33:963-964, 1995. 109. Foltz RM, McLendon RE, Friedman HS, Dodge RK, Bigner DD, DEWHIRST MW, A pial
window model for the intracranial study of human glioma microvascular function. Neurosurgery 36:976-985, 1995.
110. Page RL, Lee J, Riviere JE, Dodge RK, Thrall DE, DEWHIRST MW, Absence of whole
body hyperthermia effect on cisplatin distribution in spontaneous canine tumors. Int J Radiat Oncol Biol Phys 32:1097-1102, 1995.
111. Brizel DM, Rosner GL, Prosnitz LR, DEWHIRST MW, Patterns and variability of tumor
oxygenation in human soft tissue sarcomas, cervical carcinomas, and lymph node metastases. Int J Radiat Oncol Biol Phys 32:1121-1125, 1995.
112. Kimura H, Wu NZ, Dodge R, Spencer DP, Klitzman BM, McIntyre TM, DEWHIRST MW,
Inhibition of radiation-induced up-regulation of leukocyte adhesion to endothelial cells with the platelet activating factor inhibitor. BN52021, Int J Radiat Oncol Biol Phys 33:627-633, 1995.
113. Minsley GE, DEWHIRST MW, Tucker MR, Craniofacial implants in irradiated bone:
clinical and laboratory experiences. Proceedings of the First International Congress on Maxillofacial Prosthetics, Indian Wells, CA, April 27-30, 1994 (New York: Memorial Sloan-Kettering Cancer Center, 1995), pp. 297-304.
114. DEWHIRST MW, LaRue SM, Gerweck L, Tumor physiology and cell kinetics. Semin
Vet Med Surg Small Anim 10: 148-157, 1995. 115. Gaber MH, Wu NZ, Hong K, Huang SK, DEWHIRST MW, Papahadjopoulos D,
Thermosensitive liposomes: Extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys 36:1177-1187, 1996.
12
116. Hauck ML, DEWHIRST MW, Zalutsky MR, The effects of clinically relevant hyperthermic temperatures on the kinetic binding parameters of a monoclonal antibody. Nucl Med Biol 23:551-557, 1996.
117. Raleigh JA, DEWHIRST MW, Thrall DE, Measuring tumor hypoxia. Semin Radiat Oncol
6:37-45, 1996. 118. Lindberg RA, DEWHIRST MW, Buckley BJ, Hughes CS, Whorton AR, Calcium-
dependent nitric oxide release in EA.hy926 endothelial but not R3230Ac rat mammary adenocarcinoma cells. Am J Physiol 271:332-337, 1996.
119. Gulledge CJ, DEWHIRST MW, Tumor oxygenation: A matter of supply and demand.
AntiCancer Res 16:741-749, 1996. 120. DEWHIRST MW, Kimura H, Rehmus SWE, Braun RD, Papahadjopoulos D, Hong K,
Secomb TW, Microvascular studies on the origins of perfusion-limited hypoxia. Br J Cancer Suppl. 74:S247-S251, 1996. PMCID: PMC2149984.
121. DEWHIRST MW, Ong ET, Rosner GL, Rehmus SW, Shan S, Braun RD, Brizel DM,
Secomb TW. Arteriolar oxygenation in tumor and subcutaneous arterioles: Effects of inspired air oxygen content. Br J Cancer Suppl. 74:S241-246, 1996. PMCID: PMC2149985.
122. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, DEWHIRST
MW, Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56:941-943, 1996.
123. Rosner GL, Clegg ST, Prescott DM, DEWHIRST, MW, Estimation of cell survival in
tumors heated to nonuniform temperature distributions. Int J Hyperthermia 12:223-239, 1996
124. Thrall DE, Prescott DM, Samulski TV, Denman DL, Legorreta RL, Rosner GL, Dodge
RK, Page RL, Cline JM, Lee J, Evans SM, Oleson JR, DEWHIRST MW, Radiation plus local hyperthermia versus radiation plus the combination of local and whole body hyperthermia in canine sarcomas. Int J Radiat Oncol Biol Phys 34:1087-1096, 1996.
125. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Dodge RK, Charles HC, Samulski TV,
Prosnitz LR, DEWHIRST MW, Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. Cancer Res 56:5347-5350. 1996.
126. Kimura H, Braun RD, Ong ET, Hsu R, Secomb TW, Papahadjopoulos D, Hong K,
DEWHIRST MW, Fluctuations in red cell flux in tumor microvessels lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 56:5522-5528, 1996.
127. Jones DN, McCowage G, Sostman HD, Brizel DM, Layfield L, Charles HC, DEWHIRST
MW, Prescott DM, Friedman HS, Harrelson JM, Scully SP, Coleman RE, Monitoring of neoadjuvant therapy response of soft tissue and musculoskeletal sarcomas using F18-FDG PET: Initial evaluation. J Nucl Med 37:1438-1444, 1996.
128. Hettasch JM, Bandarenko N, Lai TS, Marks JR, Haroon Z, Peters K, DEWHIRST MW,
Iglehart, JD, Greenberg CS, Tissue transgluminase expression in human breast cancer. Lab Invest 75:637-645, 1996.
13
129. Hauck ML, Price GS, Ogilvie GK, Johnson J, Gillette EL, Thrall DE, DEWHIRST MW, Page RL, Phase I evaluation of mitoxantrone alone and combined with whole body hyperthermia in dogs with lymphoma. Int J Hyperthermia 12: 309-320, 1996.
130. Zalutsky MR, Schuster JM, Garg PK, Archer GE Jr, DEWHIRST MW, Bigner DD, Two
approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. Recent Results Cancer Res 141: 101-122, 1996.
131. Shan SQ, Rosner GL, Braun RD, Hahn J, Pearce C, DEWHIRST MW. Effects of
diethylamine/nitric oxide on blood perfusion in the R3230Ac mammary carcinoma. Br J Cancer 76(4):429-437, 1997. PMCID: PMC2227992.
132. Hauck ML, DEWHIRST MW, Bigner DD, Zalutsky ML, Local hyperthermia improves
uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model. Clin Cancer Res 3:63-70, 1997.
133. Anscher MS, Samulski TV, Rosner G, Dodge R, Prosnitz L, DEWHIRST MW, Combine
external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 37:1059-1065, 1997.
134. Braun RD, DEWHIRST MW, Hatchell DL, Quantification of erythrocyte flow in the
choroid. Am J Physiol 272:1444-1453, 1997. 135. Wu NZ, Braun RD, Gaber MH, Lin GM, Ong ET, Shan S, Papahadjopoulos D,
DEWHIRST MW, Simultaneous measurement of liposome extravasation and content release in tumors. Microcirculation 4:83-101, 1997
136. Hahn JS, Braun RD, DEWHIRST MW, Shan S, Snyder SA, Taub JM, Ong ET, Rosner
GL, Dodge RK, Bonaventura J, Bonaventura C, DeAngelo J, Meyer RE, Stroma-free human hemoglobin A decreases R3230Ac rat mammary adenocarcinoma blood flow and oxygen partial pressure. Radiat Res 147:185-194, 1997.
137. Hauck ML, Coffin DO, Dodge RK, DEWHIRST MW, Mitchell JB, Zalutsky MR, A local
hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure. Int J Hyperthermia 13:307-316, 1997.
138. Brizel DM, Prosnitz LR, Sibley GS, Scher RL, Rosner GL, DEWHIRST MW, Tumor
hypoxia adversely affects to prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38:285-289, 1997.
139. Wong AL, Haroon Z, Werner S, DEWHIRST W, Greenberg CS, Peters K, Tie2
expression and phosphyorylation of angiogenic and quiescent adult tissues. Circ Res 81:567-574,1997.
140. Brizel DM, Hage WD, Dodge RK, Munley MT, Piantadosi CA, DEWHIRST MW,
Hyperbaric oxygen improves tumor radiation response significantly more than carbogen/nicotinamide. Radiat Res 147:715-720, 1997.
141. Nozue M, Lee I, Yuan F, Teicher BA, Brizel DM, DEWHIRST MW, Milross CG, Milas L,
Song CW, Thomas CD, Guichard M, Evans SM, Koch CJ, Lord EM, Jain RK, Suit HD, Interlaboratory variation in oxygen tension measurement by Eppendorf “histograph” and comparison with hypoxic marker. J Surg Oncol 66:30-38, 1997.
14
142. Wong AL, Haroon ZA, Werner S, DEWHIRST MW, Greenberg CS, Peters KG, Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 81:567-574, 1997.
143. Lin P, Polverine P, DEWHIRST MW, Shan S, Rao PS, Peters K, Inhibition of tumor
angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 100:2072-2078, 1997.
144. Bryce TJ, DEWHIRST MW, Floyd CE, Hars V, Brizel DM, Artificial neural network model
of survival in patients treated with irradiation with and without concurrent chemotherapy for advanced carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 41:339-345, 1998.
145. Lin P, Sankar S, Shan S, DEWHIRST MW, Polverini P, Quinn T, Peters K, Inhibition of
tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 9:49-58, 1998.
146. Acker JC, Marks LB, Spencer DP, Yang W, Avery MA, Dodge RK, Rosner GL,
DEWHIRST MW, Serial in vivo observations of cerebral vasculature after treatment with a large single fraction of radiation. Radiat Res 149:350-359, 1998.
147. Wink DA, Vodovotz Y, Laval J, Laval F, DEWHIRST MW, Mitchell JB, The multifaceted
roles of NO in cancer. Carcinogenesis 19:711-712, 1998. 148. Sneed PK, DEWHIRST MW, Samulski T, Blivin J, Prosnitz LR, Should interstitial
thermometry be used for deep hyperthermia? [editorial; comment], Int J Radiat Oncol Biol Phys 40:1015-1017, 1998.
149. DEWHIRST MW, Concepts of oxygen transport at the microcirculatory level. Semin
Radiat Oncol 8:143-150, 1998. 150. DEWHIRST MW, Corry PM, Further justification for development of non-invasive
thermometry [editorial; comment], Int JHyperthermia 14:255, 1998. 151. Wilson DF, Evans SM, Jenkins WT, Vinogradov SA, Ong E, DEWHIRST MW, Oxygen
distributions within R3230Ac tumors growing in dorsal flap window chambers in rats. Adv Exp Med Biol 454: 603-609, 1998.
152. Secomb TW, Hsu R, Braun RD, Ross JR, Gross JF, DEWHIRST MW, Theoretical
simulation of oxygen transport to tumors by three-dimensional networks of microvessels. Adv Exp Med Biol 454: 629-634, 1998.
153. Lin P, Buxton JA, Acheson A, Redziewjewski C, Maisonpierre PC, Yancopoulos GD,
Channon KM, DEWHIRST MW, George SE, Peters KG, Antiangiogenic gene therapy targetting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA. 1998 July 21; 95(15):8829-8834.
154. Biaglow JE, Manevich Y, Leeper D, Chance B, DEWHIRST MW, Jenkins WT, Tuttle
SW, Wroblewski K, Glickson JD, Stevens C, Evans SM, MIBG inhibits respiration: potential for radio-and hyperthermia sensitization. Int J Radiat Oncol Biol Phys 42:871-876, 1998.
155. DEWHIRST MW, Braun RD, Lanzen JL, Temporal changes in pO2 of R3230Ac tumors
in Fischer-344 rats. Int J Radiat Oncol Biol Phys 42:723-726, 1998.
15
156. Lanzen JL, Braun RD, Ong AL, DEWHIRST MW, Variability in blood flow and pO2 in
tumors in response to carbogen breathing. Int J Radiat Oncol Biol Phys 42:855-859, 1998.
157. Larue SM, Fox MH, Ogilvie GK, Page RL, Getzy DM, Thrall DE, Johnson JL,
DEWHIRST MW, Gillette EL, Tumour cell kinetics as predictors of response in canine lymphoma treated with chemotherapy alone or combined with whole body hyperthermia. Int J Hyperthermia 15: 475-486, 1999.
158. Haroon ZA, Lai TS, Hettasch JM, Lindberg RA, DEWHIRST MW, Greenberg CS, Tissue
transglutaminase is expressed as a host response to tumor invasion and inhibits tumor growth. Lab Invest 79:1679-1686, 1999.
159. DEWHIRST MW, Ong ET, Braun RD, Smith B, Klitzman B, Evans SM, Wilson D,
Quantification of longitudinal tissue p02 gradients in window chamber tumors: Impact on tumor hypoxia. Br J Cancer 79(11/12):1717-1722, 1999. PMCID: PMC2362789.
160. Dunn TJ, Braun RD, Rhemus WE, Rosner GL, Secomb TW, Tozer GM, Chaplin DJ,
DEWHIRST MW, The effects of hyperoxic and hypercarbic gases on tumour blood flow. Br J Cancer 80(1/2):117-126, 1999. PMCID: PMC2363007.
161. Krol A, Maresca J, DEWHIRST MW, Yuan F, Available volume fraction of
macromolecules in a fibrosarcoma: Implication for drug delivery. Cancer Res 59:4136-4141, 1999.
162. Thrall DE, LaRue SM, Powers BE, Page RL, Johnson J, George SL, Kornegay JN,
McEntee MC, Case BC, DEWHIRST MW, Gillette EL, Use of whole body hyperthermia as a method to heat inaccessible tumors uniformly: A phase III trial in canine brain masses. Int J Hyperthermia 15:383-398, 1999.
163. Kong G, DEWHIRST MW, Hyperthermia and liposomes: a review. Int J Hyperthermia
15:345-370, 1999. 164. Prosnitz LR, Maguire P, Anderson JM, Scully SP, Harrelson JM, Jones EL, DEWHIRST
MW, Samulski TV, Powers BE, Rosner GL, Dodge RK, Layfield L, Clough R, Brizel DM, The treatment of high grade soft tissue sarcomas with preoperative thermoradiotherapy. Int J Radiat Oncol Biol Phys 45:941-949, 1999.
165. Braun R, Lanzen JL, DEWHIRST MW, Fourier analysis of fluctuations of oxygen tension
and blood flow in R3230Ac tumors and muscle in rats. Am J Physiol 277:551-568, 1999.
166. Haroon ZA, Hettasch JM, Lai TS, DEWHIRST MW, Greenberg CS, Tissue
transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. Faseb J 13:1787-1795, 1999.
167. Brizel DM, Dodge RK, Clough RW, DEWHIRST MW, Oxygenation of head and neck
cancer: Changes during radiotherapy and impact on treatment outcome. Radiat Oncol 53:113-117, 1999.
168. Craciunescu O, Das SK, DEWHIRST MW, Three-dimensional microvascular networks
fractal structure: potential for tissue characterization. ASME Proceedings, 1999.
16
169. Huang Q, Shan S, Braun RD, Lanzen J, Anyrhambatla G, Kong G, Borelli M, Corry P, DEWHIRST MW, Li CY, GFP based non-invasive, in vivo monitoring of gene expression. Nat Biotechnol 17:1033-1035, 1999.
170. Secomb TW, Hsu R, Braun RD, DEWHIRST MW, Analysis of oxygen transport to
tumors: Causes of heterogenous tissue oxygenation, Bioengineering Conference, Big Sky Montana. June 16-20, BED Vol. 42, pp 487-488, 1999.
171. Minning DM, Gow AJ, Bonaventura J, Braun R, DEWHIRST MW, Goldberg DE, Stamler
JS, Ascaris haemoglobin is a nitric oxide-activated 'deoxygenase. Nature 401:497-502, 1999.
172. Biaglow JE, Lee I, Donahue J, Held K, Mieyal J, DEWHIRST MW, Tuttle S, Glutathione
depletion or radiation treatment alters respiration and induces apoptosis in R3230Ac mammary carcinoma. Proceedings of the 1999 ISOTT conference, Dartmouth (in press, 1999).
173. Lee I, Glickson JD, DEWHIRST MW, Leeper DB, Burd R, Poptani H, Nada L, McKenna
G, Biaglow JE, Effect of mild hyperglycemia +/- meta-iodo-benzylguanidine on the radiation response of R3230 AC tumors. Proceedings of the 1999 ISOTT conference, Dartmouth (in press, 1999).
174. Vujaskovic Z, Poulson JM, Gaskin AA, Thrall DE, Page RL, Charles HC, MacFall JR,
Brizel DM, Meyer RE, Prescott DM, Samulski TV, DEWHIRST MW, Temperature dependent changes in physiologic parameters of spontaneous canine soft tissue sarcomas after combined radiotherapy and hyperthermia treatment. Int J Radiat Oncol Biol Phys 46:179-185, 2000.
175. Lohr F, Hu K, Haroon Z, Samulski TV, Huang Q, Beaty J, DEWHIRST MW, Li CY,
Combination treatment of murine tumors by adenovirus-mediated local B7/IL1 immunotherapy and radiotherapy, Mol Ther 2:195-203, 2000.
176. Li CY, Huang Q, Braun RD, Lanzen J, Turnage J, DEWHIRST MW, Initial stages of
tumor cell-induced angiogenesis: Evaluation via skin window chambers in rodent models. J Nat Cancer Inst 92:143-147, 2000.
177. DEWHIRST MW, Tozer G, Wilson J, Rosner G, Lanzen J, Kaz A, Snyder S, Stamler J,
Modulation of tumor blood flow by nitric oxide. In: Radiation Research Volume 2; Congress Proceedings, Moriarity M, Mothersill C, Seymour C, Eddington M, Ward JF, Fry RJM (eds), Allen Press, Lawrence, KA, pp 610 - 613, 2000.
178. DEWHIRST MW, Kong G, Needham D. Use of Hyperthermia to Augment Liposomal
Drug Delivery to Tumours. In: Radiation Research Volume 2; Congress Proceedings, Moriarity M, Mothersill C, Seymour C, Eddington M, Ward JF, Fry RJM (eds), Allen Press, Lawrence, KA, pp 853 - 856, 2000.
179. Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Inglehart JD, DEWHIRST MW,
Greenberg C, Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 18:600-608, 2000.
180. Haroon ZA, Raleigh JA, Greenberg CS, DEWHIRST MW, Early wound healing exhibits
cytokine surge without evidence of hypoxia. Ann Surg 231(1):137-147, 2000. PMCID: PMC1420978.
17
181. Prescott DM, Charles HC, Poulson JM, Page RL, Thrall DE, Vujaskovic Z, DEWHIRST MW, The relationship between intracellular and extracellular pH in spontaneous canine tumors. Clin Cancer Res 6:2501-2505, 2000.
182. Thrall D, Rosner G, Azuma C, LaRue S, Case B, Samulski T, DEWHIRST MW, Using
units of CEM 43oC T90, local hyperthermia thermal dose can be delivered as prescribed. Int J Hyperthermia 16:415-428, 2000.
183. Huang Q, Hu K, Lohr F, Zhang L, Braun R, Lanzen J, Little JB, DEWHIRST MW, Li CY,
Heat-induced gene expression as a novel targeted cancer gene therapy strategy. Cancer Res 60:3435-3439, 2000.
184. Kong G, Braun RD, DEWHIRST MW, Hyperthermia enables tumor-specific nanoparticle
delivery: Effect of particle size. Cancer Res 60:4440-4445, 2000. 185. Matteucci ML, Anyarambhatla G, Rosner G, Azuma C, Fisher PE, DEWHIRST MW,
Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas. Clin Cancer Res 6:3748-3755, 2000.
186. Adams DJ, DEWHIRST MW, Flowers JL, Gamcsik MP, Colvin OM, Manikumar G, Wani
MC, Wall ME. Camptothecin analogues with enhanced antitumor activity at acidic pH. Cancer Chemother Pharmacol 46:263-271, 2000.
187. Poulson JM, DEWHIRST MW, Gaskin AA, Vujaskovic Z, Samulski TV, Prescott DM,
Meyer RE, Page RL, Thrall DE. Acute pancreatitis assocciated with administration of a nitric oxided synthase inhibitor in tumor-bearing dogs. In Vivo 14:709-714, 2000
188. Lohr F, Hu K, Huang Q, Zhang L, Samulski TV, DEWHIRST MW, Li CY, Enhancement
of radiotherapy by hyperthermia-regulated gene therapy. Int J Radiat Oncol Biol Phys 48:1513-1518, 2000.
189. Blackwell KL, Haroon ZA, Shan S, Saito W, Broadwater G, Greenberg CS, DEWHIRST
MW, Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin Cancer Res 6:4359-4364, 2000.
190. DEWHIRST MW, Klitzman B, Braun RD, Brizel DM, Haroon ZA, Secomb TW, Review of
methods used to study oxygen transport at the microcirculatory level. Int J Cancer 90:237-255, 2000.
191. Zhang XY, Luck J, DEWHIRST MW, Yuan F, Interstitial hydraulic conductivity in a
fibrosarcoma. Am J Physiol Heart Circ Physiol 279:2726-2734 , 2000. 192. Meyer RE, Braun RD, Rosner GL, DEWHIRST MW, Local 42° C hyperthermia improves
vascular conductance of the R3230Ac rat mammary adenocarcinoma during sodium nitroprusside infusion. Radiat Res 154:196-201, 2000.
193. Anscher M, Lee C, Hurwitz H, Tyler D, Prosnitz L, Jowell P, Rosner G, Samulski T,
DEWHIRST MW, A pilot study of preoperative continuous infusion 5-fluorouracil, external microwave hyperthermia, and external beam radiotherapy for treatment of locally advanced, unresectable, or recurrent rectal cancer. Int J Radiat Oncol Biol Phys 47:719-724, 2000.
18
194. Kong G, Anyarambhatla G, Petros W, Braun R, Colvin M, Needham D, DEWHIRST MW, Efficacy of liposomes and hyperthermia in a human tumor xenograft model: Importance of triggered drug release. Cancer Res 60:6950-6957, 2000.
195. Needham D, Anyarambhatla G, Kong G, DEWHIRST MW, A new temperature-sensitive
liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 60:1197-1201, 2000.
196. Li CY, Shan SQ, Cao YT, DEWHIRST MW, Role of incipient angiogenesis in cancer
metastasis. Cancer and Metastasis reviews 19:7-11, 2000. 197. Muller P, Rosner G, Inoue L, DEWHIRST MW, A bayesian model for detecting changes
in nonlinear profiles. JASA 96:1215-1222; 2001. 198. Shan S, Lockhart AC, Saito WY, Knapp AM, Laderoute KR, DEWHIRST MW, The novel
tubulin-binding drug BTO-956 inhibits R3230 Ac mammary carcinoma growth and angiogenesis in Fischer 344 rats. Clin Cancer Res 7:2590-2596, 2001.
199. Neeman M, Dafni H, Bukhari O, Braun R, DEWHIRST MW, In vivo bold contrast MRI
mapping of subcutaneous vascular function and maturation: Validation by intravital microscopy. Magn Reson Med 45:887-898, 2001.
200. Ettinger SN, Peollmann CC, Wisniewski NA, Gaskin AA, Shoemaker JS, Poulson JM, DEWHIRST MW, Klitzman B, Urea as a recovery marker for quantitative assessment of tumor interstitial solutes with microdialysis. Cancer Res, 61:7964-7970, 2001.
201. Meyer DE, Kong GA, DEWHIRST MW, Zalutsky MR, Chilkoti A, Targeting a genetically
engineered elastin-like polypeptide to solid tumors by local hyperthermia, Cancer Res 61:1548-1554, 2001.
202. Snyder S, Lanzen J, Braun R, Rosner G, Secomb T, Biaglow, J, Brizel D, DEWHIRST
MW, Simultaneous administration of glucose and hyperoxic gas achieves greater improvement in tumor oxygenation than hyperoxic gas alone. Int J Radiat Oncol Biol Phys 51:494-506, 2001.
203. Brizel D, Schroeder T, Scher R, Walenta S, DEWHIRST MW, Mueller-Kleiser W,
Elevated tumor lactate concentrations predict for an increased risk of metastases in head and neck cancer. Int J Radiat Oncol Biol Phys 51:349-353, 2001.
204. Braun R, Lanzen J, Snyder S, DEWHIRST MW, Comparison of tumor and normal tissue
oxygen tension measurements using oxylite or microelectrodes in rodents. Am J Physiol Heart Circ Physiol 280:2533-2544, 2001.
205. Walenta S, Nat R, Snyder S, Haroon Z, Braun R, Amin K, Brizel D, Mueller-Klieser W,
Chance B, DEWHIRST MW, Tissue gradients of energy metabolites mirror oxygen tension gradients in a rat mammary carcinoma model. Int J Radiat Oncol Biol Phys 51:494-506, 2001.
206. Connor C, Norris J, Broadwater G, Willson T, Gottardis M, DEWHIRST MW, McDonnell
D, Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. Cancer Res 61:2917-2922, 2001.
19
207. Meyer D, Shin B, Kong G, DEWHIRST MW, Chilkoti A, Drug targeting using thermally responsive polymers and local hyperthermia. J Control Release 74:213-214, 2001.
208. Tozer G, Prise V, Wilson J, Cemazar M, Shan S, DEWHIRST MW, Barber P, Vojnovic B, Chaplin D, Mechanismsed associated with tumor vascular shut-down induced by combretastatin A-4 Phosphate: Intravital microscopy and measurement of vascular permeability. Cancer Res 61:6413-6422, 2001.
209. Li CY, Little JB, Hu K, Zhang W, Zhang L, DEWHIRST MW, Huang Q, Persistent
genetic instability in cancer cells induced by non-DNA- damaging stress exposures. Cancer Res. 61:428-432, 2001.
210. Vujaskovic Z, Anscher MS, Feng QF, Rabbani ZN, Amin K, Samulski TS, DEWHIRST
MW, Haroon ZA, Radiation-induced hypoxia may perpetuate late normal tissue injury. Int J Radiat Oncol Biol Phys 50:851-855, 2001.
211. Maguire PD, Samulski TV, Prosnitz LR, Jones EL, Rosner GL, Powers B, Layfield LW,
Brizel DM, Scully SP, Harrelson JM, DEWHIRST MW, A phase II trial testing the thermal dose parameter CEM43 ° T90 as a predictor of response in soft tissue sarcomas treated with pre-operative thermoradiotherapy. Int J Hyperthermia 17: 283-290, 2001.
212. Lal A, Peters H, St Croix B, Haroon ZA, DEWHIRST MW, Strausberg RL, Kaanders JH,
van Der Kogel AJ, Riggins GJ, Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 93:1337-1343, 2001.
213. Lohr F, Lo DY, Zaharoff DA, HU K, Zhang X, Li Y, Zhao, Y, DEWHIRST MW, Yuan F, Li
CY, Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation. Cancer Res 61:3281-3284, 2001.
214. Kong G, Braun RD, DEWHIRST MW, Characterization of the effect of hyperthermia on
nanoparticle extravasation from tumor vasculature. Cancer Res 61:3027-3032, 2001. 215. Lohr F, Huang Q, Kang H, DEWHIRST MW, Li C, Systemic vector leakage and
transgene expression by intratumorally injected recombinant adenovirus vectors. Clin Cancer Res 7:3625-3628, 2001.
216. Pogue B, Braun R, Lanzen J, Erickson C, DEWHIRST MW, Analysis of the
heterogeneity of pO2 dynamics during photodynamic therapy with verteporfin. Photochem Photobiol 74:700–706, 2001.
217. Needham D, DEWHIRST MW, The development and testing of a new temperature-
sensitive drug delivery system for the treatment of solid tumors. Advanced Drug Delivery Reviews 53:285-305, 2001.
218. Braun R, Lanzen J, Turnage J, Rosner G, DEWHIRST MW, Effects of the interaction
between carbogen and nicotinamide on R3230 Ac tumor blood flow in Fischer 344 rats. Radiation Research 155:724-733, 2001.
219. DEWHIRST MW, Shan, S., Cao, Y., Moeller, B., Yuan, F., and Li, C. Y. Intravital
fluorescence facilitates measurement of multiple physiologic functions and gene expression in tumors of live animals. Dis Markers, 18: 293-311, 2002.
20
220. Dynlacht, J. R., DEWHIRST MW, Hall, E. J., Rosenstein, B. S., and Zeman, E. M. Toward a consensus on radiobiology teaching to radiation oncology residents. Radiat Res, 157: 599-606, 2002.
221. Hale, L. P., Braun, R. D., Gwinn, W. M., Greer, P. K., and DEWHIRST MW, Hypoxia in
the thymus: role of oxygen tension in thymocyte survival. Am J Physiol Heart Circ Physiol, 282: H1467-1477, 2002.
222. Haroon, Z. A., Amin, K., Saito, W., Wilson, W., Greenberg, C. S., and DEWHIRST MW,
SU5416 delays wound healing through inhibition of TGF-beta 1 activation. Cancer Biol Ther, 1: 121-126, 2002.
223. Kavanagh, B. D., Secomb, T. W., Hsu, R., Lin, P. S., Venitz, J., and DEWHIRST MW, A
theoretical model for the effects of reduced hemoglobin-oxygen affinity on tumor oxygenation. Int J Radiat Oncol Biol Phys, 53: 172-179., 2002.
224. Li, C. Y. and DEWHIRST MW, Hyperthermia-regulated immunogene therapy. Int J
Hyperthermia, 18: 586-596, 2002. 225. Vujaskovic, Z., Batinic-Haberle, I., Rabbani, Z. N., Feng, Q. F., Kang, S. K., Spasojevic,
I., Samulski, T. V., Fridovich, I., DEWHIRST MW, and Anscher, M. S. A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic Biol Med, 33: 857-863, 2002.
226. Wong, C. W., Song, C., Grimes, M. M., Fu, W., DEWHIRST MW, Muschel, R. J., and
Al-Mehdi, A. B. Intravascular location of breast cancer cells after spontaneous metastasis to the lung. Am J Pathol, 161(3): 749-753. PMCID: PMC1867251.
227. Zeman, E., Dynlacht, J., Rosenstein, B., and DEWHIRST MW, Toward a national
consensus: teaching radiobiology to radiation oncology residents. Int J Radiat Oncol Biol Phys, 54: 861-872, 2002.
228. Biaglow, J. E., Lee, I., Donahue, J., Held, K., Mieyal, J., DEWHIRST MW, and Tuttle, S.
Glutathione depletion or radiation treatment alters respiration and induces apoptosis in R3230Ac mammary carcinoma. Adv Exp Med Biol, 530: 153-164, 2003.
229. Amin, K., Li, J., Chao, W. R., DEWHIRST MW and Haroon, Z. A. Dietary glycine inhibits
angiogenesis during wound healing and tumor growth. Cancer Biol Ther, 2: 173-178, 2003.
230. Blackwell, K. L., Kirkpatrick, J. P., Snyder, S. A., Broadwater, G., Farrell, F., Jolliffe, L.,
Brizel, D. M., and DEWHIRST MW, Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin. Cancer Res, 63: 6162-6165, 2003.
231. Cardenas-Navia, L. I., Braun, R., Lewis, K., and DEWHIRST MW, Comparison of
fluctuations of oxygen tension in FSA, 9L, and R3230AC tumors in rats. Adv Exp Med Biol, 510: 7-12, 2003.
232. DEWHIRST MW and Sneed, P. K. Those in gene therapy should pay closer attention to
lessons from hyperthermia. Int J Radiat Oncol Biol Phys, 57: 597-599; author reply 599-600, 2003.
21
233. DEWHIRST MW, Viglianti, B. L., Lora-Michiels, M., Hanson, M., and Hoopes, P. J. Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia. Int J Hyperthermia, 19: 267-294, 2003.
234. DEWHIRST MW, Lora-Michiels, M., Viglianti, B. L., Dewey, W. C., and Repacholi, M.
Carcinogenic effects of hyperthermia. Int J Hyperthermia, 19: 236-251, 2003. 235. DEWHIRST MW, Mechanisms underlying hypoxia development in tumors. Adv Exp Med
Biol, 510: 51-56, 2003. 236. Erickson, K., Braun, R. D., Yu, D., Lanzen, J., Wilson, D., Brizel, D. M., Secomb, T. W.,
Biaglow, J. E., and DEWHIRST MW. Effect of longitudinal oxygen gradients on effectiveness of manipulation of tumor oxygenation. Cancer Res, 63: 4705-4712, 2003.
237. Eu, J. P., Hare, J. M., Hess, D. T., Skaf, M., Sun, J., Cardenas-Navina, I., Sun, Q. A.,
DEWHIRST MW, Meissner, G., and Stamler, J. S. Concerted regulation of skeletal muscle contractility by oxygen tension and endogenous nitric oxide. Proc Natl Acad Sci U S A, 100: 15229-15234, 2003.
238. Flowers, J. L., Hoffman, R. M., Driscoll, T. A., Wall, M. E., Wani, M. C., Manikumar, G.,
Friedman, H. S., DEWHIRST MW, Colvin, O. M., and Adams, D. J. The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH. Cancer Chemother Pharmacol, 52: 253-261, 2003.
239. Goldstein, L. S., DEWHIRST MW, Repacholi, M., and Kheifets, L. Summary,
conclusions and recommendations: adverse temperature levels in the human body. Int J Hyperthermia, 19: 373-384, 2003.
240. Jones, E. L., Samulski, T. V., DEWHIRST MW, Alvarez-Secord, A., Berchuck, A.,
Clarke-Pearson, D., Havrilesky, L. J., Soper, J., and Prosnitz, L. R. A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma. Cancer, 98: 277-282, 2003.
241. Kang, S. K., Rabbani, Z. N., Folz, R. J., Golson, M. L., Huang, H., Yu, D., Samulski, T.
S., DEWHIRST MW, Anscher, M. S., and Vujaskovic, Z. Overexpression of extracellular superoxide dismutase protects mice from radiation-induced lung injury. Int J Radiat Oncol Biol Phys, 57: 1056-1066, 2003.
242. Kirkpatrick, J. P., Brizel, D. M., and DEWHIRST MW. A mathematical model of tumor
oxygen and glucose mass transport and metabolism with complex reaction kinetics. Radiat Res, 159: 336-344, 2003.
243. Krol, A., DEWHIRST MW and Yuan, F. Effects of cell damage and glycosaminoglycan
degradation on available extravascular space of different dextrans in a rat fibrosarcoma. Int J Hyperthermia, 19: 154-164, 2003.
244. Lee, I., Glickson, J. D., DEWHIRST MW, Leeper, D. B., Burd, R., Poptani, H., Nadal, L.,
McKenna, W. G., and Biaglow, J. E. Effect of mild hyperglycemia +/- meta-iodo-benzylguanidine on the radiation response of R3230 Ac tumors. Adv Exp Med Biol, 530: 177-186, 2003.
22
245. Lockhart, A. C., Braun, R. D., Yu, D., Ross, J. R., DEWHIRST MW, Klitzman, B., Yuan, F., Grichnik, J. M., Proia, A. D., Conway, D. A., Mann, G., and Hurwitz, H. I. A clinical model of dermal wound angiogenesis. Wound Repair Regen, 11: 306-313, 2003.
246. Lockhart, A. C., Braun, R. D., Yu, D., Ross, J. R., DEWHIRST MW, Humphrey, J. S.,
Thompson, S., Williams, K. M., Klitzman, B., Yuan, F., Grichnik, J. M., Proia, A. D., Conway, D. A., and Hurwitz, H. I. Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin Cancer Res, 9: 586-593, 2003.
247. Nair, S., Boczkowski, D., Moeller, B., DEWHIRST MW, Vieweg, J., and Gilboa, E.
Synergy between tumor immunotherapy and antiangiogenic therapy. Blood, 102: 964-971, 2003.
248. Richardson, R. A. and DEWHIRST MW. The effect of nicotinamide & hyperoxic gases
on blood glucose. Adv Exp Med Biol, 510: 375-378, 2003. 249. Rosen, E. L., Blackwell, K. L., Baker, J. A., Soo, M. S., Bentley, R. C., Yu, D., Samulski,
T. V., and DEWHIRST MW. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol, 181: 1275-1282, 2003.
250. Shan, S., Sorg, B., and DEWHIRST MW. A novel rodent mammary window of orthotopic
breast cancer for intravital microscopy. Microvasc Res, 65: 109-117, 2003. 251. Voss, M., Pinheiro, J., Reynolds, J., Greene, R., DEWHIRST MW, Vaslef, S. N., Clary,
E., and Eubanks, W. S. Endoscopic components separation for abdominal compartment syndrome. Am J Surg, 186: 158-163, 2003.
252. Vujaskovic, Z., Rosen, E. L., Blackwell, K. L., Jones, E. L., Brizel, D. M., Prosnitz, L. R.,
Samulski, T. V., and DEWHIRST MW. Ultrasound guided pO2 measurement of breast cancer reoxygenation after neoadjuvant chemotherapy and hyperthermia treatment. Int J Hyperthermia, 19: 498-506, 2003.
253. White, R. R., Shan, S., Rusconi, C. P., Shetty, G., DEWHIRST MW, Kontos, C. D., and
Sullenger, B. A. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci U S A, 100(9): 5028-5033, 2003. PMCID: PMC154292.
254. Zhang, X., Li, Y., Huang, Q., Wang, H., Yan, B., DEWHIRST MW and Li, C. Y.
Increased resistance of tumor cells to hyperthermia mediated by integrin-linked kinase. Clin Cancer Res, 9: 1155-1160, 2003.
255. Abdel-Wahab, O. I., Grubbs, E., Viglianti, B. L., Cheng, T. Y., Ueno, T., Ko, S., Rabbani,
Z., Curtis, S., Pruitt, S. K., DEWHIRST MW and Tyler, D. S. The role of hyperthermia in regional alkylating agent chemotherapy. Clin Cancer Res, 10: 5919-5929, 2004.
256. Blackwell, K., Hurwitz, H., Lieberman, G., Novotny, W., Snyder, S., DEWHIRST MW,
and Greenberg, C. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer, 101: 77-82, 2004.
257. Blackwell, K. L., DEWHIRST MW, Liotcheva, V., Snyder, S., Broadwater, G., Bentley,
R., Lal, A., Riggins, G., Anderson, S., Vredenburgh, J., Proia, A., and Harris, L. N. HER-
23
2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin Cancer Res, 10: 4083-4088, 2004.
258. Cardenas-Navia, L. I., Yu, D., Braun, R. D., Brizel, D. M., Secomb, T. W., and
DEWHIRST MW. Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing. Cancer Res, 64: 6010-6017, 2004.
259. Chen, Q., Tong, S., DEWHIRST MW, and Yuan, F. Targeting tumor microvessels using
doxorubicin encapsulated in a novel thermosensitive liposome. Mol Cancer Ther, 3: 1311-1317, 2004.
260. Das, S. K., Miften, M. M., Zhou, S., Bell, M., Munley, M. T., Whiddon, C. S.,
Craciunescu, O., Baydush, A. H., Wong, T., Rosenman, J. G., DEWHIRST MW, and Marks, L. B. Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions. Med Phys, 31: 1452-1461, 2004.
261. Dreher, M. R., Elas, M., Ichikawa, K., Barth, E. D., Chilkoti, A., Rosen, G. M., Halpern,
H. J., and DEWHIRST MW. Nitroxide conjugate of a thermally responsive elastin-like polypeptide for noninvasive thermometry. Med Phys, 31: 2755-2762, 2004.
262. Jones, E. L., Prosnitz, L. R., DEWHIRST MW, Marcom, P. K., Hardenbergh, P. H.,
Marks, L. B., Brizel, D. M., and Vujaskovic, Z. Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clin Cancer Res, 10: 4287-4293, 2004.
263. Kim, S. J., Rabbani, Z. N., Vollmer, R. T., Schreiber, E. G., Oosterwijk, E., DEWHIRST
MW, Vujaskovic, Z., and Kelley, M. J. Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res, 10: 7925-7933, 2004.
264. Kirkpatrick, J. P., Cardenas-Navia, L. I., and DEWHIRST MW. Predicting the effect of
temporal variations in PO2 on tumor radiosensitivity. Int J Radiat Oncol Biol Phys, 59: 822-833, 2004.
265. Moeller, B. J., Cao, Y., Li, C. Y., and DEWHIRST MW. Radiation activates HIF-1 to
regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell, 5: 429-441, 2004.
266. Moeller, B. J. and DEWHIRST MW. Raising the bar: how HIF-1 helps determine tumor
radiosensitivity. Cell Cycle, 3: 1107-1110, 2004. 267. Peters, K. G., Kontos, C. D., Lin, P. C., Wong, A. L., Rao, P., Huang, L., DEWHIRST
MW, and Sankar, S. Functional significance of Tie2 signaling in the adult vasculature. Recent Prog Horm Res, 59: 51-71, 2004.
268. Poulson, J. M., Vujaskovic, Z., Gaskin, A. A., Larue, S. M., Meyer, R. E., Prescott, D. M.,
Samulski, T. V., Thrall, D. E., and DEWHIRST MW. Effect of calcitonin gene related peptide vs sodium nitroprusside to increase temperature in spontaneous canine tumours during local hyperthermia. Int J Hyperthermia, 20: 477-489, 2004.
269. Sarraf-Yazdi, S., Mi, J., DEWHIRST MW and Clary, B. M. Use of in vivo
bioluminescence imaging to predict hepatic tumor burden in mice. J Surg Res, 120: 249-255, 2004.
24
270. Secomb, T. W., Hsu, R., and DEWHIRST MW. Synergistic effects of hyperoxic gas breathing and reduced oxygen consumption on tumor oxygenation: a theoretical model. Int J Radiat Oncol Biol Phys, 59: 572-578, 2004.
271. Secomb, T. W., Hsu, R., Park, E. Y., and DEWHIRST MW. Green's function methods
for analysis of oxygen delivery to tissue by microvascular networks. Ann Biomed Eng, 32: 1519-1529, 2004.
272. Viglianti, B. L., Abraham, S. A., Michelich, C. R., Yarmolenko, P. S., MacFall, J. R.,
Bally, M. B., and DEWHIRST MW. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med, 51: 1153-1162, 2004.
273. Ward, E. R., Hedlund, L. W., Kurylo, W. C., Wheeler, C. T., Cofer, G. P., DEWHIRST
MW, Marks, L. B., and Vujaskovic, Z. Proton and hyperpolarized helium magnetic resonance imaging of radiation-induced lung injury in rats. Int J Radiat Oncol Biol Phys, 58: 1562-1569, 2004.
274. Zhang, X., Kon, T., Wang, H., Li, F., Huang, Q., Rabbani, Z. N., Kirkpatrick, J. P.,
Vujaskovic, Z., DEWHIRST MW, and Li, C. Y. Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res, 64: 8139-8142, 2004.
275. Anscher, M. S., Chen, L., Rabbani, Z., Kang, S., Larrier, N., Huang, H., Samulski, T. V.,
DEWHIRST MW, Brizel, D. M., Folz, R. J., and Vujaskovic, Z. Recent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapy. Int J Radiat Oncol Biol Phys, 62: 255-259, 2005.
276. Das, S. K., Baydush, A. H., Zhou, S., Miften, M., Yu, X., Craciunescu, O., Oldham, M.,
Light, K., Wong, T., Blazing, M., Borges-Neto, S., DEWHIRST MW, and Marks, L. B. Predicting radiotherapy-induced cardiac perfusion defects. Med Phys, 32: 19-27, 2005.
277. DEWHIRST MW, Poulson, J. M., Yu, D., Sanders, L., Lora-Michiels, M., Vujaskovic, Z.,
Jones, E. L., Samulski, T. V., Powers, B. E., Brizel, D. M., Prosnitz, L. R., and Charles, H. C. Relation between pO2, 31P magnetic resonance spectroscopy parameters and treatment outcome in patients with high-grade soft tissue sarcomas treated with thermoradiotherapy. Int J Radiat Oncol Biol Phys, 61: 480-491, 2005.
278. Jones, E. L., Oleson, J. R., Prosnitz, L. R., Samulski, T. V., Vujaskovic, Z., Yu, D.,
Sanders, L. L., and DEWHIRST MW. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol, 23: 3079-3085, 2005.
279. Mazooz, G., Mehlman, T., Lai, T. S., Greenberg, C. S., DEWHIRST MW, and Neeman,
M. Development of magnetic resonance imaging contrast material for in vivo mapping of tissue transglutaminase activity. Cancer Res, 65: 1369-1375, 2005.
280. Sonveaux, P., Kaz, A. M., Snyder, S. A., Richardson, R. A., Cardenas-Navia, L. I.,
Braun, R. D., Pawloski, J. R., Tozer, G. M., Bonaventura, J., McMahon, T. J., Stamler, J. S., and DEWHIRST MW. Oxygen Regulation of Tumor Perfusion by S-Nitrosohemoglobin Reveals a Pressor Activity of Nitric Oxide. Circ Res, 96: 1119-26, 2005.
281. Alvarez Secord, A., Jones, E. L., Hahn, C. A., Petros, W. P., Yu, D., Havrilesky, L. J.,
Soper, J. T., Berchuck, A., Spasojevic, I., Clarke-Pearson, D. L., Prosnitz, L. R., and
25
DEWHIRST MW. Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer. Int J Hyperthermia, 21: 333-347, 2005.
282. Cao, Y., Li, C. Y., Moeller, B. J., Yu, D., Zhao, Y., Dreher, M. R., Shan, S., and
DEWHIRST MW. Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation. Cancer Res, 65: 5498-5505, 2005.
283. Hahn, C. A., Jones, E. L., Blivin, J. L., Sanders, L. L., Yu, D., DEWHIRST MW, Secord,
A. A., and Prosnitz, L. R. Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicin. Int J Hyperthermia, 21: 349-357, 2005.
284. Hart, J. P., Broadwater, S. G., Rabbani, D. Z., Moeller, B. J., Clough, R., Huang, D.,
Sempowski, G. A., DEWHIRST MW, Pizzo, S. V., Vujaskovic, Z., and Anscher, M. S. Cytokine profiling for prediction of symptomatic radiation-induced lung injury. Int J Radiat Oncol Biol Phys, 2005.
285. Jones, E. L., Prosnitz, L. R., DEWHIRST MW, Vujaskovic, Z., Samulski, T. V., Oleson,
J. R., Yu, D., Myerson, R. J., Moros, E. G., Hurwitz, M. D., and Bull, J. M. In regard to Vasanathan et al. (Int J Radiat Oncol Biol Phys 2005;61:145-153). Int J Radiat Oncol Biol Phys, 63: 644, 2005.
286. Kim, S. J., Rabbani, Z. N., DEWHIRST MW, Vujaskovic, Z., Vollmer, R. T., Schreiber, E.
G., Oosterwijk, E., and Kelley, M. J. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer, 49: 325-335, 2005.
287. Moeller, B. J., Batinic-Haberle, I., Spasojevic, I., Rabbani, Z. N., Anscher, M. S.,
Vujaskovic, Z., and DEWHIRST MW. A manganese porphyrin superoxide dismutase mimetic enhances tumor radioresponsiveness. Int J Radiat Oncol Biol Phys, 63: 545-552, 2005.
288. Moeller, B. J., Dreher, M. R., Rabbani, Z. N., Schroeder, T., Cao, Y., Li, C. Y., and
DEWHIRST MW. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell, 8: 99-110, 2005.
289. Provenzale, J. M., Mukundan, S., and DEWHIRST MW. The role of blood-brain barrier
permeability in brain tumor imaging and therapeutics. AJR Am J Roentgenol, 185: 763-767, 2005.
290. Rabbani, Z. N., Anscher, M. S., Folz, R. J., Archer, E., Huang, H., Chen, L., Golson, M.
L., Samulski, T. S., DEWHIRST MW, and Vujaskovic, Z. Overexpression of extracellular superoxide dismutase reduces acute radiation induced lung toxicity. BMC Cancer, 5:59: 10.1186/1471-2407, 2005. PMCID: PMC1177930.
291. Schroeder, T., Yuan, H., Viglianti, B. L., Peltz, C., Asopa, S., Vujaskovic, Z., and
DEWHIRST MW. Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. Cancer Res, 65: 5163-5171, 2005.
292. Sorg, B. S., Moeller, B. J., Donovan, O., Cao, Y., and DEWHIRST MW. Hyperspectral
imaging of hemoglobin saturation in tumor microvasculature and tumor hypoxia development. J Biomed Opt, 10: 44004, 2005.
26
293. Sorg, B. S., Peltz, C. D., Klitzman, B., and DEWHIRST MW. Method for improved accuracy in endogenous urea recovery marker calibrations for microdialysis in tumors. J Pharmacol Toxicol Methods, 2005.
294. Thrall, D. E., LaRue, S. M., Yu, D., Samulski, T., Sanders, L., Case, B., Rosner, G.,
Azuma, C., Poulson, J., Pruitt, A. F., Stanley, W., Hauck, M. L., Williams, L., Hess, P., and DEWHIRST MW. Thermal dose is related to duration of local control in canine sarcomas treated with thermoradiotherapy. Clin Cancer Res, 11(14): 5206-5214, 2005. PMCID: PMC2751856.
295. Adams, D. J., Wahl, M. L., Flowers, J. L., Sen, B., Colvin, M., DEWHIRST MW,
Manikumar, G., and Wani, M. C. Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient. Cancer Chemother Pharmacol, 57: 145-154, 2006.
296. Corry, P. M. and DEWHIRST MW Thermal medicine, heat shock proteins and cancer.
Int J Hyperthermia, 21: 675-677, 2005. 297. Das, S. K., Macfall, J., McCauley, R., Craciunescu, O., DEWHIRST MW, and Samulski,
T. V. Improved magnetic resonance thermal imaging by combining proton resonance frequency shift (PRFS) and apparent diffusion coefficient (ADC) data. Int J Hyperthermia, 21: 657-667, 2005.
298. DEWHIRST MW, Vujaskovic, Z., Jones, E., and Thrall, D. Re-setting the biologic
rationale for thermal therapy. Int J Hyperthermia, 21: 779-790, 2005. 299. Hardee, M. E., Kirkpatrick, J. P., Shan, S., Snyder, S. A., Vujaskovic, Z., Rabbani, Z. N.,
DEWHIRST MW. Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. Br J Cancer, 93(12): 1350-1355, 2005.
300. Mi, J., Sarraf-Yazdi, S., Zhang, X., Cao, Y., DEWHIRST MW, Kontos, C. D., Li, C. Y.,
and Clary, B. M. A Comparison of Antiangiogenic Therapies for the Prevention of Liver Metastases. J Surg Res, 2005.
301. Moeller, B. J. and DEWHIRST MW. In regard to Arvold et al. (Int J Radiat Oncol Biol
Phys 2005;62:207-212). Int J Radiat Oncol Biol Phys, 63: 970-971; author reply 971, 2005.
302. Shan, S., Flowers, C., Peltz, C. D., Sweet, H., Maurer, N., Kwon, E. J., Krol, A., Yuan,
F., and DEWHIRST MW. Preferential extravasation and accumulation of liposomal vincristine in tumor comparing to normal tissue enhances antitumor activity. Cancer Chemother Pharmacol 1-11, 2005.
303. Batinic-Haberle I, Spasojevic I, Stevens RD, Bondurant B, Okado-Matsumoto A,
Fridovich I, Vujaskovic Z, DEWHIRST MW: New PEG-ylated Mn(III) porphyrins approaching catalytic activity of SOD enzyme. Dalton Trans:617-24, 2006.
304. Dreher MR, Liu W, Michelich CR, DEWHIRST MW, Yuan F, Chilkoti A: Tumor vascular
permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 98:335-44, 2006
305. Dressman HK, Hans C, Bild A, Olson JA, Rosen E, Marcom PK, Liotcheva VB, Jones
EL, Vujaskovic Z, Marks J, DEWHIRST MW, West M, Nevins JR, Blackwell K: Gene
27
expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 12:819-26, 2006
306. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, DEWHIRST MW: Erythropoietin
biology in cancer. Clin Cancer Res 12:332-9, 2006 307. Hardee ME, Rabbani ZN, Arcasoy MO, Kirkpatrick JP, Vujaskovic Z, DEWHIRST MW,
Blackwell KL: Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther 5:356-61, 2006
308. Kirkpatrick JP, Hardee ME, Snyder SA, Peltz CM, Zhao Y, Brizel DM, DEWHIRST MW,
Blackwell KL: The effect of darbepoetin alfa on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma. Radiat Res 165:192-201, 2006
309. Ko SH, Ueno T, Yoshimoto Y, Yoo JS, Abdel-Wahab OI, Abdel-Wahab Z, Chu E, Pruitt
SK, Friedman HS, DEWHIRST MW, Tyler DS: Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. Clin Cancer Res 12:289-97, 2006
310. Lanzen J, Braun RD, Klitzman B, Brizel D, Secomb TW, DEWHIRST MW: Direct
demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. Cancer Res 66:2219-23, 2006
311. Mi J, Sarraf-Yazdi S, Zhang X, Cao Y, DEWHIRST MW, Kontos CD, Li CY, Clary BM: A
comparison of antiangiogenic therapies for the prevention of liver metastases. J Surg Res 131:97-104, 2006
312. Yan B, Wang H, Peng Y, Hu Y, Wang H, Zhang X, Chen Q, Bedford JS, DEWHIRST
MW, Li CY: A unique role of the DNA fragmentation factor in maintaining genomic stability. Proc Natl Acad Sci U S A 2006 January 31; 103(5):1504-1509. PMCID: PMC1360538.
313. Hauck, ML, Larue, SM, Petros, WP, Poulson, JM, Yu, D, Spasojevic, I, Pruitt, AF, Klein,
A, Case, B, Thrall, DE, Needham, D, and DEWHIRST MW Phase I trial of Doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. Clin Cancer Res 12: 4004-4010, 2006
314. Jackson, IL, Batinic-Haberle, I, Sonveaux, P, DEWHIRST MW, and Vujaskovic, Z ROS
production and angiogenic regulation by macrophages in response to heat therapy. Int J Hyperthermia 22: 263-273, 2006.
315. Jones, E, Alvarez Secord, A, Prosnitz, LR, Samulski, TV, Oleson, JR, Berchuck, A,
Clarke-Pearson, D, Soper, J, DEWHIRST MW, and Vujaskovic, Z Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma. Int J Hyperthermia 22: 161-172, 2006.
316. Jones, E, Thrall, D, DEWHIRST MW, and Vujaskovic, Z Prospective thermal dosimetry:
the key to hyperthermia's future. Int J Hyperthermia 22: 247-253, 2006. 317. Kelly, P, Moeller, BJ, Juneja, J, Booden, MA, Der, CJ, Daaka, Y, DEWHIRST MW,
Fields, TA, and Casey, PJ. The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. Proc Natl Acad Sci USA 2006 May 23; 103(21): 8173-8178. PMCID: PMC1472448.
28
318. Moeller BJ and DEWHIRST MW, HIF-1 and tumour radiosensitivity. Br J Cancer
2006:95(1):1-5. PMCID: PMC2360497. 319. Ponce, AM, Vujaskovic, Z, Yuan, F, Needham, D, and DEWHIRST MW Hyperthermia
mediated liposomal drug delivery. Int J Hyperthermia 22: 205-213, 2006. 320. Siddiqui, F, Li, CY, Zhang, X, Larue, SM, DEWHIRST MW, Ullrich, RL, and Avery, PR
Characterization of a recombinant adenovirus vector encoding heat-inducible feline interleukin-12 for use in hyperthermia-induced gene-therapy. Int J Hyperthermia 22: 117-134, 2006.
321. Kleiter MM, Yu D, Mohammadian LA, Niehaus N, Spasojevic I, Sanders L, Viglianti BL,
Yarmolenko PS, Hauck M, Petry NA, Wong TZ, DEWHIRST MW, Thrall DE. A tracer dose of technetium-99m-labeled liposomes can estimate the effect of hyperthermia on intratumoral doxil extravasation. Clin Cancer Res 2006;12(22):6800-7.
322. McGuire SM, Zhou S, Marks LB, DEWHIRST MW, Yin FF, Das SK. A methodology for
using SPECT to reduce intensity-modulated radiation therapy (IMRT) dose to functioning lung. International journal of radiation oncology, biology, physics 2006;66(5):1543-52.
323. Thrall, DE, DEWHIRST MW, Jones, EL, Vujaskovic, Z, Yu, D, and Craciunescu, OI A
clinically proven, prospective, thermal dose descriptor exists. Clin Cancer Res 12: 1944-1945, 2006.
324. Tong, S, Chen, Q, Shan, SQ, DEWHIRST MW, and Yuan, F Quantitative comparison of
the inhibitory effects of GW5638 and tamoxifen on angiogenesis in the cornea pocket assay. Angiogenesis, 2006.
325. Yan, B, Wang, H, Wang, H, Zhuo, D, Li, F, Kon, T, DEWHIRST MW, and Li, CY
Apoptotic DNA fragmentation factor maintains chromosome stability in a P53-independent manner. Oncogene, 2006.
326. Yuan, H, Schroeder, T, Bowsher, JE, Hedlund, LW, Wong, T, and DEWHIRST MW
Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 47: 989-998, 2006.
327. Adams, D. J., Wahl, M. L., Flowers, J. L., Sen, B., Colvin, M., DEWHIRST MW,
Manikumar, G., and Wani, M. C. Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient. Cancer Chemother Pharmacol, 57: 145-154, 2006.
328. Anscher, M. S., Garst, J., Marks, L. B., Larrier, N., Dunphy, F., Herndon, J. E., 2nd,
Clough, R., Marino, C., Vujaskovic, Z., Zhou, S., DEWHIRST MW, Shafman, T. D., and Crawford, J. Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. Int J Radiat Oncol Biol Phys, 66: 477-482, 2006.
329. Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., DEWHIRST MW,
Bigner, D. D., and Rich, J. N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444: 756-760, 2006.
29
330. Hicks, K. O., Pruijn, F. B., Secomb, T. W., Hay, M. P., Hsu, R., Brown, J. M., Denny, W. A., DEWHIRST MW, and Wilson, W. R. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst, 98: 1118-1128, 2006.
331. Lora-Michiels, M., Yu, D., Sanders, L., Poulson, J. M., Azuma, C., Case, B., Vujaskovic,
Z., Thrall, D. E., Charles, H. C., and DEWHIRST MW. Extracellular pH and P-31 magnetic resonance spectroscopic variables are related to outcome in canine soft tissue sarcomas treated with thermoradiotherapy. Clin Cancer Res, 12: 5733-5740, 2006.
332. Oldham, M., Sakhalkar, H., Oliver, T., Wang, Y. M., Kirpatrick, J., Cao, Y., Badea, C.,
Johnson, G. A., and DEWHIRST MW. Three-dimensional imaging of xenograft tumors using optical computed and emission tomography. Med Phys, 33: 3193-3202, 2006.
333. Oltean, S., Sorg, B. S., Albrecht, T., Bonano, V. I., Brazas, R. M., DEWHIRST MW, and
Garcia-Blanco, M. A. Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc Natl Acad Sci U S A, 2006 September 19; 103(38): 14116-14121. PMCID: PMC1562548.
334. Shan, S., Flowers, C., Peltz, C. D., Sweet, H., Maurer, N., Kwon, E. J., Krol, A., Yuan,
F., and DEWHIRST MW. Preferential extravasation and accumulation of liposomal vincristine in tumor comparing to normal tissue enhances antitumor activity. Cancer Chemother Pharmacol, 58: 245-255, 2006.
335. Siddiqui, F., Ehrhart, E. J., Charles, B., Chubb, L., Li, C. Y., Zhang, X., Larue, S. M.,
Avery, P. R., DEWHIRST MW, and Ullrich, R. L. Anti-angiogenic effects of interleukin-12 delivered by a novel hyperthermia induced gene construct. Int J Hyperthermia, 22: 587-606, 2006.
336. Thrall, D. E., Larue, S. M., Pruitt, A. F., Case, B., and DEWHIRST MW. Changes in
tumour oxygenation during fractionated hyperthermia and radiation therapy in spontaneous canine sarcomas. Int J Hyperthermia, 22: 365-373, 2006.
337. Viglianti, B. L., Ponce, A. M., Michelich, C. R., Yu, D., Abraham, S. A., Sanders, L.,
Yarmolenko, P. S., Schroeder, T., MacFall, J. R., Barboriak, D. P., Colvin, O. M., Bally, M. B., and DEWHIRST MW. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med, 56: 1011-1018, 2006.
338. Vlahovic, G., Rabbani, Z. N., Herndon, J. E., 2nd, DEWHIRST MW, and Vujaskovic, Z.
Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br J Cancer, 95: 1013-1019, 2006.
339. Yan B, Wang H, Rabbani ZN, Zhao Y, Li W, Yuan Y, Li F, DEWHIRST MW, Li CY.
Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. Cancer research 2006;66(24):11565-70.
340. Yan B, Wang H, Wang H, Zhuo D, Li F, Kon T, DEWHIRST MW, Li CY. Apoptotic DNA
fragmentation factor maintains chromosome stability in a P53-independent manner. Oncogene 2006;25(39):5370-6.
30
341. Cao Y, Sonveaux P, Liu S, Zhao Y, Mi J, Clary BM, Li CY, Kontos CD, DEWHIRST MW. Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer research 2007;67(8):3835-44.
342. Cardenas-Navia LI, Richardson RA, DEWHIRST MW. Targeting the molecular effects of
a hypoxic tumor microenvironment. Front Biosci 2007;12:4061-78. 343. Cardenas-Navia LI, Secomb TW, DEWHIRST MW. Effects of fluctuating oxygenation on
tirapazamine efficacy: Theoretical predictions. International journal of radiation oncology, biology, physics 2007;67(2):581-6.
344. Chi SL, Wahl ML, Mowery YM, Shan S, Mukhopadhyay S, Hilderbrand SC, Kenan DJ,
Lipes BD, Johnson CE, Marusich MF, Capaldi RA, DEWHIRST MW, Pizzo SV. Angiostatin-like activity of a monoclonal antibody to the catalytic subunit of F1F0 ATP synthase. Cancer research 2007;67(10):4716-24.
345. Das SK, Zhou S, Zhang J, Yin FF, DEWHIRST MW, Marks LB. Predicting lung
radiotherapy-induced pneumonitis using a model combining parametric Lyman probit with nonparametric decision trees. Int J Radiat Oncol Biol Phys. 2007 July 15; 68(4): 1212-1221. PMCID: PMC2668833.
346. Davis BH, Schroeder T, Yarmolenko PS, Guilak F, DEWHIRST MW, Taylor DA. An in
vitro system to evaluate the effects of ischemia on survival of cells used for cell therapy. Annals of biomedical engineering 2007;35(8):1414-24.
347. DEWHIRST MW. Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-
1 targeting. Cancer research 2007;67(3):854-5. 348. DEWHIRST MW, Cao Y, Li CY, Moeller B. Exploring the role of HIF-1 in early
angiogenesis and response to radiotherapy. Radiother Oncol 2007; June; 83(3):249-255. PMCID: PMC2694841.
349. DEWHIRST MW, Navia IC, Brizel DM, Willett C, Secomb TW. Multiple etiologies of
tumor hypoxia require multifaceted solutions. Clin Cancer Res 2007;13(2 Pt 1):375-7. 350. Dreher MR, Liu W, Michelich CR, DEWHIRST MW, Chilkoti A. Thermal cycling
enhances the accumulation of a temperature-sensitive biopolymer in solid tumors. Cancer research 2007;67(9):4418-24.
351. Hardee ME, Cao Y, Fu P, Jiang X, Zhao Y, Rabbani ZN, Vujaskovic Z, DEWHIRST MW,
Arcasoy MO. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE 2007 Jun 20;2(6):e549. PMCID: PMC1891087.
352. Huang JH, Cardenas-Navia LI, Caldwell CC, Plumb TJ, Radu CG, Rocha PN, Wilder T,
Bromberg JS, Cronstein BN, Sitkovsky M, DEWHIRST MW, Dustin ML. Requirements for T lymphocyte migration in explanted lymph nodes. J Immunol 2007;178(12):7747-55.
353. Li F, Sonveaux P, Rabbani ZN, Liu S, Yan B, Huang Q, Vujaskovic Z, DEWHIRST MW,
Li CY. Regulation of HIF-1alpha stability through S-nitrosylation. Molecular cell 2007;26(1):63-74.
354. Moeller BJ, Richardson RA, DEWHIRST MW. Hypoxia and radiotherapy: opportunities
for improved outcomes in cancer treatment. Cancer metastasis reviews 2007;26(2):241-8.
31
355. Moon EJ, Brizel DM, Chi JT, DEWHIRST MW. The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxidants & redox signaling 2007;9(8):1237-94. PMID: 17571959.
356. Oldham M, Sakhalkar H, Wang YM, Guo P, Oliver T, Bentley R, Vujaskovic Z,
DEWHIRST MW. Three-dimensional imaging of whole rodent organs using optical computed and emission tomography. Journal of biomedical optics 2007;12(1):014009.
357. Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, Bally MB,
DEWHIRST MW. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. Journal of the National Cancer Institute 2007;99(1):53-63.
358. Rabbani ZN, Batinic-Haberle I, Anscher MS, Huang J, Day BJ, Alexander E,
DEWHIRST MW, Vujaskovic Z. Long-term administration of a small molecular weight catalytic metalloporphyrin antioxidant, AEOL 10150, protects lungs from radiation-induced injury. Int J Radiat Oncol Biol Phys. 2007 February 1; ;67(2):573-580. PMCID: PMC1819401.
359. Sakhalkar HS, DEWHIRST MW, Oliver T, Cao Y, Oldham M. Functional imaging in bulk
tissue specimens using optical emission tomography: fluorescence preservation during optical clearing. Physics in medicine and biology 2007;52(8):2035-54.
360. Siddiqui F, Li CY, Larue SM, Poulson JM, Avery PR, Pruitt AF, Zhang X, Ullrich RL,
Thrall DE, DEWHIRST MW, Hauck ML. A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas. Molecular cancer therapeutics. 2007;6(1):380-9.
361. Zennadi R, Moeller BJ, Whalen EJ, Batchvarova M, Xu K, Shan S, Delahunty M,
DEWHIRST MW, Telen MJ. Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. Blood 2007, Oct.1; 110(7): 2708-2717. PMCID: PMC1988948.
362. Gridley DS, Makinde AY, Luo X, Rizvi A, Crapo JD, DEWHIRST MW, Moeller BJ, Pearlstein RD, Slater JM. Radiation and a metalloporphyrin radioprotectant in a mouse prostate tumor model. Anticancer Res. 2007; (5A):3101-9. PMID: 17970050. 363. Rabbani ZN, Salahuddin FK, Yrmolenko P, Batinic-Haberle I, Thrasher BA, Gauter- Fleckenstein B, DEWHIRST MW, Anscher MS, Vujaskovic Z. Low molecular weight catalytic metalloporphyrin antioxidant AEOL 10150 protects lungs from franctionated radiation. Free Radic Res. 2007; 1-10. PMID: 17957541. 364. Cheng KS, Stakhursky V, Stauffer P, DEWHIRST MW, Das SK. Online feedback focusing algorithm for hyperthermia cancer treatment. Int J Hyperthermia. 2007; Nov;23(7):539-54. PMCID: PMC2699762. 365. Zhou SM, Das SK, Wang Z, Sun X, DEWHIRST MW, Yin FF, Marks LB. Self- consistent tumor control probability and normal tissue complication probability models based on generalized EUD. Med Phys. 2007; 34(7):2807-15. PMID: 17821988. 366. Vlahovic G, Ponce AM, Rabbani Z, Salahuddin FK, Zgonjanin L, Spasojevic I, Vujaskovic Z and DEWHIRST MW. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer. 2007 September 11;97(6):735-740. PMCID: PMC2360385.
32
367. Mi J, Zhang X, Rabbani ZN, Liu Y, Reddy SK, Su Z, Salahuddin FK, Viles K, Giangrande PH, DEWHIRST MW, Sullenger BA, Kontos CD, Clary BM. RNA Aptamer-targeted Inhibition of NF-kappaB Suppresses Non-small Cell Lung Cancer Resistance to Doxorubicin. Mol Ther. 2008 Jan;16(1):66-73. PMID: 17912235. 368. Tashjian JA, DEWHIRST, MW, Needham D, and Viglianti BL. Rationale for and measurement of liposomal drug delivery with hyperthermia using non-invasive imaging techniques. Int J Hyperthermia. 2008 February; 24(1): 79-90. PMCID: PMC2755546. 369. Wong TZ, Lacy JL, Petry NA, Hawk TC, Sporn TA, DEWHIRST MW, Vlahovic G. PET of hypoxia and perfusion with 62Cu-ATSM and 62Cu-PTSM using a 62Zn/62Cu generator. AJR Am J Roentgenol. 2008 Feb;190(2):427-32. PMID: 18212229. 370. Chen Q, Krol A, Wright A, Needham D, DEWHIRST MW, Yuan F. Tumor microvascular
permeability is a key determinant for antivascular effects of doxorubicin encapsulated in a temperature sensitive liposome. Int J Hyperthermia. 2008 September; 24(6): 475-482. PMCID: PMC2577202.
371. Cheng KS, Stakhursky V, Craciunescu OI, Stauffer P, DEWHIRST MW, Das SK. Fast
temperature optimization of multi-source hyperthermia applicators with reduced-order modeling of 'virtual sources. Phys Med Biol. 2008 Mar 21;53(6):1619-35. PMCID: PMC2721279.
372. DEWHIRST MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate
angiogenesis and radiotherapy response. Nat Rev Cancer. 2008 Jun;8(6):425-37. PMID: 18500244.
373. Fitzhugh DJ, Shan S, DEWHIRST MW, Hale LP. Bromelain treatment decreases
neutrophil migration to sites of inflammation. Clin Immunol. 2008 July; 128(1):66-74. PMCID: PMC2516972.
374. Manzoor AA, Schroeder T, DEWHIRST MW. One-stop-shop tumor imaging: buy
hypoxia, get lactate free. J Clin Invest. 2008 May 1; 118(5):1616-9. PMCID: PMC2323196.
375. Mi J, Zhang X, Rabbani ZN, Liu Y, Reddy SK, Su Z, Salahuddin FK, Viles K,
Giangrande PH, DEWHIRST MW, Sullenger BA, Kontos CD, Clary BM. RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Mol Ther 2008;16(1):66-73.
376. Oldham M, Sakhalkar H, Oliver T, Allan Johnson G, DEWHIRST MW. Optical clearing of
unsectioned specimens for three-dimensional imaging via optical transmission and emission tomography. J Biomed Opt. 2008 Mar-Apr;13(2):021113. PMCID: PMC2746042.
377. Kirkpatrick JP, DEWHIRST MW. Analytic solution to steady-state radial diffusion of a
substrate with first-order reaction kinetics in the tissue of a Krogh’s cylinder. Radiat Res. 2008 Mar;169(3):350-4. PMID: 18302491.
378. Sarraf-Yazdi S, Mi J, DEWHIRST MW, Clary BM. Use of bioluminescence imaging to
detect enhanced hepatic and systemic tumor growth following partial hepatectomy in mice. Eur J Surg Oncol 2008;34(4):476-81.
33
379. Sarraf-Yazdi S, Mi J, Moeller BJ, Niu X, White RR, Kontos CD, Sullenger BA, DEWHIRST MW, Clary BM. Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. J Surg Res. 208 May 1;146(1):16-23. PMID: 17950331.
380. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE, 2nd, McLendon RE, Desjardins A,
Friedman HS, DEWHIRST MW, Vredenburgh JJ, Rich JN. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008; Jan 10; 26(2):271-278. PMID: 18182667.
381. Sonveaux P, Végran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer
CJ, Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O, DEWHIRST MW. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008; 118(12): 3930-42. PMCID: PMC2582933.
382. Viola RJ, Provenzale JM, Li F, Li CY, Yuan H, Tashjian J, DEWHIRST MW. In Vivo
Bioluminescence Imaging Monitoring of Hypoxia-Inducible Factor 1alpha, a Promoter That Protects Cells, in Response to Chemotherapy. AJR Am J Roentgenol. 2008 Dec; 191
(6):1779-84. PMID: 19020250 383. Stein RA, Chang CY, Kazmin DA, Way J, Schroeder T, Wergin M, DEWHIRST
MW,McDonnell DP. Estrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer. Cancer Res. 2008;68(21):8805-12. PMCID: PMC2633645.
384. Kirkpatrick JP, Rabbani ZN, Bentley RC, Hardee ME, Karol S, Meyer J, Oosterwijk E,
Havrilesky L, Secord AA, Vujaskovic Z, DEWHIRST, MW, and Jones, E. Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer. Biomark Insights. 2008; Feb. 1; 3: 45-55. PMCID: PMC2688355.
385. Cárdenas-Navia LI, Mace D, Richardson RA, Wilson DF, Shan S, DEWHIRST MW. The pervasive presence of fluctuating oxygenation in tumors. Cancer Res. 2008. July
15; 68(14):5812-9. PMID: 18632635 386. Mertyna P, DEWHIRST MW, Halpern E, Goldberg W, Goldberg SN. Radiofrequency
ablation: the effect of distance and baseline temperature on thermal dose required for coagulation. Int J Hyperthermia. 2008 Nov 24 (7):550-9
387. Schroeder T, Viglianti BL, DEWHIRST MW. Low-intensity alternating electric fields: a
potentially safe and effective treatment of cancer? Onkologie. 2008;31(7):357-8. PMCID: PMC2776831.
388. Siddiqui F, Avery PR, Li CY, Zhang X, LaRue SM, DEWHIRST MW, Ullrich RL.
Induction of the human heat shock promoter HSP70B by nutritional stress: implications for cancer gene therapy. Cancer Invest. 2008;26(6):553-61. PMID: 18584345.
389. Sorg BS, Hardee ME, Agarwal N, Moeller BJ, DEWHIRST MW. Spectral imaging
facilitates visualization and measurements of unstable and abnormal microvascular oxygen transport in tumors. J Biomed Opt. 2008;13(1):014026. PMID: 18315384.
390. Chen JL, Lucas JE, Schroeder T, Mori S, Wu J, Nevins J, DEWHIRST MW, West M, Chi JT. The genomic analysis of lactic acidosis and acidosis response in human
34
cancers. PLoS Genet. 2008 Dec;4(12):e1000293. Epub 2008 Dec 5. PMCID: PMC2585811.
391. Kim H, Kasper AC, Moon EJ, Park Y, Wooten CM, DEWHIRST MW, Hong J. Nucleophilic addition of organozinc reagents to 2-sulfonyl cyclic ethers: stereoselective synthesis of manassantins A and B. Org Lett. 2009 1;11(1):89-92. PMCID: PMC2656112.
392. Hardee ME, Eapen RJ, Rabbani ZN, Dreher MR, Marks J, Blackwell KL, DEWHIRST
MW. Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu(+) tumors. Cancer Chemother Pharmacol. 2009 Jan;63(2):219-28. PMID: 18365198.
393. Dewey WC, Diederich CJ, DEWHIRST MW. Hyperthermia classic commentary: ‘Arrhenius relationships from the molecule and cell to the clinic’. Int. J. Hyperthermia, 10:457-483, 1994. Int. J Hyperthermia. 2009 Feb;25(1):21-4. No abstract available. Erratum in: Int J Hyperthermia. 2009 May;25(3):248. Dewhirst, Mark W. (added). PMID: 19219696.
394. Skala MC, Fontanella A, Hendargo H, DEWHIRST MW, Izatt JA. Combined hyperspectral and spectral domain optical coherence tomography microscope for noninvasive hemodynamic imaging. Opt Lett. 2009 Feb 1;34(3):289-91. PMCID: PMC2715151.
395. Kim SJ, Rabbani ZN, Dong F, Vollmer RT, Schreiber EG, DEWHIRST MW, Vujaskovic Z, Kelley MJ. Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. Med Oncol. 2009 Feb 24. (Epub ahead of print)
396. Palmer GM, Viola RJ, Schroeder T, Yarmolenko PS, DEWHIRST MW, Ramanujam N. Quantitative diffuse reflectance and fluorescence spectroscopy: tool to monitor tumor physiology in vivo. J Biomed Opt. 2009 Mar-Apr;14(2):024010. PMCID: PMC2724679.
397. Cheng KS, Yuan Y, Li Z, Stauffer PR, Maccarina P, Joines WT, DEWHIRST MW, Das SK. The performance of a reduced-order adaptive controller when used in multi-antenna hyperthermia treatments with nonlinear temperature-dependent perfusion. Phys Med Biol. 2009; Apr 7;54(7):1979-95. PMCID: PMC2699754.
398. Hardee ME, DEWHIRST MW, Agarwal N, Sorg BS. Novel imaging provides new insights into mechanisms of oxygen transport in tumors. Curr Mol Med. 2009; 9(4):435-41. PMCID: PMC2841217.
399. Stakhursky VL, Arabe O, Cheng KS, Macfall J, Maccarini P, Craciunescu O, DEWHIRST M, Stauffer P, Das SK. Real-time MRI-guided hyperthermia treatment using a fast adaptive algorithm. Phys Med Biol. 2009 Apr 7;54(7):2131-45. PMCID: PMC2699770.
400 Pries AR, Cornelissen AJ, Sloot AA, Hinkeldey M, Dreher MR, Höpfner M, DEWHIRST MW, Secomb TW. Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput Biol. 2009 5(5):e1000394. PMCID: PMC2682204.
401. Vishwanath K, Klein D, Chang K, Schroeder T, DEWHIRST MW, Ramanajam N. Quantiative optical spectroscopy can identify long-term local tumor control in irradiated murine head and neck xenografts. J Biomed Opt 2009; 14(5):054051. PMCID: PMC2776819.
402. Yan B, Wang H, Xie D, Wakamatsu N, Anscher MS, DEWHIRST MW, Mitchel RE, Chen BJ, Li CY. Increased skin carcinogenesis in caspase-activated Dnase knockout mice. Carcinogenesis. 2009 Oct;30(10):1776-80. PMID: 19541853.
35
403. Craciunescu OI, Stauffer PR, Soher BJ, Wyatt CR, Arabe O, Maccarini P, Das SK, Cheng KS, Wong TZ, Jones EL, DEWHIRST MW, Vujaskovic Z, MacFall JR. Accuracy of real time noninvasive termperature measurements using magnetic resonance thermal imaging in patients treated for high grade extremity soft tissue sarcomas. Med Phys. 2009 Nov;36(11):4848-58. PMCID: PMC2773239.
404. DEWHIRST, MW. Relationships between Cycling Hypoxia, HIF-1, Angiogenesis and Oxidative Stress. Radiat Res 2009; Dec;172(6):653-65. PMCID: PMC2790140.
405. Kos I, Rebouças JS, DeFreitas-Silva G, Salvemini D, Vujaskovic Z, DEWHIRST MW, Spasojević I, Batinić-Haberle I. Lipophilicity of potent porphyrin-based antioxidants: comparison of ortho and meta isomers of Mn(III) N-alkylpyridylporphyrins. Free Radic Biol Med. 2009 Jul 1;47(1):72-8. PMCID: PMC2694496.
406. Rabbani ZN, Spasojevic I, Zhang X, Moeller BJ, Haberle S, Vasquez-Vivar J, DEWHIRST MW, Vujaskovic Z, Batinic-Haberle I. Anti-angiogenic action of redox modulating Mn(III) ortho tetrakis N-ethylpyridylporphyrin, MnTE-2-PyP(5+)via suppression of oxidative stress in a mouse model of breast tumor. Radic Biol Med. 2009 Oct 1;47(7):992-1004. PMCID: PMC2749298.
407. Kasper AC, Moon EJ, Hu X, Park Y, Wooten CM, Kim H, Yang W, DEWHIRST MW, Hong J. Analysis of HIF-1 inhibition by manassantin A and an alogues with modified tetrahydrofuran configurations. Bioorg Med Chem Lett. 2009 Jul 15;19(14):3783-6. PMCID: PMC2709708.
408. Craciunescu, O. I., Blackwell KL, Jones EL, MacFall JR, Yu D, Vujaskovic Z, Wong TZ, Liotcheva V, Rosen LE, Prosnitz LR, Samulski TV, DEWHIRST MW. "DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: A pilot study." Int J Hyperthermia: 1-11, 2009, 25(6): 405-15. PMCID: PMC2783501. 409. Vishwanath, Karthik, Yuan, Hong, Barry, William T., DEWHIRST, M.W. and Ramanujam, Nimmi. Using Optical Spectroscopy to Longitudinally Monitor Physiological Changes within Solid Tumors. Neoplasia. 2009; 11(9): 889– 900. PMCID: PMC2735810. 410. Zhang GQ, Palmer GM, DEWHIRST MW, Fraser CL. A dual-emissive-materials design concept enables tumour hypoxia imaging. Nature Materials 2009;8(9): 747-51. PMCID: PMC2846459. 411. Viglianti BL, Lora-Michiels M. Poulson JM, Lan L, Yu D, Sanders L, Craciunescu O, Vujaskovic Z, Thrall DE, MacFall J, Charles CH, Wong T, DEWHIRST, MW. Dynamic contrast-enhanced magnetic resonance imaging as a predictor of clinical outcome in canine spontaneous soft tissue sarcomas treated with thermoradiotherapy. Clin Cancer Res. 2009 Aug 1:15(15):4993-5001. PMCID: PMC2763531. 412. Brady SL, Toncheva G, DEWHIRST MW, Yoshizumi TT. Characterization of a 137Cs irradiator from a new perspective with modern dosimetric tools. Health Phys. 2009 Sep;97(3):195-205. PMID: 19667802. 413. Stein, Rebecca A., Chang, Ching-yi, Kazmin, Dmitri A., Way, James, Schroeder, Thies, Wergin, Melanie, DEWHIRST M.W., and McDonnell, Donald P. Estrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer. Cancer Res. Nov. 1, 2009. PMCID: PMC2633645.
36
414. Kennedy KM, DEWHIRST MW. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol. 2010 Jan; 6(1):127- 48. PMCID: PMC2819205. 415. Skala MC, Fontanella A. Lan L, Izatt JA, DEWHIRST, MW. Longitudinal optical imaging of tumor metabolism an dhemodynamics. J Biomed Opt. 2010 Jan- Feb;15(1):011112. PMCID: PMC2816992. 416. Jones LW, Viglianti BL, Tashjian JA, Kothadia SM, Keir ST, Freedland SJ, Potter MQ, Moon Jung E, Schroeder T, Herndon JE, 2nd, DEWHIRST MW. Effect of Aerobic Exercise on Tumor Physiology in an Animal Model of Human Breast Cancer. J Appl Physiol. 2010;108(2):343-8. PMCID: PMC2822670. 417. Robinson TJ, Dinan MA, DEWHIRST M, Garcia-Blanco MA, Pearson JL. SplicerAV: a tool for mining microarray expression data for changes in RNA processing. BMC Bioinformatics. 2010 Feb 25;11:108. PMCID: PMC2838864.
418. Palmer GM, Boruta RJ, Viglianti BL, Lan L, Spasojevic I, DEWHIRST MW. Non-invasive monitoring of intra-tumor drug concentration and therapeutic response using optical spectroscopy. J Control Release. 2010 19;142(3):457-64. PMCID: PMC2833231.
419. DEWHIRST, MW, Thrall DE, Palmer G, Schroeder T, Vujaskovic Z, Cecil Charles H. Macfall J, Wong T. Utility of functional imaging in prediction or assessment of treatment response and prognosis following thermotherapy. Int J Hyperthermia. 2010;26(3):283-93. PMCID: PMC2854850. 420. Cheng KS, DEWHIRST MW, Stauffer PR, Das S. Effective learning strategies for real- time image-guided adaptive control of multiple-source hyperthermia applicators. Med Phys. 2010 Mar;37(3):1285-97. PMCID: PMC2842289. 421. Kim SJ, Rabbani ZN, Dong F, Vollmer RT, Schreiber EG, DEWHIRST MW, Vujaskovic Z, Kelley MJ. Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. Med Oncol. 2010 Mar;27(1):91-7. PMID: 19235531. 422. Cheng KS, DEWHIRST MW, Stauffer PF, Das S. Mathematical formulation and analysis of the nonlinear system reconstruction of the online image-guided adaptive control of hyperthermia. Med Phys. 2010 Mar;37(3):980-94. PMCID: PMC2833184. 423. Vujaskovic Z, Kim DW, Jones E, Lan L, McCall L, DEWHIRST MW, Craciunescu O, Stauffer P, Liotcheva V, Betof A, Blackwell K. A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia. 2010;26(5):514-21. PubMed: 20377362. NIHMSID: NIHMS 237516. PMCID: PMC2956498. 424. Batinic-Haberle I, Spasojevic I, Tse HM, Tovmasyan A, Rajic Z, St Clair DK, Vujaskovic Z, DEWHIRST MW, Piganelli JD. Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities. Amino Acids. 2010 May 16. PMID: 20473774, NIHMSID #: 238133. 425. Yarmolenko PS, Zhao Y, Landon C, Spasojevic I, Yuan F, Needham D, Viglianti BL, DEWHIRST MW. Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumors. Int J Hyperthermia. 2010;26(5):485-98. NIHMSID: NIHMS237520. PMCID: PMC2956508.
37
426. Jenista ER, Galiana G, Branca RT, Yarmolenko PS, Stokes AM, DEWHIRST MW, Warren WS. Application of mixed spin iMQCs for temperature and chemical-selective imaging. J Magn Reson. 2010 Jun; 204(2):208-18. PMCID: PMC2874652. 427. Tailor TD, Hanna G, Yarmolenko PS, Dreher MR, Betof AS, Nixon AB, Spasojevic I, DEWHIRST MW. Effect of pazopanib on tumor microenvironment and liposome delivery. Mol Cancer Ther. 2010 June;9(6):1798-808. PMCID: PMC2909540. 428. Kennedy KM, DEWHIRST MW. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncology (London, England). 2010;6(1):127-48. PMCID: PMC2819205 429. Thomas A, Bowsher J, Roper J, Oliver T, DEWHIRST M, Oldham M. A comprehensive method for optical-emission computed tomography. Phys Med Biol. 2010. Jul 21;55(14):3947-57. PMID: 20577042. 430. Craciunescu, O. I., Thrall DE, Vujaskovic Z, DEWHIRST MW. Magnetic resonance
imaging: a potential tool in assessing the addition of hyperthermia to neoadjuvanttherapy in patients with locally advanced breast cancer. Int J Hyperthermia. 2010;26(7): 625-37. PMCID: 2998919.
431. Zagar TM, Oleson JR, Vujaskovic Z, DEWHIRST MW, Craciunescu OI, Blackwell KL, Prosnitz LR, Jones EL. Hyperthermia for locally advanced breast cancer. Int J Hyperthermia. 2010;26(7):618-24. PMCID: PMC2949291. 432. Zagar TM, Oleson JR, Vujaskovic Z, DEWHIRST MW, Craciunescu OI, Blackwell KL, Prosnitz LR, Jones EL. Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomized data. Int J Hyperthermia. 2010;26(7):612-7. PMCID: PMC2956421.
433. Tei L, Mazooz G, Shellef Y, Avni R, Vandoome K, Barge A, Kalchenko V, DEWHIRST MW, Chaabane L, Miragoli L, Longo D, Neeman M, Aime S. Novel MRI and fluorescent probes responsive to the Factor XIII transglutaminase activity. Contrast Media Mol Imaging. 2010 Jul-Aug;5(4):213-22. PMID: 20812289. PMCID: In Process.
434. Pries AR, Hopfner M, le Noble F, DEWHIRST MW, Secomb TW. The shunt problem: control of functional shunting in normal and tumor vasculature. Nat Rev Cancer. 2010 Aug;10(8):587-93. PMID: 20631803. NIHMSID: NIHMS296511. PMCID: PMC3109666. 435. Brady SL, Gunasingha R, Yoshizumi TT, Howell CR, Crowell AS, Fallin B, Tonchev AP, DEWHIRST, MW. A feasibility study using radiochromic films for fast neutron 2D passive dosimetry. Phys Med Biol. 2010 Aug 6;55(17):4977-4992. PMID: 20693612. PMCID: In Process. 436. Il’yasova D, Kennedy K, Spasojevic I, Wang F, Tolun AA, Base K, Young SP, Marcom P, Marks J, Millington DS, DEWHIRST MW. Individual responses to chemotherapy- induced oxidative stress. Breast Cancer Res Treat. 2010 Sep 10. PMID: 20830514. NIHMSID: NIHMS353628. PMCID: PMC3500598. 437. Masko EM, Thomas JA 2nd, Antonelli JA, Lloyd JC, Phillips TE, Poulton SH, DEWHIRST MW, Pizzo SV, Freedland SJ. Low-carbohydrate diets and prostate
38
cancer: how low is “low enough”? Cancer Prev Res (Phila). 2010 Sept;;3(9):1124-31. PMID: 20716631. 438 Kersey FR, Zhang G, Palmer, DEWHIRST MW, Fraser CL. Stereocomplexed poly(ethylene glycol) nanoparticles with dual-emissive boron dyes for tumor accumulation. ACS Nano. 2010 Sep 28;4(9):4989-96. PMCID: PMC2955982. 439. Spasojevic I, Kos I, Benov LT, Rajic Z, Fels D. Dedeugd C, Ye X, Vujaskovic Z, Reboucas JS, Leong KW, DEWHIRST MW, Batinic-Haberle I. Bioavailability of metalloporphyrin-based SOD mimics is greatly influenced by a single charge residing on a Mn site. Free Radic Res. 2010 Oct 13. PMID: 20942564. NIHMSID #: 353637. PMCID: PMC3500599. 440. Moon EJ, Sonveaux P, Porporato PE, Danhier P, Gallez B, Batinic-Haberle I, Nien YC, Schroeder T, DEWHIRST MW. NADPH oxidase-mediated reactive oxygen species
production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment. Proc Natl Acad Sci USA. 2010 Nov. 8. PMCID: PMC2996638.
441. Zagar TM, Higgins KA, Miles EF, Vujaskovic Z, DEWHIRST MW, Clough RW, Prosnitz LR, Jones EL. Durable palliation of breast cancer chest wall recurrence with radiation therapy, hyperthermia, and chemotherapy. Radiother Oncol. 2010 Dec;97(3):535-40. PMID: 21074876. NIHMSID: NIHMS326211.
442. Batinic-Haberle I, Spasojevic I, Tse HM, Tovmasyan A, Rajic Z, Clair DK, Vujaskovic Z,
DEWHIRST MW, Piganelli JD. Erratum to: Design of Mn porphyrins for treating oxidative stress injuris and their redox-based regulation of cellular transcriptional activities. Amino Acids. 2010 Dec 24. PMID: 21184120. PubMed: In Process.
443. Palmer GM, Fontanella AN, Zhang G, Hanna G, Fraser CL, DEWHIRST MW. Optical
imaging of tumor hypoxia dynamics. J Biomed Opt. 2010 Nov-Dec;15(6):066021. PMCID: 3025596.
444. Chitneni SK, Palmer GM, Zalutsky MR, DEWHIRST, MW. Molecular imaging of
hypoxia. J Nucl Med. 2011 Feb;52(2): 165-8. PMID: 21233176. NIHMSID: 353661. 445. Keir ST, DEWHIRST, MW, Kirkpatrick JP, Bigner DD, Batinic-Haberle I. Cellular redox
modulator, ortho Mn(III) meso-tetrakis (N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP(5+) in the treatment of brain tumors. Anticancer Agents Med Chem. 2011 Feb;11(2):202-12. PMID: 21291403. NIHMSID: 353673. PMCID: PMC3357315.
446. Landon CD, Park JY, Needham D, DEWHIRST MW. Nanoscale Drug Delivery and
Hyperthermia: The materials design and preclinical and clinical testing of low temperature—ensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer. Open Nanomedicine Journal, 2011, 3, 38-64. NIHMSID: NIHMS326176.
447. Chi JT, Thrall DE, Jiang C, Snyder S, Fels D, Landon C, McCall L, Lan L, Hauck M,
Macfall JR, Viglianti BL, DEWHIRST, MW. Comparison of genomics and functional imaging from canine sarcomas trerated with thermoradiotherapy predics therapeutic response and identifies combination therapeutics. Clin Cancer Res. 2011 Apr 15;17(8):2549-60. PMCID: PMC3078971.
39
448. Negussie AH, Yarmolenko PS, Partanen A, Ranjan A, Jacobs G, Woods D, Bryant H, Thomasson D, DEWHIRST, MW, Wood BJ, Dreher MR. Formulation and characterization of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided high intensity focused ultrasound. Int J Hyperthermia. 2011;27(2):140-55. PMID: 21314334. NIHMSID: NIHMS326201.
449. Aird KM, Allensworth JL, Batinic-Haberle I, Lyerly HK, DEWHIRST MW. ErbB1/2
tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res Treat. 2011 May 11. PMID: 21559822. PubMed: In Process.
450. Yarmolenko PS, Moon EJ, Landon C, Manzoor A, Hochman DW, Viglianti BL,
DEWHIRST MW. Thresholds for thermal damage to normal tissues: An update. Int J Hyperthermia. 2011;27(4):320-43. PMID: 21591897. NIHMSID: NIHMS326207.
451. Batinic-Haberle I, Rajic Z, Tovmasyan A, Ye X, Leong KW, DEWHIRST MW, Vujaskovic
Z, Benov L, Spasojevic I. Diverse functions of cationic Mn(III) substituted N-pyridylporphyrins, known as SOD mimics. Free Radic Biol Med. 2011 May 6. PMID: 21616142. NIHMS: 295138. PMCID: PMC3178885.
452. Gatza ML, Kung HN, Blackwell KL, DEWHIRST MW, Marks JR, Chi JT. Analysis of
tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Res. 2011 Jun 7;13(3):R62. PMID: 21672245. PMCID: PMC3218951.
453. Palmer GM, Fontanella AN, Shan S, Hanna G, Zhang G, Fraser CL, DEWHIRST MW.
In vivo optical molecular imaging and analysis in mice using dorsal window chamber models applied to hypoxia, vasculature and fluorescent reporters. Nat Protoc. 2011 Aug 18;6(9): 1355-66. PMID: 21886101. NIHMSID: NIHMS353625. PMCID: PMC3500601.
454. Fisher DT, Chen Q, Skitzki JJ, Muhitch JB, Zhou L, Appenheimer MM, Vardam TD,
Weis EL, Passanese J, Wange WC, Gollnick SO, DEWHIRST MW, Rose-John S, Repasky EA, Baumann H, Evans SS. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest. 2011 Oct; 12 1(10):3846-59. PMID: 21926464. PMCID: PMC3195455.
455. Simnick AJ, Amiram M, Liu W, Hanna G, DEWHIRST MW, Kontos CD, Chilkoti A. In
vivo tumor targeting by a NGR-decorated micelle of a recombinant diblock copolypeptide. J Control Release. 2011 Oct 30; 155(2): 144-51. PMID: 21763734. PMCID: PMC3196042.
456. Heymach JV, Shackleford TJ, Tran HT, Yoo SY, Do KA, Wergin M, Saintigny P, Vollmer
RT, Polascik TJ, Snyder DC, Ruffin IV MT, Yan S, DEWHIRST MW, Kunnumakkara AB, Aggarwal BB, Demark-Wahnefried W. Effect of Low-Fat Diets on Plasma Levels of NF-kB-Regulated Inflammatory Cytokines and Angiogenic Factors in Men with Prostate Cancer. Cancer Prev Res; 4(10) Oct 2011. PMID: 21764858. NIHMSID: NIHMS353669. PMCID: PMC3438697.
457. Ye X, Fels D, Tovmasyan A, Aird KM, Dedeugd C, Allensworth JL, Kos I, park W,
Spasojevic I, Devi GR, DEWHIRST MW, Leong KW, Batinic-Haberle I. Cytoxic effects of Mn(III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate. Free Radic Res. 2011 Nov; 45(11-12): 1289-306. PMID: 21859376. NIHMSID: NIHMS353631. PMCID: PMC3500602.
40
458. Shenoy SK, Han S, Zhao YL, Hara MR, Oliver T, Cao Y, DEWHIRST MW. β-arrestin1
mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression. Oncogene. 2012 Jan 19;31 (3): 282-92. PMID: 21685944. PMCID: PMC3179824.
459. Batinic-Haberle I, Spasojevic I, Tse HM, Tovmasyan A, Rajic Z, St Clair DK, Vujaskovic
Z, DEWHIRST MW, Piganelli JD. Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities. Amino Acids. 2012 Jan; 42(1): 95-113. PMID: 20473774. PMCID: PMC3022969.
460. Aird KM, Allensworth JL, Batinic-Haberle I, Lyerly HK, DEWHIRST MW, Devi GR.
ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res Treat. 2012 Feb; 132(1): 109-19. PMID: 21559822. PMCID: PMC3734382.
461. Sonveaux P, Copetti T, De Saedeleer CJ, Vegran F, Verrax J, Kennedy KM, Moon EJ,
Dhup S, Danhier P, Frerart F, Gallez B, Ribeiro A, Michiels C, DEWHIRST MW, Feron O. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One. 2012;7(3):e33418. PMID: 22428047. PMCID: PMC3302812.
462. Secomb TW, DEWHIRST MW, Pries AR. Structural adaptation of normal and tumour
vascular networks. Basic Clin Pharmacol Toxicol. 2012 Jan; 110(1): 63-9. PMID: 21995550. NIHMSID: NIHMS353659. PMCID: PMC3500595.
463. Yuan Y, Cheng KS, Craciunescu OI, Stauffer PR, Maccarini PF, Arunachalam K,
Vujaskovic Z, DEWHIRST MW, Das SK. Utility of treatment planning for thermochemotherapy treatment of nonmuscle invasive bladder carcinoma. Med Phys. 2012 Mar; 39(3): 1170-81. PMID: 22380348. PMCID: PMC3292595.
464. Kim HS, Masko EM, Poulton SL, Kennedy KM, Pizzo SV, DEWHIRST MW, Freedland
SJ. Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model. BJU Int. 2012 Mar 6. PMID: 22394625. PMCID: PMC3371292.
465. Palmer GM, Vishwanath K, DEWHIRST MW. Application of optical imaging and
spectroscopy to radiation biology. Radiat Res. 2012 Apr; 177(4): 365-75. PMID: 22360397. NIHMSID: NIHMS438309. PMCID: PMC3581040.
466. Humm JL, DEWHIRST MW, Bhujwalla ZM. Introduction to the special issue on
molecular imaging in radiation biology. Radiat Res. 2012 Apr; 177(4): 329-30. PMID: 22332930. PubMed: In Process. Palmer GM, Vishwanath K, DEWHIRST MW. Application of optical imaging and spectroscopy to radiation biology. Radiat Res. 2012 Apr; 177(4): 365-75. PMID: 22360397. NIHMSID: NIHMS438309. PMCID: PMC3581040.
467. Turley RS, Fontanella A, Padussis J, Toshimitsu H, Tokuhisa Y, Cho EH, Hanna G,
Beasley GM, Augustine CK, DEWHIRST MW, Tyler DS. Bevacizumab-induced alterations in vascular permeability and drug delivery: A novel approach to augment regional chemotherapy for in-transit melanoma. Clin Cancer Res. 2012 Apr 17. PMID: 22496203. NIHMSID: NIHMS438319. PMCID: PMC3618183.
468. Yu B, Shah A, Wang B, Rajaram N, Wang Q, Ramanujam N, Palmer GM, DEWHIRST MW. Measuring tumor cycling hypoxia and angiogenesis using a side-firing fiber optic
41
probe. J Biophotonics. 2012. PMCID: PMC3702687. 469. Jones LW, Antonelli J, Masko EM, Boardwater G, Lascola CD, Fels D, DEWHIRST MW,
Dyck JR, Nagendran J, Flores CT, Betof AS, Nelson ER, Pollak M, Dash RC, Young ME, Freedland SJ. Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. J Appl Physiol. 2012 Jul; 113(2): 263-72. PMID: 22604887. PMCID: PMC3404704.
470. Sonveaux P, Copetti T, De Saedeleer CJ, Vegran F, Verrax J, Kennedy KM, Moon EJ,
Dhup S, Danhier P, Frerart F, Gallez B, Ribeiro A, Michiels C, DEWHIRST MW, Feron O. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One. 2012;7(3):e33418. PMID: 22428047. PMCID: PMC3302812.
471. Palmer GM, Fontanella AN, Shan S, DEWHIRST MW. High-resolution in vivo imaging of
fluorescent proteins using window chamber models. Methods Mol Biol. 872:31-50, 2012. (Book chapter).
472. Betof AS, Rabbani ZN, Hardee ME, Kim SJ, Broadwater G, Bentley RC, Snyder SA,
Vujaskovic Z, Oosterwijk E, Harris LN, Horton JK, DEWHIRST MW, Blackwell KL. Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. Br J Cancer. 106(5):916-22, 2012. PMCID: PMC3305967.
473. Betof AS, DEWHIRST MW, Jones LW. Effects and potential mechanisms of exercise
training on cancer progression: A translational perspective. Brain Behav Immun. 2012. NIHMSID: NIHMS438332. PMCID: PMC3638811.
474. Salahi S, Maccarini PF, Rodrigues DB, Etienne W, Landon CD, Inman BA, DEWHIRST
MW, Stauffer PR. Miniature microwave applicator for murine bladder hyperthermia studies. Int J Hypterthermia. 2012; 28 (5): 456-65. PMID: 22690856. PMCID: PMC3399990.
475. Klink JC, Tewari AK, Masko EM, Antonelli J, Febbo PG, Cohen P, DEWHIRST MW,
Pizzo SV, Freedland SJ. Reservatrol Worsens Survival in SCID Mice with Prostate Cancer Xenografts in a Cell-Line Specific Manner, Through Paradoxical Effects on Oncogenic Pathways. The Prostate. DOI 10.1002/pros 22619. 2012; 10 (17). PMID: 23192356. PMCID: PMC3628095.
476. Thrall DE, Maccarini P, Stauffer P, Macfall J, Hauck M, Snyder S, Case B, Linder K, Lan
L, McCall L, DEWHIRST MW. Thermal dose fractionation affects tumor physiological response. Int J Hyperthermia. 2012; 28(5): 431-40. PMID: 22804741. PMCID: PMC3727142.
477. Manzoor AA, Lindner LH, Landon CD, Park JY, Simnick AJ, Dreher MR, Das S, Hanna
G, Park W, Chilkoti A, Koning GA, ten Hagen TL, Needham D, DEWHIRST MW. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res. 2012 Nov 1; 72(21): 5566-75. PMID: 22952218. PMCID: PMC3517817.
478. Chitneni SK, Bida GT, DEWHIRST MW, Zalutsky MR. A simplified synthesis of the
hypoxia imaging agent 2- (2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18) F]pentafluoropropyl)-acetamide ([18F]EF5). Nucl Med Biol. 39(7):1012-8, 2012. PMCID: PMC3478693.
42
479. Beasley GM, Sharma K, Wong J, Miller M, Turley RS, Lidsky M, Masoud M, DEWHIRST MW, Mosca PJ, Zager JS, Tyler DS. A multi-institution experience
comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion. Cancer. 2012 Dec 15; 118(24): 6136- 43. PMID: 22674423. PubMed – In Process.
480. Azrad M, Vollmer RT, Madden J, DEWHIRST MW, Polascik TJ, Snyder DC, Ruffin MT,
Moul JW, Brenner DE, Demark-Wahnefried W. Flaxseed-Derived Enterolactone Is Inversely Associated with Tumor Cell Proliferation in Men with Localized Prostate Cancer. Journal of Medicinal Food. 2013;16(4):357-60. doi: 10.1089/jmf.2012.0159. PubMed PMID: WOS:000317352400013. PMID: 23566060. PMCID: PMC3624628.
481. Cao YT, Eble JM, Moon E, Yuan H, Weitzel DH, Landon CD, Nien CYC, Hanna G, Rich
JN, Provenzale JM, DEWHIRST MW. Tumor Cells Upregulate Normoxic HIF-1 alpha in Response to Doxorubicin. Cancer Research. 2013;73(20):6230-42. doi: 10.1158/0008-5472.can-12-1345. PubMed PMID: WOS:000325796100015. PMID: 23959856. PMCID: PMC3800255.
482. Caso J, Masko EM, Thomas JA, Poulton SH, DEWHIRST MW, Pizzo SV, Freedland SJ.
The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model. Prostate. 2013;73(5):449-54. doi: 10.1002/pros.22586. PubMed PMID: WOS:000316287600001. PMID: 23038057. PMCID: PMC3594433.
483. Chitneni SK, Bida GT, Yuan H, Palmer GM, Hay MP, Melcher T, Wilson WR, Zalutsky
MR, DEWHIRST MW. F-18-EF5 PET Imaging as an Early Response Biomarker for the Hypoxia-Activated Prodrug SN30000 Combined with Radiation Treatment in a Non-Small Cell Lung Cancer Xenograft Model. Journal of Nuclear Medicine. 2013;54(8):1339-46. doi: 10.2967/jnumed.112.116293. PubMed PMID: WOS:000322692400045. PMID: 23740105. PMCID: PMC3770943.
484. Davis RM, Viglianti BL, Yarmolenko P, Park JY, Stauffer P, Needham D, DEWHIRST
MW. A method to convert MRI images of temperature change into images of absolute temperature in solid tumours. International Journal of Hyperthermia. 2013;29(6):569-81. doi: 10.3109/02656736.2013.790091. PubMed PMID: WOS:000323484600009. PMID: 23957326. PMCID: PMC3779909.
485. DEWHIRST MW, Chi JT. Understanding the Tumor Microenvironment and
Radioresistance by Combining Functional Imaging With Global Gene Expression. Seminars in Radiation Oncology. 2013;23(4):296-305. doi: 10.1016/j.semradonc.2013.05.004. PubMed PMID: WOS:000324352600009. PMID: 24012344. PMCID: PMC3773177.
486. DEWHIRST MW, Landon CD, Hofmann CL, Stauffer PR. Novel Approaches to
Treatment of Hepatocellular Carcinoma and Hepatic Metastases Using Thermal Ablation and Thermosensitive Liposomes. Surgical Oncology Clinics of North America. 2013;22(3):545--61. doi: 10.1016/j.soc.2013.02.009. PubMed PMID: WOS:000319085200011. PMID: 23622079. PMCID: PMC3738918.
487. Fontanella AN, Schroeder T, Hochman DW, Chen RE, Hanna G, Haglund MM, Secomb
TW, Palmer GM, DEWHIRST MW. Quantitative Mapping of Hemodynamics in the Lung, Brain, and Dorsal Window Chamber-Grown Tumors Using a Novel, Automated Algorithm. Microcirculation. 2013;20(8):724-35. doi: 10.1111/micc.12072. PubMed PMID: WOS:000326607600009. PMID: 23781901. PMCID: 3843942.
43
488. Hanna G, Fontanella A, Palmer G, Shan SQ, Radiloff DR, Zhao YL, Irwin D, Hamilton K,
Boico A, Piantadosi CA, Blueschke G, DEWHIRST MW, McMahon T, Schroeder T. Automated measurement of blood flow velocity and direction and hemoglobin oxygen saturation in the rat lung using intravital microscopy. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2013;304(2):L86-L91. doi: 10.1152/ajplung.00178.2012. PubMed PMID: WOS:000313738100002. PMID: 23161885.
489. Inman BA, Etienne W, Rubin R, Owusu RA, Oliveira TR, Rodriques DB, Maccarini PF,
Stauffer PR, Mashal A, DEWHIRST MW. The impact of temperature and urinary constituents on urine viscosity and its relevance to bladder hyperthermia treatment. International Journal of Hyperthermia. 2013;29(3):206-10. doi: 10.3109/02656736.2013.775355. PubMed PMID: WOS:000317928500004. PMID: 23489163.
490. Jones LW, Fels DR, West M, Allen JD, Broadwater G, Barry WT, Wilke LG, Masko E,
Douglas PS, Dash RC, Povsic TJ, Peppercorn J, Marcom PK, Blackwell KL, Kimmick G, Turkington TG, DEWHIRST MW. Modulation of Circulating Angiogenic Factors and Tumor Biology by Aerobic Training in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Cancer Prevention Research. 2013;6(9):925-37. doi: 10.1158/1940-6207.capr-12-0416. PubMed PMID: WOS:000324171000006. PMID: 23842792. PMCID: PMC3800005.
491. Kennedy KM, Scarbrough PM, Ribeiro A, Richardson R, Yuan H, Sonveaux P, Landon
CD, Chi JT, Pizzo S, Schroeder T, DEWHIRST MW. Catabolism of Exogenous Lactate Reveals It as a Legitimate Metabolic Substrate in Breast Cancer. Plos One. 2013;8(9). doi: 10.1371/journal.pone.0075154. PubMed PMID: WOS:000326240100122. PMID: 24069390. PMCID: PMC3771963.
492. Kinev AV, Levering V, Young K, Ali-Osman F, Truskey GA, DEWHIRST MW, Il'yasova
D. Endothelial Colony Forming Cells (ECFCs) As a Model for Studying Effects of Low-Dose Ionizing Radiation: Growth Inhibition by a Single Dose. Cancer Investigation. 2013;31(5):359-64. doi: 10.3109/07357907.2013.789903. PubMed PMID: WOS:000319228300008. PMID: 23621632. PMCID: PMC3754852.
493. Klink JC, Tewari AK, Masko EM, Antonelli J, Febbo PG, Cohen P, DEWHIRST MW,
Pizzo SV, Freedland SJ. Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways. Prostate. 2013;73(7):754-62. doi: 10.1002/pros.22619. PubMed PMID: WOS:000317930600009. PMID: 23192356. PMCID: PMC3628095.
494. Kurokawa M, Kim J, Geradts J, Matsuura K, Liu L, Ran X, Xia WL, Ribar TJ, Henao R,
DEWHIRST MW, Kim WJ, Lucas JE, Wang SM, Spector NL, Kornbluth S. A Network of Substrates of the E3 Ubiquitin Ligases MDM2 and HUWE1 Control Apoptosis Independently of p53. Science Signaling. 2013;6(274). doi: 10.1126/scisignal.2003741. PubMed PMID: WOS:000318691600002. PMID: 23652204. PMCID: PMC3770270.
495. Landon CD, Benjamin SE, Ashcraft KA, DEWHIRST MW. A role for the copper
transporter Ctr1 in the synergistic interaction between hyperthermia and cisplatin treatment. International Journal of Hyperthermia. 2013;29(6):528-38. doi: 10.3109/02656736.2013.790563. PubMed PMID: WOS:000323484600004. PMID: 23879689. PMCID: PMC3895488.
44
496. McDaniel JR, DEWHIRST MW, Chilkoti A. Actively targeting solid tumours with thermoresponsive drug delivery systems that respond to mild hyperthermia. International Journal of Hyperthermia. 2013;29(6):501-10. doi: 10.3109/02656736.2013.819999. PubMed PMID: WOS:000323484600001. PMID: 23924317.
497. Oliveira TR, Stauffer PR, Lee CT, Landon CD, Etienne W, Ashcraft KA, McNerny KL,
Mashal A, Nouls J, Maccarini PF, Beyer WF, Inman B, DEWHIRST MW. Magnetic fluid hyperthermia for bladder cancer: A preclinical dosimetry study. International Journal of Hyperthermia. 2013;29(8):835-44. doi: 10.3109/02656736.2013.834384. PubMed PMID: WOS:000327485800014. PMID: 24050253. PubMed – In Process.
498. Rajaram N, Frees AE, Fontanella AN, Zhong J, Hansen K, DEWHIRST MW,
Ramanujam N. Delivery Rate Affects Uptake of a Fluorescent Glucose Analog in Murine Metastatic Breast Cancer. Plos One. 2013;8(10). doi: 10.1371/journal.pone.0076524. PubMed PMID: WOS:000326029300033. PMID: 24204635. PMCID: PMC3799786.
499. Secomb TW, Alberding JP, Hsu R, DEWHIRST MW, Pries AR. Angiogenesis: An
Adaptive Dynamic Biological Patterning Problem. Plos Computational Biology. 2013;9(3). doi: 10.1371/journal.pcbi.1002983. PubMed PMID: WOS:000316864200053. PMID: 23555218. PMCID: PMC3605064.
500. Terman DS, Viglianti BL, Zennadi R, Fels D, Boruta RJ, Yuan H, Dreher MR, Grant G,
Rabbani ZN, Moon E, Lan L, Eble J, Cao YT, Sorg B, Ashcraft K, Palmer G, Telen MJ, DEWHIRST MW. Sickle Erythrocytes Target Cytotoxics to Hypoxic Tumor Microvessels and Potentiate a Tumoricidal Response. Plos One. 2013;8(1). doi: 10.1371/journal.pone.0052543. PubMed PMID: WOS:000313551500017. PMID: 23326340. PMCID: PMC3541382.
501. van Rhoon GC, Samaras T, Yarmolenko PS, DEWHIRST MW, Neufeld E, Kuster N.
CEM43A degrees C thermal dose thresholds: a potential guide for magnetic resonance radiofrequency exposure levels? European Radiology. 2013;23(8):2215-27. doi: 10.1007/s00330-013-2825-y. PubMed PMID: WOS:000321523500021. PMID: 23553588. PMCID: 3799975.
502. Zhang T, Das SK, Fels DR, Hansen KS, Wong TZ, DEWHIRST MW, Vlahovic G. PET
With Cu-62-ATSM and Cu-62-PTSM Is a Useful Imaging Tool for Hypoxia and Perfusion in Pulmonary Lesions. American Journal of Roentgenology. 2013;201(5):W698-W706. doi: 10.2214/ajr.12.9698. PubMed PMID: WOS:000326097900006. PMID: 24147499.
503. Zhong J, Rajaram N, Brizel DM, Frees AE, Ramanujam N, Batinic-Haberle I,
DEWHIRST MW. Radiation induces aerobic glycolysis through reactive oxygen species. Radiotherapy and Oncology. 2013;106(3):390-6. doi: 10.1016/j.radonc.2013.02.013. PubMed PMID: WOS:000322295800022. PMID: 23541363. PMCID: PMC3770265.
Non-Refereed Publications 1. Schallberger JA, DEWHIRST MW, Lebel JL, Lymph transport of soluble and insoluble
plutonium, Proceedings of the 14th Annual Hanford Biology Symposium. ERDA Symposium Series No. 37, pp. 19-27, 1976.
2. DEWHIRST MW, Moon T, Carlin D, Analysis of tumor volume and thermal dosimetric
effects on tumor response to heat, radiation and heat plus radiation: Results of a
45
phase III randomized clinical trial in pet animals, AAPM Summer School, Physical Aspects of Hyperthermia, Dartmouth, 1981.
3. DEWHIRST MW, Sim DA, Gross JF, Kundrat MA, Effect of heating rate on tumour and
normal tissue microcirculatory function. In: J Overgaard (ed.), Hyperthermic Oncology. London: Taylor & Francis, 1984. Pp. 177-180.
4. DEWHIRST MW, Sim DA, Grochowski KJ, Thermal influence on radiation induced
complications vs. tumor response in a phase III randomized trial. In: J Overgaard (ed.), Hyperthermic Oncology. London: Taylor & Francis, 1984. Pp. 313-316.
5. Sim DA, DEWHIRST MW, Oleson JR, Grochowski KJ, Estimating the therapeutic
advantage of adequate heat (D). In: J Overgaard (ed.), Hyperthermic Oncology. London: Taylor & Francis, 1984. Pp. 359-362.
6. Deshmukh R, Demento M, Demer L, Forsyth K, DeYoung D, DEWHIRST MW, Cetas
TC, Ferromagnetic alloys with curie temperatures near 50°C for use in hyperthermia therapy. In: J Overgaard (ed.), Hyperthermic Oncology. London: Taylor & Francis, 1984. Pp. 571-574.
7. Forsyth K, Deshmukh R, DeYoung DW, DEWHIRST MW, Cetas TC, Recent clinical
experience in pet animals with hyperthermic therapy in the head and neck region induced with inductively heated ferromagnetic implants. In: J Overgaard (ed.), Hyperthermic Oncology. London: Taylor & Francis, 1984. Pp. 589-602.
8. Thrall DE, DEWHIRST MW, Radiation and/or hyperthermia in the treatment of
lymphosarcoma and mast cell tumors in dogs, Vet Clin North Am 15:835-843, 1985.
9. Oleson JR, DEWHIRST MW, Duncan D, Engler M, Thrall D, Temperature gradients: Prognostic and dosimetric implications, Proceedings of the Seventh Annual Conference of the IEEE-EMB Society 1:355-360, 1985.
10. DEWHIRST MW, Considerations in the correlation between thermal dose and tumor and normal tissue response, Proceedings of the Seventh Annual Conference of the IEEE-EMB Society 1:55-59, 1985.
11. Winget JM, DEWHIRST MW, Engler MJ, Oleson JR, The use of limited temperature
observations to predict complete temperature fields, Proceedings of the Eighth Annual Conference of the IEEE-EMB Society 3:1507-1511, 1986.
12. Rine G, DEWHIRST MW, Samulski TV, Wallen A, Modeling of SAR values in tissue due
to slab loaded waveguide applicators, Proceedings of the Ninth Annual Conference of the IEEE-EMB Society 1987.
13. DEWHIRST MW, Thermal Dosimetry. In: EW Gerner and TC Cetas (eds.),
Hyperthermic Oncology 1992, Vol. 2, Proceedings of the 6th International Congress on Hyperthermic Oncology, Vol 2, Pp 39-43, 1992.
14. Gillette EL, McChesney-Gillette S, DEWHIRST MW, Thrall DE, Response of canine soft
tissue sarcomas to radiation and hyperthermia. In: EW Gerner and TC Cetas (eds.), Hyperthermic Oncology, Proceedings of the 6th International Congress on Hyperthermic Oncology, Vol 2, Pp 281-284, 1992.
15. Oleson JR, Leopold KA, DEWHIRST MW, Samulski TV, Harrelson J, Tucker JA, Dodge
RK, George SL, Blivin JL, Grant W, Clegg S, Prosnitz LR: Preoperative radiation and
46
hyperthermia for soft tissue sarcomas provides a model system for developing thermal dosimetry. In: EW Gerner and TC Cetas (eds.), Hyperthermic Oncology 1992, Vol. 2, Proceedings of the 6th International Congress on Hyperthermic Oncology, Vol 2, Pp 293-294, 1992.
16. Needham D., Da D., Rudoll TL, Ting-Beall HP, Wu N., DEWHIRST MW, Permeability of
implanted-tumor vasculature to polymer-grafted liposomes. Biophysics Journal, 64:A338, 1993.
17. DEWHIRST MW, Ong E, Smith B, Evans S, Secomb T, Wilson D, Plenary Lecture:
Longitudinal gradients of vascular PO2 in R3230AC tumor microvessels in dorsal flap window chambers. Sixth World Congress for Microcirculation, 1996 pp. 343-346.
18. DEWHIRST MW, Hyperthermic treatment of malignant disease: current status and a
view toward the future. In: Carl Mansfield (ed.), Seminars in Oncology. Philadelphia:WB Saunders Co., 1997. Vol 24, Pp 616-625.
19. Secomb TW, Hsu R, Braun RD, DEWHIRST MW, Analysis of oxygen transport to
tumors: causes of heterogeneous tissue oxygenation. Proceeedings of the 1999 Bioengineering Conference ASME 42:487-488, 1999.
20. Pogue B., Braun R, Lanzen J, DEWHIRST MW, Erickon C, Oxygen microelectrode
measurements in R3230Ac tumors during photodynamic therapy with verteporfin. Proceedings of the International Societyu for Optical Engineering (SPIE), International Symposium on Biomedical Optics 4248, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynami Therapy X, San Jose CA, January 2001.
21. Neeman M, Provenzale JM, DEWHIRST MW, MRI applications in the evaluation of
tumor angiogenesis, Semin Radiat Oncol 11:70-82, 2001.
22. DEWHIRST MW, Vigliante BL, Lora-Michaels M, Hanson M, Hoopes PJ, Thermal dose requirements for tissue effect: Experimental and clinical findings thermal treatment of tissue: Energy delivery and assessment II. Proceedings of SPIE 4953: 37-57, 2003.
23. Goldstein, L. S., DEWHIRST MW, Repacholi, M., and Kheifets, L. Summary,
conclusions and recommendations: adverse temperature levels in the human body. Int J Hyperthermia, 19: 373-384, 2003.
24. DEWHIRST MW, Richardson, R., Cardenas-Navia, I., and Cao, Y. The relationship
between the tumor physiologic microenvironment and angiogenesis. Hematol Oncol Clin North Am, 18: 973-990, vii, 2004.
25. Moeller, B. J., Cao, Y., Vujaskovic, Z., Li, C. Y., Haroon, Z. A., and DEWHIRST MW.
The relationship between hypoxia and angiogenesis. Semin Radiat Oncol, 14: 215-221, 2004.
Chapters in Books 1. Ferguson HR, DEWHIRST MW, Morrison WB, Neoplasms of the hematopoietic and
lymphopoietic systems. In: MJ Bojrab (ed.), Pathophysiology in Small Animal Surgery. Philadelphia: Lea and Febiger, 1981. Pp 483-501.
47
2. DEWHIRST MW, Moon T, Carlin D, Analysis of tumor volume and thermal dosimetric effects on tumor response to heat, radiation, and heat plus radiation: Results of a phase III randomized clinical trial in pet animals. In: H Nussbaum (ed.), Physical Aspects of Hyperthermia. New York: American Institute of Physics, 1982. Pp 495-510.
3. DEWHIRST MW, Sim DA, Analysis of prognostic variables which influence early and
long term responses of spontaneous pet animal tumors to heat and radiation. In: JM Vaeth (ed.), Frontiers in Radiation Oncology. Basel: S. Karger, 1984. Vol. 18, pp 47-55.
4. DEWHIRST MW, Connor WG, Hyperthermia. In: IM Gourley and PB Vasseur (eds.),
General Small Animal Surgery. Philadelphia: J.B. Lippincott Co., 1985. Pp 941-960. 5. DEWHIRST MW, Connor WG, Hyperthermia. In: DH Slatter (ed.), Textbook of Small
Animal Surgery. Philadelphia: J.B. Lippincott Co., 1985. Pp 941-960. 6. DEWHIRST MW, Hyperthermia. In: GH Theilen and BR Madewell (eds.), Veterinary
Cancer Medicine. Philadelphia: Lea & Febiger, 1987. Pp 197-214. 7. DEWHIRST MW, Animal modeling and thermal dose. In: RS Steeves and BR Paliwal
(eds.), Syllabus: A Categorical Course in Radiation Therapy: Hyperthermia. Oakbrook: The Radiological Society of North America, 1987. Pp 37-44.
8. DEWHIRST MW, Page RL, Thrall DE, Hyperthermia. In: SJ Withrow and EG MacEwen
(eds.), Clinical Veterinary Oncology. Philadelphia: J.B. Lippincott Co., 1989. Pp 113-123.
9. DEWHIRST MW, A review of the University of Arizona experience in the treatment of
spontaneous pet animal malignancies with hyperthermia and/or radiotherapy. In: M Urano and E Douple (eds.), Hyperthermia and Oncology. The Netherlands:VSP, 1989. Vol. 2, Pp 147-164.
10. Kim JH, DEWHIRST MW, Young CW, Hyperthermia: Current status. In: VT DeVita Jr, S
Hellman, and SA Rosenberg (eds.), Cancer: Principles and Practices of Oncology, 3rd Edition. Philadelphia: J.B. Lippincott Company, 1989. Pp 2-11.
11. DEWHIRST MW, Hyperthermia. In: PV Woolley (ed.), Cancer Growth and Progression.
The Netherlands: Kluwer Academic Publishers, 1989. Vol. 10, Pp 159-164. 12. DEWHIRST MW, Animal modeling and thermal dose. In: RA Steeves (ed.), The
Radiologic Clinics of North America. Philadelphia:W.B. Saunders, 1989. Vol. 27, Pp 509-518.
13. DEWHIRST MW, Hyperthermia in cancer therapy: Model systems. In: R Morimoto, A
Tissieres, C Georgopoulus (eds.), Stress Proteins in Biology and Medicine. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1990. Pp 101-116.
14. DEWHIRST MW, Microvascular changes induced by radiation exposure: Implications for
therapy. In: P Vaupel and R Jain (eds.), Tumor Blood Supply and Metabolic Microenvironment. New York:Gustav Fischer Verlag, 1991. Pp 109-122.
15. Secomb TW, Hsu R, DEWHIRST MW, Models for oxygen exchange between
microvascular networks and surrounding tissue. In: JJ McGrath (ed.), Advances in Biological Heat and Mass Transfer. New York:The American Society of Mechanical Engineers, 1992. Vol. 231, Pp 121-127.
48
16. Prescott, DM, DEWHIRST MW, Hyperthermia: Update and current indications. In: RW
Kirk amd JD Bonagura (eds.), Kirk's Current Veterinary Therapy XI, Small Animal Practice. Philadelphia: W.B. Saunders, 1992. Pp. 418-423.
17. DEWHIRST MW, Angiogenesis and blood flow in solid tumors. In: BA Teicher (ed.), Drug Resistance in Oncology. New York:Marcel Dekker, Inc., 1993. Pp 3-24.
18. DEWHIRST MW, Mechanisms of hyperthermic cytotoxicity and effects at the tissue
level. In: RB Roemer (ed.), Advances in Bioheat and Mass Transfer. New York:The American Society of Mechanical Engineers, 1993. Vol. 268.
19. DEWHIRST MW, Needham D, Extravasation of Stealth® liposomes into tumors: Direct
measurement of accumulation and vascular permeability using a skin-flap window chamber. In: D Lasic and F Martin (eds.), Stealth® Liposomes, Boca Raton: CRC Press, 1995. Pp 127-137.
20. DEWHIRST MW, Thermal dosimetry. In: MH Seegenschmiedt, P Fessenden and CC
Vernon (eds.), Principles and Practice of Thermoradiotherapy and Thermochemotherapy. Berlin: Springer-Verlag, 1995. Vol. 1, Pp 123-136.
21. Hauck ML, Zalutsky MR, DEWHIRST MW, Enhancement of radiolabeled monoclonal
antibody uptake in tumors with local hyperthermia. In: Torchilin VP (ed.) Targeted delivery of imaging agents, Boca Raton, CRC Press, 1995. Pp 335-361.
22. DEWHIRST MW, Considerations for hyperthermia clinical trial designs. In: MH
Seegenschmiedt, P Fessenden and CC Vernon (eds.), Principles and Practice of Thermoradiotherapy and Thermochemotherapy. Berlin: Springer-Verlag, 1996. Vol. 2, Pp 361-372.
23. Marks LB, Spencer DP, Acker JC, Yang W, Avery MA, Dodge RK, DEWHIRST MW,
Radiosurgery in rat brain. In: Kondziolka D (ed): Radiosurgery. Basel:Karger, 1996. Vol. 1, Pp 308-315.
24. Zalutsky MR, Schuster JM, Garg PK, Archer GE, Jr., DEWHIRST MW, Bigner DD, Two
approaches for enhancing radioimmunotherapy: Alpha emitters and hyperthermia. In: H Bihl (ed.), Recent Results in Cancer Research. Berlin: Springer-Verlag, 141: 101-22, 1996.
25. Freeman ML, Henle KJ, DEWHIRST MW, Hyperthermia. In: Bertino JR (ed.),
Encyclopedia of Cancer. New York City:Academic Press, 1997. Vol. 2, Pp 447-459. 26. Meyer RE, DEWHIRST MW, The Use of blood substitutes in tumor therapy. In: Rudolph
AS, Feuerstein G, Rabinovivi (eds), Fundamental Principles and Clinical Applications of Red Cell Substitutes. New York:Marcel Dekker, Inc., 1998. Pp.287-307.
27. DEWHIRST MW, Hyperthermia. In: JD Bonagura (ed.), Kirk's Current Veterinary Therapy
XIII, Philadelphia:W.B. Saunders, (In Press 1998). 28. Haroon ZA, Peters KG, Greenberg CS, DEWHIRST MW, Angiogenesis and oxygen
transport in solid tumors. In: Teicher BA (ed). Antiangiogenic Agents in Cancer Therapy. Totowa :Humana Press Inc., 1998. Pp 3-21.
29. DEWHIRST MW, Hyperthermia. In: Bonagura JD (ed). Kirk's Current Veterinary
49
Therapy XIII Small Animal Practice. Philadelphia:WB Saunders Co., 1999. Pp 486-493 30. DEWHIRST MW, Gibbs FA, Roemer RB, Samulski TV, Hyperthermia. In: Leonard L.
Gunderson and Joel E. Tepper (eds.), Clinical Radiation Oncology, Philadelphia :Churchill Livingstone Inc., 2000. Pp. 256-282.
31. Meyer RE, Braun RD, DEWHIRST, MW, Anesthetic considerations for the study of
murine tumor models. In: Teicher BA (ed). Tumor Models in Cancer Research, Totowa:Humana Press, 2000. Pp 407-431.
32. DEWHIRST MW, Thrall D, Macewen E, Spontaneous pet animal cancers. In: Teicher BA
(ed). Tumor Models in CancerResearch, Totowa:Humana Press, 2000. Pp 565-589. 33. DEWHIRST MW, Jones, E., Samulski, T. V., Vujaskovic, Z., Li, C., and Prosnitz, L.
Hyperthermia. In: D. Kufe, R. Pollock, R. Weischelbaum, R. Bast, T. Gansler, J. Holland, and E. Frei (eds.), Cancer Medicine, 6th edition, Vol. 1, pp. 623-636. Hamilton: BC Decker, 2003.
34. Jones, E., Samulski, T., Vujaskovic, Z., Prosnitz, L., DEWHIRST MW, Hyperthermia. In:
C. A. Perez, L. W. Brady, E. C. Halperin, and R. K. Schmidt-Ullrich (eds.), Principles and Practice of Radiation Oncology, pp. 699-735. Philidelphia: Lippincott Williams & Wilkins, 2004.
35. DEWHIRST MW, Jones, E., Samulski, T. V., Vujaskovic, Z., Li, C., and Prosnitz, L.
Hyperthermia. In: D. Kufe, R. Bast, W.N. Hait, W.K. Hong, R. Pollock, R. Weischelbaum, J.F. Holland, and E. Frei (eds.), Cancer Medicine, 7th edition, pp. 549-561. Hamilton: BC Decker, 2006.
36. DEWHIRST MW, Jones, E., Samulski, T. V., Das, S., Craciunescu, O., Vujaskovic, Z., Li, C. Y., and Prosnitz, L. R. Hyperthermia. In: L. L. Gunderson and J. E. Tepper (eds.), Clinical Radiation Oncology, pp. 385-405. Philadelphia: Elsevier Churchill Livingstone, 2006. Books Editor 1. Paliwal BR, Hetzel FW, DEWHIRST MW (eds.), Biological, Physical, and Clinical
Aspects of Hyperthermia. New York:American Institute of Physics, 1988. Medical Physics Monograph No.16.
Other
Published Scientific Reviews 1. Oleson JR, DEWHIRST MW, Hyperthermia: An overview of current progress and
problems. In: RC Hickey (ed.), Current Problems in Cancer. Chicago:Year Book Medical Publishers, 1983. Vol. VIII, No. 6.
2. DEWHIRST MW, Samulski TV, Hyperthermia in the treatment of cancer. Current
Concepts. Kalamazoo: The Upjohn Company, 1988. INVITED PRESENTATIONS
50
1. INVITED LECTURE: Practical Cancer Biology. Arizona Academy of Veterinary Practice, 1982.
2. INVITED LECTURE: Sim DA: Analysis of prognostic variables which influence early and long
term response of pet animal tumors to radiation plus heat (XRT+v). Eighteenth Annual West Coast Cancer Foundation Conference on Hyperthermia, 1983.
3. INVITED LECTURE: Sim DA, Sapareto SA: The importance of minimum tumor temperatures
in determining early and long term responses of spontaneous pet animal tumors to heat and radiation. Symposium on Thermal Dosimetry; Annual Radiation Research Society Meeting, 1983.
4. INVITED LECTURE: Sim DA: The utility of thermal dose as a predictor of tumor and normal
tissue responses to combined radiation and hyperthermia. Workshop Conference on Hyperthermia in Cancer Treatment, 1984.
5. INVITED LECTURE: Hyperthermia, Biologic Overview. Hyperthermia Short Course
Mallinckrodt Institute of Radiology, 1984.
6. INVITED LECTURE: Hyperthermia, Biologic Overview, In Vivo. Hyperthermia Workshop Sponsored by Atomic Energy of Canada, 1984.
7. INVITED LECTURE: Thermal dose concepts in clinical hyperthermia. First Annual Clinical
Hyperthermia Symposium and Workshop Mallinckrodt Institute of Radiology, Washington University, 1985.
8. INVITED LECTURE: Considerations in the correlation between thermal dose and tumor and
normal tissue response. Seventh Annual Conference of the IEEE-EMB, 1985.
9. INVITED LECTURE: Thermal dose concepts in clinical hyperthermia. A Practical Course of Hyperthermia in Cancer Therapy, University of Wisconsin, Madison, 1985.
10. INVITED LECTURE: Animal Experience-physiologic effects of heat. Concepts in Cancer
Treatment: Hyperthermia-Past, Present, and Future. American Cancer Society, 1986.
11. INVITED LECTURE: Drug modifiers in hyperthermia. Concepts in Cancer Treatment: Hyperthermia—Past, Present, and Future. American Cancer Society, 1986.
12. VISITING PROFESSOR: Clinical utilization of thermal dose. Radiation Oncology Training
Program. University of Illinois at Champaign, Urbana, 1986.
13. VISITING PROFESSOR: Effect of rate of heating on tumor and normal tissue microcirculatory blood flow. Radiation Oncology Training Program. University of Illinois at Champaign, Urbana, 1986.
14. INVITED LECTURE: Animal modeling and thermal dose. Syllabus: A categorical course in
radiation therapy: Hyperthermia. Seventy-third Scientific Assembly and Annual Meeting of the Radiological Society of North America, 1987.
15. VISITING PROFESSOR: Heat and radiation effects in tumor and normal tissue
microcirculation. Visiting Professor, Joint Center for Radiation Therapy, Harvard Medical School, 1987.
51
16. VISITING PROFESSOR: Utilization of thermal isoeffect dose in hyperthermia therapy. Joint Center for Radiation Therapy, Harvard Medical School, 1987.
17. INVITED LECTURE: Physiological effects in hyperthermia. 1987 Hyperthermia School,
Physical Aspects of Hyperthermia, Duke University Medical Center, 1987.
18. INVITED LECTURE: Biology of interaction of hyperthermia, radiation, and drugs. The Promise of Hyperthermia Symposium, Cross Cancer Institute, 1989.
19. INVITED LECTURE: A critical analysis of the status of hyperthermia as an adjuvant to
radiation and chemotherapy. NCI Grand Rounds, 1991.
20. VISITING PROFESSOR: A critical analysis of the status of hyperthermia as an adjuvant to radiation and chemotherapy. Vincent T. Lombardi Cancer Research Center, Georgetown University, 1991.
21. VISITING PROFESSOR: A review of the Hyperthermia Program at Duke University.
Department of Radiation Oncology, Arizona Health Sciences Center, 1992.
22. VISITING PROFESSOR: Studies of oxygen transport in tumor tissues. Department of Radiation Oncology, Stanford University, 1992.
23. VISITING PROFESSOR: Thermal dosimetric principles in clinical hyperthermia. Kyoto
University, Japan, 1992.
24. INVITED LECTURE: Present status of Hyperthermic Oncology in the United States of America. Health Research Foundation of Japan, Tokyo Metropolitan Komagome Hospital, 1992.
25. VISITING PROFESSOR: Studies of tumor oxygenation and reoxygenation after radiation
exposure. Department of Radiation Biology, Colorado State University, 1992.
26. INVITED LECTURE: Prediction and monitoring of tumor response to thermoradiotherapy. Department of Radiation Oncology, Washington University, 1992.
27. INVITED LECTURE: Studies of tumor oxygenation and reoxygenation after radiation
exposure. Radiation Biology Branch, National Cancer Institute, 1993.
28. INVITED LECTURE: Plenary Lecture: Current concepts in hyperthermic dose prognostic variables. Radiat Res Society Forty-first Annual Meeting / North American Hyperthermia Society Thirteenth Annual Meeting, 1993.
29. INVITED LECTURE: Studies of tumor oxygenation and reoxygenation after radiation
exposure. Department of Radiation Oncology, William Beaumont Hospital, 1993.
30. INVITED LECTURE: Future directions in cancer biology and therapeutics. Symposium on Cancer Therapy, William Beaumont Hospital, 1993.
31. INVITED LECTURE: Future directions in hyperthermia biology. Stanford Hyperthermia
Symposium. Stanford University, 1993.
32. INVITED LECTURE: Mechanisms of hyperthermic damage. American Society of Mechanical Engineers Annual Meeting, 1993.
52
33. VISITING PROFESSOR: Current studies on response prediction and therapy monitoring in
hyperthermia. Department of Radiation Oncology, Thomas Jefferson University, 1994.
34. INVITED LECTURE: Modulation of tumor blood flow by nitric oxide. Radiation Biology Branch, National Cancer Institute, National Institutes of Health, 1994.
35. INVITED LECTURE: Rationale and historical results utilizing hyperthermia in the clinic.
American Society for Therapeutic Radiology and Oncology. Thirty-Sixth Annual Meeting, 1994.
36. INVITED LECTURE: Feasibility and techniques of modifying tumor blood flow. Radiation
Research Society Forty- third Annual Meeting, 1995.
37. VISITING PROFESSOR: Studies in oxygen transport in tumors. Department of Radiation Oncology, University of Pennsylvania, Philadelphia, 1995.
38. VISITING PROFESSOR: Oxygen transport in tumors. Department of Radiation Oncology,
Thomas Jefferson University, 1995.
39. INVITED LECTURE: Plenary Lecture: Oxygen transport in tumors: Clinical implications. Veterinary Cancer Society Annual Meeting, 1995.
40. VISITING PROFESSOR: Instability in tumor oxygen transport. Department of Radiation
Oncology, University of Pennsylvania, Philadelphia, 1995.
41. PLENARY LECTURE: Clinical implications and techniques for modification of tumor oxygenation. Sixth World Congress for Microcirculation, 1996.
42. PLENARY LECTURE: New concepts regarding the physiologic effects of hyperthermia:
Suggestions for new therapeutic strategies. The Japan Radiation Research Society, Osaka, Japan, 1996.
43. PLENARY LECTURE: New concepts in thermal dosimetry. Seventh International Congress
on Hyperthermic Oncology, Rome, Italy, 1996.
44. INVITED LECTURE: New concepts in oxygen transport in tumors. Semi-Annual Research Retreat, William Beaumont Hospital, Detroit, Michigan, 1996
45. VISITING PROFESSOR: Angiogenesis and inflammation in tumors. Louisiana State
University Medical School, Shreveport, 1997.
46. INVITED LECTURE: President's Symposium, Annual Meeting Radiation Research Society, Studies of flow instability in dorsal flap window chamber tumors: Implications for transient hypoxia. Providence, RI, 1997.
47. VISITING PROFESSOR: New concepts in tumor oxygen transport. CRC Gray Laboratory,
Middlesex, England, 1997.
48. VISITING PROFESSOR: New concepts in tumor oxygen transport. St. George's Hospital, London, England, 1997.
53
49. VISITING PROFESSOR: New concepts in tumor oxygen transport. University of Bath, Bath, England, 1997.
50. VISITING PROFESSOR: Mechanisms of oxygen transport in tumor tissues. British Columbia
Cancer Agency, 1998.
51. VISITING PROFESSOR: Pathophysiologic mechanisms of tumor hypoxia: Biological & clinical implications. College of Veterinary Medicine, North Carolina State University, 1998.
52. VISITING PROFESSOR: Manipulation of tumor blood flow by nitric oxide: lessons in nitric
oxide biology. University of Pennsylvania, 1998.
53. VISITING PROFESSOR: Mechanisms of oxygen transport in tumor tissues. Washington University, 1998.
54. VISITING PROFESSOR: Mechanisms of oxygen transport in tumor tissues; Inflammation,
angiogenesis and metastasis in solid tumors. College of Veterinary Medicine, University of Pennsylvania, 1998
55. PLENARY LECTURE: Hyperthermia: Emphasis on Drug Delivery and Gene Therapy. 2nd
Asian Congress of Hyperthermic Oncology, Tokyo, Japan, 1998.
56. VISITING PROFESSOR: Mechanisms of oxygen transport in tumor tissues. St. Jude Children’s Research Hospital, 1999.
57. VISITING PROFESSOR AND CONSULTANT: Oxygen transport mechanisms. University of
Arizona, Comprehensive Cancer Center, College of Medicine, 1999
58. VISITING PROFESSOR AND CONSULTANT: Study of solid tumor physiology with spontaneous canine malignancies. University of Missouri, College of Veterinary Medicine, 1999.
59. INVITED LECTURE: Hyperthermia as a means to trigger gene therapy. Annual DEGRO
conference, Karlsrue, Germany, 1999.
60. VISITING PROFESSOR: Basic and clinical studies of tumor angiogenesis. Medical College of Wisconsin, Milwaukee, 2000.
61. VISITING PROFESSOR: Basic and clinical studies of tumor angiogensis. University of
Pennsylvania, College of Medicine, 2000.
62. VISITING PROFESSOR: Hypoxia and Angiogenesis. University of Texas, MD Anderson Hospital, 2001.
63. CANCER CENTER LECTURER: Role of hypoxia in tumor angiogenesis. Georgetown University, 2001.
64. INVITED LECTURE: Control of gene therapy by the heat shock promoter. 7th International
meeting on Progress in Radio-Oncology, Salzburg, Austria, 2002.
65. VISITING PROFESSOR: Role of hypoxia in tumor angiogenesis. Vanderbilt University, October, 2002.
54
66. INVITED LECTURE: Clinical relevance and mechanisms underlying development of hypoxia in solid tumors. Biomedical Imaging Research Opportunities Workshop, Bethesda, MD, January 31-February 1, 2003.
67. SYMPOSIUM LECTURE: Microenvironmental influence on angiogenesis and tumor cell
survival, International Society for Biological Therapy, San Francisco, CA, October 3, 2004.
68. VISITING PROFESSOR: Microenvironmental influence on angiogenesis and tumor cell survival, Wayne State University, November 30, 2004.
69. EXTERNAL PHD THESIS EXAMINER: Pierre Sonveaux, Clinical relevance and physiologic
determinants of hypoxia, University of Louvain, Brussels Belgium, January 16, 2004.
70. VISITING PROFESSOR AND SPEAKER: Clinical relevance/physiologic determinants and implications of hypoxia in cancer immunotherapy, Rosewell Park Cancer Center, February 27, 2004.
71. SYMPOSIUM SPEAKER: Paradoxical HIF-1 signaling during tumor reoxygenation: The role
of free radicals and stress granules, Keystone Symposium on Hypoxia Response, Steamboat Springs, Colorado, March 26-29, 2004.
72. SYMPOSIUM SPEAKER: What is translational research and how can it be applied to pet
animal cancers?, American College of Veterinary Internal Medicine, June 10-11, 2004.
73. SYMPOSIUM SPEAKER: 25 years of clinical trials with spontaneous pet animal cancers: Lessons learned and taught. American College of Veterinary Internal Medicine, June 10-11, 2004.
74. BRUCE CAIN MEMORIAL LECTURE: Tumor-endothelial cell interactions – evidence for
paracrine survival signals with and without hypoxia and therapy. New Zealand Society for Oncology, Christ Church, New Zealand, June 25, 2004.
75. VISITING PROFESSOR: Tumor-endothelial cell interactions–evidence for paracrine survival signals with and without hypoxia and therapy. University of Aukland, June 14, 2004.
76. SYMPOSIUM SPEAKER: Microenvironmental influence on angiogenesis and tumor cell
survival. Gordon Conference on Translation in Radiation Oncology, Ventura, CA, January 30-February 4, 2005.
77. LECTURER: Microenvironmental influence on angiogenesis and tumor cell survival. 7th
International Symposium on Antiangiogenic Agents, La Jolla, CA, March 8-12, 2005.
78. AC BURTON MEMORIAL LECTURE: Progress toward understanding the inter-relationship between tumor hypoxia and angiogenesis: A technology-enabled quest. Western Medicine and Dentistry, London, Canada. March 23, 2005.
79. LECTURER: Redefining the biology of hyperthermia. Educational Symposium on
Hyperthermia, Society for Thermal Medicine, Bethesda, MD, March 31, 2005.
80. LECTURER: Microenvironmental influence on tumor-endothelial cell interactions: implications for modulation of treatment response, Josephine Nefkins Institute Lecture, Erasmus Medical Center, Rotterdam, The Netherlands, September 16, 2005.
55
81. LECTURER: Hypoxia and Radio/Chemoresistance. 7th International Symposium on
Antiangiogenic Agents, La Jolla, CA, February 2-5, 2006.
82. LECTURER: HIF Signaling during Tumor Reoxygenation. Keystone Conference: Hypoxia and Development, Physiology and Disease, Beaver Run Resort, Colorado, January 16-21, 2006.
83. LECTURER: What are the key physiological consequences of hyperthermia treatment?
Society for Thermal Medicine, Bethesda, MD, April 5-8, 2006.
84. LECTURER: What are the key physiological consequences of hyperthermia treatment? European Society for Hyperthermic Oncology. Berlin, Germany, May 22-26, 2006.
85. VISITING PROFESSOR: Understanding the role between hypoxia and tumor angiogenesis:
The role of HIF-1. Wake Forest University, Winston Salem, NC, May 4th, 2006.
86. LECTURER: Oncogenesis and Thermal Ablation. World Congress of Interventional Oncology, Lake Como, Italy, June 11-16th, 2006.
87. SYMPOSIUM LECTURER: Rationale for combining thermal ablation with radiotherapy. World
Congress of Interventional Oncology, Lake Como, Italy, June 11-16th, 2006.
88. LECTURER: Exploring HIF-1 as a therapeutic target when combined with radio and chemotherapy. BACR Conference on Tumour Vasculature: New targets and therapies, Cirencester, England, June 25-28, 2006.
89. VISITING PROFESSOR: Exploring HIF-1 as a therapeutic target when combined with
radiotherapy, chemotherapy and Hyperthermia, Retirement Symposium for Chang W. Song, University of Minnesota, Minneapolis, MN, August 14th, 2006.
90. LECTURER: Development of a heat triggered drug release method. Cancer Biology
Symposium. Wake Forest University Cancer Center, Winston Salem, NC, August 25th, 2006.
91. LECTURER: Evaluation of factors involved in incipient angiogenesis. 5th Annual meeting of
the Society for Molecular Imaging. Waikoloa, Hawaii, August 29-September 3rd, 2006.
92. LECTURER: Targeting the interrelationship between tumor hypoxia and angiogenesis: the role of HIF-1. Duke Comprehensive Cancer Center Post ASCO Symposium, Durham, NC, October 15, 2006
93. REFRESHER COURSE LECTURE: Angiogenesis and Metastasis. ASTRO Annual Meeting,
Philadelphia, PA, November 5th, 2006
94. PLENARY SESSION COMMENTARY: Characterization of intermittent hypoxia – a commentary. ASTRO Annual Meeting, Philadelphia, PA, November 5-9th, 2006.
95. LECTURER: Evaluation of factors involved in incipient angiogenesis and cytotoxic therapy
response. Annual Molecular Imaging Symposium, University of Texas Southwest, November 16th, 2006.
96. SYMPOSIUM LECTURE: Biologic principles of cell killing by radiation. Radiological Society
of North America Annual Meeting, Chicago Ill, November 29th, 2006.
56
97. SYMPOSIUM LECTURE: Rationale for combining thermal ablation with radiotherapy.
Radiological Society of North America Annual Meeting, Chicago Ill, November 29th, 2006.
98. VISITING PROFESSOR: Evaluation of factors involved in incipient angiogenesis and cytotoxic therapy response. Memorial Sloan Kettering Cancer Center, December 19th, 2006.
99. LECTURER: Exploring HIF-1 as a therapeutic target with radiotherapy and chemotherapy.
8th International Symposium on Antiangiogenic Agents, La Jolla, CA, January 31-Feb 2, 2007.
100. VISITING PROFESSOR: Targeting the Hypoxia Response in Cancer Therapy and Clinical
and Physical Aspects of Hyperthermia. Cancer Center Lecturer, Johns Hopkins University, March 21-23, 2007.
101. SYMPOSIUM LECTURE: Targeting the Hypoxia Response in Cancer Therapy, American
Society of Physiology, FASEB Annual Meeting, Washington, DC, April 27-29, 2007.
102. SYMPOSIUM LECTURE: Characterizing temporal instabilities in oxygenation, Microcirculatory Society, FASEB Annual Meeting, Washington, DC, April 27-29, 2007.
103. KEYNOTE SPEAKER AND SESSION CHAIR: Role of HIF-1 in early tumor angiogenesis and
tumor response to radiation and chemotherapy, 10TH International Wolfsberg Meeting on Molecular Radiation Biology/Oncology, Wolfsberg, Switzerland, May 11-13, 2007.
104. SYMPOSIUM LECTURE: A commentary regarding combined modality approaches with
hyperthermia and thermal ablation, Society for Thermal Medicine and World Congress of Interventional Oncology, Washington, DC, May 14-18, 2007.
105. SYMPOSIUM LECTURE: Development of a heat-targeted drug release method, European
Society of Hyperthermic Oncology, Prague, June 11-15, 2007.
106. SYMPOSIUM LECTURE: Biological considerations for thermal therapy, European Society of Hyperthermic Oncology, Prague, June 11-15, 2007.
107. SYMPOSIUM LECTURE: Two novel approaches for monitoring hypoxia response, RTOG
Annual Meeting, Philadelphia, June 23, 2007.
108. SYMPOSIUM LECTURE AND SESSION CHAIR: Exploring the role of HIF-1 in angiogenesis and response to therapy, -STROMA CONSORTIUM INTERNATIONAL CONFERENCE ON Vascular Targeted Therapies in Oncology, Mandeliu, France, October 4-6, 2007.
109. VISITING PROFESSOR: Exploring the role of HIF-1 in angiogenesis and response to therapy,
University of Louvain, Brussels, October 23, 2007.
110. PARTICIPANT: David Koch Forum on Screening for new concepts in controlling advanced cancer, Johns Hopkins University, Donald Coffey, Chair, November 12, 2007.
111. VISITING PROFESSOR: Evaluation of factors in incipient angiogenesis and cytotoxic
treatment response, University of Texas Southwest Medical Center, Dallas, TX, December 17-18, 2007
112. SYMPOSIUM LECTURE AND SESSION CHAIR: Oxidative stress and HIF-1 in early
angiogenesis and response to radiotherapy and chemotherapy, Keystone Conference
57
“Molecular, cellular, physiologic and pathogenic responses to hypoxia, Vancouver BC, January 15-20, 2008.
113. LECTURER: Targeting the Achilles Heel of Hypoxic Tumor Cells, University of Texas, M.D.
Anderson Cancer Center, Houston, TX, April 7, 2010.
114. LECTURER: Novel Development in Tumor Metabolism, University of Chicago, Chicago, IL, April 28, 2010.
115. LECTURER: Overview of Hyperthermia, University of California, San Francisco (UCSF
Radiation Oncology Update: Management of Recurrent Disease Conference), May 1, 2010.
116. LECTURER: Lecture 1 – Future of Biological Rationale and Thermo-Liposomes; Lecture 2 – Design and in vitro testing of novel thermally sensitive liposomal formulation for treatment of local tumors: how to achieve drug release in the blood stream. ESHO 26th
Annual Meeting , Rotterdam, The Netherlands, May 20, 2010. 117. LECTURER: Mechanism of hypoxia response after hyperthermia treatment. ESHO 26th Annual Meeting, Rotterdam, The Netherlands, May 21, 2010. 118. LECTURER: Cycling hypoxia, HIF-1 and response to therapy. Cerulean Pharma Incorporated, Cambridge, MA, June 23, 2010. 119. LECTURER: Cancer effects of Mn porphyrins. Sixth International Conference on Porphyrins
and Phthalocyanines, Hyatt Regency Tamaya Resort, Santa Ana Pueblo, New Mexico, July 9, 2010.
120. LECTURER: Hypoxia as a confounding factor in radiation therapy. The National Cancer Institute (NCI) Workshop (The Molecular Bases of Radiation Resistance of Human Cancers), Bethesda, MD, September 2, 2010. 121. LECTURER: Brain Tumor SPORE. (2011 Mid-Winter Meeting of the NCI/NIH Brain Tumor SPORES, University of California, San Francisco, CA, January 28, 2011. 122. LECTURER: Targeting the Achilles Heel of Hypoxic Tumor Cells. (Distinguished Lecturer Series, Thomas Jefferson University, Dept. of Pathology, Anatomy and Cell Biology, Phildelphia, PA., February 9, 2011.) 123. LECTURER: Clinical Application of Hyperthermia. (UCLA- Clark Urology Center, Los Angeles, CA, Feb. 22, 2011.) 124. LECTURER: Role of Reactive Species Stress on the HIF-1 Response after CytoxicTherapies.
(UCLA U19 Annual Symposium and EAC Meeting, David Geffen School for Medicine, UCLA, Divison of Molecular and Cellular Oncology, Dept. of Radiation Oncology, Los Angeles, CA., February 25, 2011.)
125. LECTURER: Paradoxical Effects of Cytotoxic Therapies: Activatiion of HIF 1 by Tumor and Stromal Cells. (American Association for Cancer Reserarch 102nd Annual Meeting, Orange County Convention Center, Orlando, Florida, April 5, 2011.) 126. LECTURER: Hypoxia, Free Rdicals, VEGF and HIF-1; Harbingers of Unstable Vascular Networks in Tumors. (Program Farewell Conference for Bert van der Kogel and Adrian
Begg, Nijmegen, The Netherlands, April 29, 2011).
58
127. LECTURER: Development of novel thermally sensitive liposomes from bench to bedside. (6th Annual Cancer nanobiology Think Tank: Triggered nanoparticles, NCI-Frederick, Frederick, MD, May 17, 2011). 128. LECTURER: Thermo Dosimetry. (27th Annual Meeting at ESHO, Aarhus, Denmark, May 25, 2011). 129. SYMPOSIUM SPEAKER: “Lactate metabolism as a target for therapeutic intervention”
AACR Metabolism and Cancer, Special Conference, Baltimore, MD, October 17, 2011 130. VISITING PROFESSOR: New metabolic targets as novel cancer therapeutics. University of
Pittsburgh, Cancer Center Lecture Series, October 25, 2011. 140. SYMPOSIUM SPEAKER: An Historical Overview of Hodgkin's Disease, Radiation Biology
and Cancer of the Breast; Notable Discoveries in Radiobiology, ASTRO 53rd Annual Meeting, Miami, Fl, October 4th, 2011
141. VISITING PROFESSOR: New metabolic targets as novel cancer therapeutics, Yale University,
Radiation Oncology Grand Rounds, November 15th, 2011 142. VISITING PROFESSOR: New metabolic targets as novel cancer therapeutics, University of
Massachusetts, Biology Departmental Seminar, November 16th, 2011 143. SYMPOSIUM SPEAKER: Therapeutic Targeting of Hypoxia Response Pathways, Keystone
Conference on Hypoxia and Tumor Metabolism, Banff, Canada, February 16th, 2012 144. VISITING PROFESSOR: New metabolic targets as novel cancer therapeutics, Moffitt Cancer
Center, Tampa Bay, Fl, March 16th, 2012 145. SYMPOSIUM SPEAKER: A critical Evaluation of Methods for Imaging Tumor Hypoxia,
NYAS Symposium on Tumor Hypoxia, New York, NY, March 14th, 2012 146. KEYNOTE SPEAKER/EXTERNAL ADVISOR: New metabolic targets as novel cancer
therapeutics, Biophysical Therapies Program Retreat, Buffalo, NY, May 6, 2012. 147. SYMPOSIUM SPEAKER: Vascular Response to Microbeam Radiation Therapy In Vivo
using a Murine Window Camber Tumor Model: Symposium on “Biophysical Modeling for High-Dose Hypofractionated Radiotherapy, American Association of Physicists in Medicine, Charlotte, NC, August 1, 2012.
148. INVITED SPEAKER: Low Temperature Sensitive Liposomes: A Revoluntionary Paradigm
for Triggered Intravascular Drug Release: 11th International Congress of Hyperthermic Oncology and the 29th Japanese Congress of Thermal Medicine (ICHO & JCTM2012), Kyoto, Japan, August 28, 2012.
149. INVITED SPEAKER: Primer on Grant Writing Preparation: Keys to Being Competitive:
NUS Graduate Medical School, Singapore, Japan, September 1, 2012. 150. INVITED SPEAKER/HOST: Host: Nuclear Medicine/Molecular Imaging CME Session and
CME Posters. Rational Approaches to Combination Therapy: The Case for Mechanistic Study: VSI041 – Interventional Oncology Series, RSNA 98th Scientific Assembly and Annual Meeting, Chicago, Illinois, Nov. 25, 2012.
59
151. KEYNOTE SPEAKER: Taking Advantage of Lactate and Exercise to Inhibit Tumor Growth. Kallman Lecturer: Stanford University, Stanford, CA, January 24, 2013.
152. KEYNOTE SPEAKER: A Critical Evaluation of Methods for Imaging Tumor Hypoxia. 2013
Cancer Imaging and Radiatiion Therapy Symposium, Orlando, Florida, February 9, 2013. 153. INVITED SPEAKER: Novel Metabolic Targets for Cancer Therapeutics. Sympoisium
Honoring Gloria Li, Memorial Sloan-Kettering Cancer Center, New York, New York, April 9, 2013.
154. INVITED SPEAKER: 1) A Preclinical Study Assessing the Pharmacokinetic Profiles of Novel
Cisplatin-Loaded Thermosensitive Liposomes; 2) Biological Considerations for Failure to Achieve Full Thermal Ablation. Society for Thermal Medicine, Aruba, April 13, 2013.
155. INVITED SPEAKER: Harnessing Imaging to Achieve Controlled Drug Delivery to Tumors.
European Society for Molecular Imaging, Torino, Italy, May 24, 2013. 156. INVITED SPEAKER: 1) New Metabolic Targets for Cancer Therapeutics; 2)Hypoxia,
Angiogenesis and the HIF-1 Response. American College of Veterinary International Medicine (ACVIM), Seattle, Washington, June 12, 2013.
157. INVITED SPEAKER: Biological Considerations for Failure to Achieve Full Thermal Ablation.
European Society for Hyperthermic Oncology (ESHO), Munich, Germany, June 19-22, 2013. 158. INVITED SPEAKER: Imaging and Radiotherapy: New Metabolic Targets as Novel Cancer
Therapeutics. 2nd Gray Institute for Radiation Oncology & Biology Symposium 2013, Worchester College, Oxford, UK, September 5-6, 2013.
159. PARTICIPANT/CHAIR: Hypoxia in Cancer Treatment. 59th Annual Meeting of the Radiation
Research Society (RRS), New Orleans, LA, September 15-18, 2013. 160. INVITED SPEAKER/PARTICIPANT: HIF-1a: Ready for Prime Time? The Joseph B. Martin
Conference Center at Harvard Medical School, Boston, MA, October 22, 2013. 161. INVITED KEYNOTE SPEAKER: New metabolic targets for cancer therapeutics. Veterinary
Cancer Society (VCS) and Veterinary Society of Surgical Oncology (VSSO) Meeting, Grove Park Inn, Asheville, North Carolina, March 16-19, 2014.
PATENTS
1. Engler, M.W. DEWHIRST, and J.R. Oleson: Probe Translation System for Use in Hyperthermia Treatment. U.S. Patent # 07-066, 047, Issued April 1988. 2. Z. Haroon, M.W. DEWHIRST, C.S. Greenberg, M. Neeman: Contrast enhancement
agent for magnetic resonance imaging. International Patent # PCT/US01/49269, Issued, US Patent # 10/025,698, Issued, Canadian Patent # 2,433,657, Pending.
3. M.W. DEWHIRST, M. Dreher, H. Halpern, A. Chilkoti, G. Rosen: Method for non-
invasive thermomertry using elastin-like polypeptide conjugates. US Patent # PCT/US2004/019132, Issued June 15, 2004, International Patent # PCT/US04/19132, Pending.
4. B.L. Viglianti, M.W. DEWHIRST, J.R. MacFall, Z. Vujaskovic: Compounds and methods
for blood pool identification, drug distribution quantification, and and drug release
60
verification. International Patent # PCT/US03/28674, European Patent # 01987446.0, Pending.
5. M.W. DEWHIRST, et al: Methods for improving therapeutic effectiveness of treatment
of vascularization disorders US Patent # 6,020,308, Pending. 6. C.Y. Li, M.W. DEWHIRST, Q. Huang. A method for selective expression of therapeutic
genes by hyperthermia. Serial #10/172,399, Pending. 7. J. DeAngelo, W.M. Cromwell, M.W. DEWHIRST, R.E. Meyer, J. Bonaventura. Methods
for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders. Canadian Patent # 2,163,638, US Patent # 5,788,958, U.S. Patent # 5,554,638, Issued September 1996.
8. Z. Haroon, C.S. Greenberg, M.W. DEWHIRST, Chamber for in vivo screening of
angiogenesis and tumor growth modulating compounds. US Patent # 5,964,745, Issued October 1999, International Patent # PCT/US01/47124, Pending.
9. B. Viglianti, M.W. DEWHIRST, J.R. MacFall, Z. Vujaskovic, Compounds and methods
for blood pool identification, drug distribution qualification, and drug release verification. International Patent # PCT/US03/28674, Pending.
10. M.W. DEWHIRST, S. Shan, B. Sorg. Rodent mammary window for invitral microscopy
of orthotopic breast cancer and related method. U.S. Patent # 10/354,367, Pending. 11. A. Wijayaratne, M.W. DEWHIRST, J. D. Norris, C. E. Connor, Donald P. McDonnell.
Method of Preventing or Treating Estrogen-Dependent Diseases and Disorders, Pending.
12. M.W. DEWHIRST, X. Zhang, C. Y. Li. A novel siRNA-based approach to target the HIF-
alpha Factors for Cancer GeneTherapy, Pending. 13. M.W. DEWHIRST, C. S. Greenberg, Z. Haroon. In Vivo Delivery of An Active Agent and
Methods Relating Thereto, Pending. 14. A. Chilkoti, G. Rosen, E. C. Halperin, M. R. Dreher, M.W. DEWHIRST, Method for
noninvasive thermometry using a nitroxide conjugate of an Elastin-like polypeptide, Pending.
15. A. Wijayaratne, C. E. Connor, M.W. DEWHIRST, J. D. Norris, D. P. McDonnell, Non-
Steroidal Ligands for the Estrogen Receptor, US Patent # 6207716 B1, Pending. CONSULTANT / COLLABORATOR APPOINTMENTS Consultant, Clinitherm Corporation, Dallas, TX, 1984 - 1987. Consultant on RO1 application: The Effect of Photoradiation Therapy on Blood Flow. S.
Selman, PI; Medical College of Ohio, 1984 - 1987. Consultant on PO1 grant: Photodynamic Therapy: Basic Science, 316 Hetzel, PI;; Presbyterian/St. Luke’s Medical Center, Denver, 1987 - Present. Consultant on P01 grant: Nuclear Determinants of Therapeutic Response.
61
317 Roti Roti, PI; University of Washington, 1990 - present Consultant on PPG grant: Optimized hyperthermia treatments for prostate cancer, and selected
large/deep tumors, CN Coleman, PI, Joint Center for Radiation Therapy, Harvard Medical School, 1991 - 1995
Consultant on Army R&D Command grant application: Use of Combination Thermal Therapy
and Radiation in Breast-Conserving Treatment of Extensive Intraductal Breast Cancer. G.K. Svensson, PI; Harvard Medical School, 1992 - 1995.
Consultant on PO1 grant: Modification of Hyperthermia Response, DB Leeper, PI; Thomas Jefferson University, 1992 - Present Consultant on R01 grant: Tissue dielectric changes during hyperthermia, 318 McRae, PI, Georgetown University, 1992 - 1998 Collaborator on proposed Study of vasomotor regulation in tumor microvasculature by ET-1 and
nitric oxide, Katrina Bell, PI, CRC Gray Laboratories, 1995 Collaborator on RO1 grant application: Mechanisms of modification of radiation sensitivity,
Edward Bump, PI, Harvard Medical School, 1995 Collaborator on PO1 grant: Phosphorescence imaging and oxygenation of tumors, J Biaglow, PI, University of Pennsylvania Medical Center, 1995-1996 Consultant on RO1 grant: RB Roemer, PI, University of Utah, 1995-1998 Scientific Advisory Board: Venture Alliance, Knoxville, TN, 1997 Member: Program Committee Member, 8th International Congress on Hyperthermic Oncology,
Korea, 2000, North American Hyperthermia Society Member: Medical Advisory Board: Angiogenesis Panel; Proctor and Gamble, Cincinatti, OH.
May 1999. Member: Medical Advisory Board: Endovascular Branchytherapy, Cordis Corporation,
1999. Consultant and Member: Medical Advisory Board, Celsion Corporation, 1997-2011. Consultant: Piedmont Research Center, Morrisville, NC, 2002- 2011 Consultant, Massey Cancer Center Core Grant, Medical College of Virginia, 2007-present. LAMMP External Advisory Board, Bruce Tromberg, PI UC Irvine, 2007- present Consultant: Actium Biosystems, Inc. Boulder, Co, January 2012-present PROFESSIONAL AWARDS AND SPECIAL RECOGNITIONS Who's Who in American Universities and Colleges, 1974 Cecil B. Matlock Award: Colorado State University, 1974
62
NIH /NRSA Individual Post-Doctoral Fellowship 06/01/75 - 05/31/78 Radiation Effects on the Immune System.
Young Investigator Award: 3rd International Symposium: Cancer Therapy by Hyperthermia,
Drugs, and Radiation, Fort Collins, CO, 1983. Travel Award: Seventh International Congress of Radiat Res, Amsterdam, Netherlands, 1983. Travel Award: Fourth International Symposium on Hyperthermic Oncology, Aarhus, Denmark,
1984. Member NIH/NCI Radiation Study Section 1987 - 1991. Travel Award: Fifth International Symposium on Hyperthermic Oncology, Kyoto, Japan, 1988. Eugene Robinson Lecture, North American Hyperthermia Society, 1992. Norris Cotton Cancer Center Radiation Bioengineering Research Program Research
Excellence Award, Dartmouth Medical School, 1993 R. Wayne Rundles Award for Excellence in Cancer Research, Duke Comprehensive Cancer
Center, 2001 Gustavo Montana Chair in Radiation Oncology, Duke University, July 1, 2002. Madison Who’s Who, 2004. Bruce Cain Lecture, New Zealand Society for Oncology, Christ Church New Zealand, June 25,
2004. A.C Burton Invited Lectureship, University of Western Ontario, London, Canada, March 23,
2005. Josephine Nefkins Institute Lecturer Erasmus Medical Center, Rotterdam, The Netherlands,
September 16, 2005. 1st Mentor-of-the-Year Award, Duke Comprehensive Cancer Center, March 12, 2007. Virginia Logan Lectureship, Radiation Oncology Department, Thomas Jefferson University,
Philadelphia, PA, April 3, 2008. Failla Award and Lectureship, Radiation Research Society, presented at the 54th Annual
Meeting of the Radiation Research Society, Boston, MA. September 21, 2008. Mentor of the Year Award, Medical Physics Training Program, 2009. Duke University School of Medicine Research Mentoring Award for Translational Research,
2010 Fellow of American Society of Therapeutic Radiation and Oncology, 2009 Fellow of American Association for the Advancement of Science, 2010
63
EDITORIAL ACTIVITIES Senior Editor (North America), International Journal of Hyperthermia 1993-2006 Editor-in-Chief, International Journal of Hyperthermia, 2006 Associate Editor, Radiation Research, 1991 - 1995 Associate Editor, International Journal of Radiation Oncology, Biology and Physics, 1992 - 2009. Associate Editor, Experimental Oncology 2000 -present Associate Editor, Clinical Cancer Research 2003-2009 Associate Editor, Cancer Research 2003-2009; Senior Editor, 2010-present Editorial Board, Radiation Oncology Investigation 1992 – 2002 Editorial Board, Microvascular Research 1999 - present Editorial Board, Molecular Cancer Therapeutics 2001-present Served as Ad Hoc Editor for PNAS – 2008-2009 Medical Physics - 2009 Reviewed numerous articles for British Journal of Cancer Cancer Research International Journal of Radiation Oncology, Biology, and Physics International Journal of Hyperthermia Journal of National Cancer Institute Journal of Neuro-Oncology Microcirculation Nature Nature Reviews Cancer PNAS Radiation Research Science Molecular Cancer Therapeutics Clinical Cancer Research ORGANIZATIONS AND PARTICIPATION American Association for Cancer Research Abstract Selection Committee, 1998 American Association for the Advancement of Science American College of Radiology Committee on Hyperthermia, 1986 – 1988 Committee on Government and Public Relations, Commission on Radiation Oncology, 1999-2000
64
American College of Veterinary Radiology Organizing Committee, ACVR Subspecialty in Radiation Oncology Charter Diplomate, ACVR Subspecialty in Radiation Oncology American Society of Radiologic Technologists Task Force on Hyperthermia, 1989-1990. American Society of Therapeutic Radiology and Oncology, Abstract Selection Committee, 1990 - 1994 Committee on Radiation Oncology Research, 1996 Member, Cancer and Radiobiology Committee, 1997-2004 Chairman, Cancer and Radiation Biology Committee, 1997-1998
Member, Committee on Endovascular Brachytherapy, 1998 Board of Directors, 1998-2001 Joint ASTRO/ACR Government Relations Committee, 1999 Subcommittee on Combined Modality Therapy, 1999-2002 Chairman, Joint Commission on Cancer and Radiobiology Curriculum, 2000-2003 Nuclear/Radiologic Response Task Force Annual Meeting - Refresher Courses Sub-Committee- 2001-2004 Government Relations Committee – 2002-present Refresher Course Presenter – 2001-2004 Nominating Committee, 2012
American Veterinary Medical Association International Congress of Hyperthermia, Program Committee 1996, 1999, 2003, 2007 International Society for the Study of Comparative Oncology Intersociety Council on Radiation Oncology 1990 - 1992 The Microcirculatory Society NCI Workshop on Future Directions for Multi-Institutional Clinical Trials in Hyperthermia Co-
Chairman, 1992 NCI Workshop on Future Directions for Study of Normal Tissue Damage from Radiation
Therapy, 2000 NCI Workhop on Future Directions in Brachytherapy, 2001 New York Academy of Sciences North American Hyperthermia Society (Now Society for Thermal Medicine) Councilor - Biology Organizing Committee, 1982 - 1984 Chairman, Election Committee, 1985 President, 1985 - 1986 Program Committee, 1985; 1995; 1996, 1998, 1999, 2000, 2001, 2006 Chairman, Site Selection Committee for International Congress, 1986 - 1987 Local Arrangements Co-Chairman, 1987 Hyperthermia School, Physical Aspects of Hyperthermia, Durham, NC April 27 - May 1, 1987 Member, Professional Affairs Committee, 1989 – 1994 Finance Committee, 2000-2004
65
Chairman, Long Range Planning Committee, 2002-2003 North Carolina Association for Biomedical Research, 1994 - present Radiation Research Society Membership Committee, 1981 - 1988 Chairman, Membership Committee, 1986 - 1988 Program Committee, 1985; 1995; 1996; 2000 Research Award Selection Committee, 1990 - 1991 Council, 1990 – 1993 Finance Committee (ex officio), 1998-2002 Secretary-Treasurer, 1998-2002 Chairman Fundraising Committee, 1999-2002 Vice President Elect 2005 Vice President 2006
President 2007 Co-Chair Program Committee – 13th International Congress of Radiation Research Chair- Student Travel Award Committee – same as above Radiation Therapy Oncology Group Chairman, Hyperthermia Quality Assurance Task Force, 1989 – 1991 Member, Translational Science Committee, 2006 TEACHING RESPONSIBILITIES INCLUDING EDUCATION Radiobiology for Radiotherapy Technical Trainees and Residents in Radiation Oncology,
University of Arizona, 1981-1984 Participation in Cancer Biology Training Program: teaching, training post-doctorates and
collaboration in multidisciplinary research activities, University of Arizona, 1982 - 1984 Coordinator, Fundamentals of Cancer and Radiobiology for residents in Radiation Oncology,
Duke University, 1986 - 2006. Lecturer, Tumor Immunology Seminar Series, Duke University, Department of Immunology,
1995-1997. Radiobiology and Principles of Radiotherapy, Veterinary Students, North Carolina State
University, 1985 AREAS OF RESEARCH INTEREST Tumor Microcirculatory Physiology and Metabolism Hyperthermia Drug Transport Experimental Radiotherapy Angiogenesis Functional Imaging PARTICIPATION IN ACADEMIC AND ADMINISTRATIVE ACTIVITIES OF THE UNIVERSITY AND MEDICAL CENTER Member, Mathematical Modeling Committee, 1986 Member, Selection Committee for University Veterinarian, 1986 Member, Graduate College Faculty, 1991 - present Member Residency Applicant Committee, Radiation Oncology, 1993-2003 Member Promotions and Tenure Committee, Radiation Oncology, 1990-present Member, Center for Biosurface Engineering, School of Engineering, 1993-present Member, Search Committee for Chairman of Radiation Oncology, 1995-1996 and 2003 Member, Advisory Committee, Medical Free Electron Laser Program, Department of Physics,
66
1995-2003 Member, Search Committee for Director of Medical Free Electron Laser Program, 1997 Member. Advisory Board, Marine Biology Research Center, School of the Environment, 1995-2002 Member, Search Committee for two faculty positions in Pharmacology, 1998 Member, Prostate Cancer Program Advisory Committee Member, Faculty Liaison Committee on Animal Care and Use, 2001– Present Member, Search Committee for Chief of Radiation Physics, 2004 Member, Task Force on Functional Imaging, 2005-present Member, Endowed Chair Review Committee, DUMC 2006-present Committee Chair, 2009 Member, Strategic Plan Implementation Committee, DUMC, 2006 Member, Dean’s Committee on Molecular Imaging Initiative, DUMC, 2007 Member, Search Committee for Chair of Radiology, 2008-2009 Chair, Dean’s Committee for Translational Science, 2008 Cancer Center Activities Member, Executive Committee, Duke Comprehensive Cancer Center, 1994-present Co-Director, Radiation Oncology Research Program, Duke Comprehensive Cancer Center, 1994-2011 Core Director: In vivo Molecular Imaging Facility 2003-present Chair: Shared Resources Committee, 2008-present Vice Director, Basic Science Research, Duke Cancer Institute, 2012-present SPONSOR'S PREVIOUS FELLOWS/TRAINEES Total Medical Students: 20 (7 Howard Hughes Fellows) Total Thesis/CoThesis Advisor: 24 (11 DOD pre-doctoral and 2 NIH funded
predoctoral fellows) Total Graduate Committee: 38 Total Postdoctoral Fellows: 19 Total Residents and Clinical Fellows: 9 Total Mentored Faculty: 6 Medical Students: Name: Jeffrey Acker, MD Fellowship: None Current Position Title: Radiation Oncologist Institution: Moore Regional Hospital P.O. Box 3000 Pinehurst, NC 28374 Name: R.J Boruta, MD Fellowship: None Current Position Title: Fellow, Pediatric Cardiology Institution: University of Colorado Name: Thomas Bryce, MD Fellowship: None Current Position Title: Radiologist Institution: Cypress Point Hospital, San Francisco Name: Sharon Castellino, MD
67
Fellowship: None Current Position Title: Assistant Professor, Pediatrics Institution: Wake Forest University Baptist Medical Center Winston Salem, NC Name: Duncan Chapman, MD Fellowship: None Current Position Title: Staff Radiologist Institution: Wake Radiology, Raleigh, NC Name: Jonathan Dewey, MD Fellowship: Hughes Fellow Current Position Title: Director of Clinical Products Institution: Remedy Informatics, Salt Lake City, UT Name: Toby Dunn, MD Fellowship: None Current Position Title: Surgeon Institution: Texas Vascular Associates, PA Dallas, TX Name: Christian Erickson, MD Fellowship: Hughes Fellow Current Position Title: Emergency Medical Medicine Institution: Reliant Immediate Care Medical Group, Los Angeles, CA Name: Nicole Joy, MD Fellowship: Hughes Fellow Current Position Title: Resident in Dermatology Institution: John H. Stoger Hospital, Chicago, IL Name: Andrew Kaz, MD Fellowship: None Current position: Acting Assistant Professor of Gastroenterology Institution: University of Washington Seattle, WA Name: David Kryzmowski, MD Fellowship: None Current position: General Surgeon Institution: Roosevelt, UT Name: Daniel Laskowitz, MD Fellowship: None Current Position Title: Professor, Neurology Institution: Duke University Medical Center Durham, NC Name: Eric Lee Fellowship: Hughes Fellow Current Position Title: In Lab Rotation Institution: Duke University Medical Center
68
Name: David Madwed, MD Fellowship: None Current Position Title: Radiologist Institution: Kaiser Permanente, 275 Hospital Prkwy. San Jose, CA 95119 Name: Benjamin Moeller, MD, PhD Fellowship: Hughes Fellow Current Position Title: Radiation Oncologist Institution: SE Radiation Oncology Group, Charlotte, NC Name: Rose Payapilli-Eapen, MD Fellowship: None Current Position Title: Assistant Professor of Surgery Institution: Duke University Medical Center Name: Jessica Tasjian, MD Fellowship: Fellowship in Hyberbaric Medicine Current Position Title: Anesthesiology Resident Institution: University of Virginia Name: Tina Tailor, MD Fellowship: Hughes Fellow Current Position Title: Radiology Resident Institution: Duke University Medical Center Name: Ronald Viola, MD Fellowship: Hughes Fellow Current Position Title: Radiologist Institution: Durham VA Medical Center Name: Ellen Zakris, MD Fellowship: None Current Position Title: Radiation Oncologist Institution: Ochsner Clinic 1514 Jefferson Highway New Orleans, LA 70121 Thesis Advisor: Name: Yiting Cao, MD, PhD Date: 2000-2005 Position: Graduate Student –DOD grant recipient Program: Pathology
Thesis: Tumor Angiogenesis: Its initiation and a novel angiolytic therapy
Current Position: Research Associate, Duke University Medical Center, Durham, NC Institution: Duke University Medical Center Role: Thesis Advisor Name: Allison Betof, MD, PhD Date: 2007 – 2011 Position: MSTP Graduate Student – DOD grant recipient
69
Program: Pathology Thesis: Therapeutic exercise in a mouse model of breast cancer:
Effects on tumor progression, angiogenesis and response to chemotherapy
Current Position: Intern Institution: Massachusetts General Hospital, Boston, MA Role: Thesis Advisor Name: Isabel Cardenas-Navia, PhD Dates: 2002-2008 Position: Graduate Student –DOD grant recipient Program: Biomedical Engineering
Thesis: Characterization and modeling of fluctuating hypoxia in breast cancer
Current Position: President and Founder Institution: Alta Vision, Washington, DC Role: Thesis Advisor Name: Matthew Dreher, PhD Dates: 2002-2006 Position: Graduate Student Program: Biomedical Engineering Thesis: Drug delivery to solid tumors with elastin-like polypeptide drug carriers. Current Position: Technical Director Institution: Biocompatibles, Inc. West Conshohocken, PA Role: Thesis Co-Advisor Name: Andrew Fontanella, PhD Dates: 2007 – 2013 Position: Graduate Student – DOD Grant Recipient Program: Biomedical Engineering
Thesis: Novel methods of optical data analysis to assess radiation responses in the tumor microenvironment
Current Position: Postdoctoral Fellow in Medical Physics Institution: Memorial Sloan Kettering Cancer Center Role: Thesis Advisor Name: Christopher Gulledge, MS, MD Date: 1994-1996 Position: Masters Candidate Program: Pathology
Thesis: The importance of supply and demand in tumor oxygenation
Current Position Title: Anatomic & Clinical Pathologist, Forensic Pathologist Institution: University of North Carolina at Chapel Hill Role: Thesis Advisor Name: Matthew Hardee, MD, PhD Dates: 2003-2006 Position: MSTP Graduate Student – DOD grant recipient Program: Pathology
Thesis: Erythropoeitin biology in cancer: A role in apoptosis and angiogenesis
70
Current Position: Assistant Professor Radiation Oncology Institution: University of Arkansas Medical Center, Little Rock, AR Role: Thesis Advisor Name: Kristina Hofmann Dates: 2010 – present Position: Graduate Student Program: Biomedical Engineering Current Position: Graduate Student Institution: Duke University Medical Center Role: Thesis Advisor Name: Zishan Haroon, MD, PhD Date: 1994-1999 ` Position: Graduate Student Program Pathology Thesis: Hypoxia and tissue transglutaminase: A wound healing perspective.
Current Position; Associate Director Institution: Institute for Nanomedicine University of North Carolina Role: CoThesis Advisor Name: Nora Katzen McGhee, PhD Dates: 2002-2006 Position: Graduate Student Program: Pharmacology
Thesis: The molecular consequences of low pH induced camptothecin potentiation and the function of BCL-2 associated transcription factor, BTF, as a tumor suppressor gene
Current Position: Corporate Manager, Material Clinical Resources Institution: LifeBridge Health, Washington, DC Role: Thesis Advisor Name: Kelly Kennedy, PhD Dates: 2006 – Present Position: Ph.D. Student – DOD grant recipient Program: Pathology
Thesis: Lactate Metabolism in Cancer Cell Lines Current Position: Postdoctoral Fellow, Pathology Institution: Duke University Medical Center Role: Thesis Advisor Name: Garheng Kong, MD, PhD Date: 1997-2000 Fellowship: MSTP Graduate Student
Thesis: Optimization of combination liposome and hyperthermia for cancer
Current position: Managing General Partner Institution: Sofinovva Ventures, Menlo Park, CA. Role: Thesis Advisor Name: Chelsea Landon, PhD
71
Date: 2008 – Present Fellowship: NRSA indivdual grant recipient Current Position: Veterinary Student
Institution: North Carolina State University College of Veterinary Medicine
Role: Thesis Advisor Name: Ashley Manzoor, PhD Dates: 2006-2010 Position: Graduate Student – DOD grant recipient Program: Medical Physics Thesis: Drug Delivery and Anti-‐vascular Effects of Temperature Sensitive Liposomal Doxorubicin Current Position: Associate Institution: McKinsey & Company, Marietta, GA Role: Thesis Advisor Name: Michael Lora Michels, DVM, MS Dates: 2002-2005 Position: Graduate Student Program: Biomedical Engineering
Thesis: Extracellular pH and 31-P MR spectroscopic parameters are related to outcome in canine soft tissue sarcomas treated with thermoradiotherapy
Current Position: Veterinary Radiologist Institution: New York City Role: Thesis Advisor Name: Benjamin Moeller, MD, Ph.D. Dates: 2001-2005 Position: MSTP Graduate Student – Hughes Fellowship Program: Pathology
Thesis: The role of hypoxia-inducible factor -1 in regulating tumor radiosensitivity
Current Position Title: Radiation Oncologist Institution: SE Radiation Oncology Group, Charlotte, NC Role: Thesis Advisor Name: Ejung Moon, PhD Dates: 2005-2010 Position: Graduate Student – DOD grant recipient Program: Pathology
Thesis: The role of hypoxia inducible factor 1 in hyperthermia induced tumor reoxygenation and therapy resistance
Current Position: Post-Doctoral Fellow Institution: Stanford University Role: Thesis Advisor Name: Stephen Odaibo, MD, MS Dates: 2007 - 2009 Position: MSTP Graduate Student Program: Computer Science Thesis: Microvasculature-Adaptive Discretization of Tumor and Tissue Current Position: Resident, Opthalmology
72
Institution: Duke University Medical Center Role: Co-Thesis Advisor Name: Anna Ponce, MD, Ph.D. Dates: 2004-2007 Position: MSTP Graduate Student – DOD grant recipient Program: Biomedical Engineering
Thesis: The development and utilization of magnetic resonance-imageable temperature sensitive liposomes
Current Position: Assistant Professor, Radiation Oncology Institution: John’s Hopkins School of Medicine Role: Thesis Advisor
Name: Rachel Richardson, DVM, PhD Date: 2000-2006 Position: NCI Post-Doctoral Fellow – NRSA grant recipient Program: North Carolina State University-Comparative Biomed. Sci.
Thesis: Glucose and Lactate Consumption by the R3230 Mammary Adenocarcinoma
Current Position: Manager, Clinical Development Projects Institution: Beyer Health Care Animal Health, Shawnee Mission, KS Role: Thesis Advisor Name: Timothy Robinson, MD, PhD Dates: 2006-2011 Position: MSTP Student – DOD grant recipient Program: Molecular Cancer Biology
Thesis: Detecting Changes in Alternative mRNA Processing From Microarray Expression Data
Current Position: Resident, Radiation Oncology Institution: Duke University Medical Center Role: Co-Thesis Advisor Name: Benjamin Viglianti, PhD, MD Dates: 2001-2004 Position: Graduate Student –DOD grant recipient Program: Biomedical Engineering
Thesis: Chemodosimetry of in vivo tumor liposome/drug concentration using MRI
Current Position: Resident, Radiology Institution: University of Michigan Role: Thesis Advisor Name: Pavel Yarmolenko Dates: 2006-present Position: Graduate Student Program: Biomedical Engineering Current Position: Student Institution: Duke University Medical Center Role: Thesis Advisor Graduate Committees Name: Katherine Aird, PHD Date: 2007 - 2010
73
Position: Graduate Student Program: Pathology Advisor: Gayathri Devi, PhD
Thesis: Role of X-linked inhibitor of apoptosis protein in therapeutic resistance of inflammatory breast cancer cells.
Current Position Title: Postdoctoral Fellow Institution: Vanderbilt University Role: Committee Member Name: Iain Asplin, MD, PhD Date: 2000 Program: Pathology Advisor: Salvatore Pizzo, MD, PhD Thesis: Biological Roles of Alpha (2) – macroglobulin Current Position Title: Staff Physician, Pediatric Critical Care Institution: Tacoma, WA Role: Committee Member
Name: Jennifer Brennan, PhD Date: 1998-2003 Program: Cell Biology Advisor: Blanche Capel, PhD Thesis: From Sry to Z: Cellullar and molecular mechanisms of testis development. Current Position Title: Post Doctoral Fellow in Genetics Institution: University of NC, Chapel Hill Role: Committee Member Name: Julia Ling-Yu Chen Date: 2007 -2010 Program: G-MGM Advisor: Jen Tsan Chi, PhD Thesis: Cellular responses to lactic acidosis in human cancers. Current Position Title: Postdoctoral Fellow Institution: Stanford University Role: Committee Member Name: Marc Cline, DVM, PhD Date: 1988-1993 Program: Pathology College of Veterinary Medicine North Carolina State University Advisor: Donald Thrall, DVM, PhD Current Position Title: Associate Professor of Pathology/Comparative Medicine Institution: Bowman Grey School of Medicine, Wake Forest Univ. Role: Final Defense Committee Member Name: Caroline Conner, PhD Date: 1996-2000 Program: Cancer Molecular Biology Current Position Title: Stay at home mother Institution: N/A Role: Committee Member
74
Name: Carolyn DuSell, PhD Date: 2007 - 2008 Mentor: Donald McDonnell, PhD Program: Molecular Cancer Biology Duke Unversity
Thesis: The molecular pharmacology of endogenous and therapeutic estrogen receptor modulators in the breast and skeleton
Current Position Title: Staff Scientist Institution: Genentech, Inc Role: Committee Member Name: Marlene Hauck, DVM, PhD Date: 1992-1997 Program: Pathology Advisor: Michael Zalutsky, PhD Thesis: The interactions of local hyperthermia with monoclonal antibody targeted tumor therapy. Current Position: Associate Professor, Companion Animal Medicine Institution: North Carolina State University College of Veterinary Medicine Role: Committee Member Name: Tilanthi Jayawardena, PhD Date: 2008 Advisor: Daniel Kenan, MD, PhD Program: Medicine-Cardiology Thesis: A transgenic model for isolation of endothelial-specific transcripts by ribonucleoprotein tagging. Current Position: Postdoctoral Associate Institution: Duke University Role: Committee Member Name: Patrick Kiser, PhD Date: 1997-1999 Program: Cellular & Biosurface Engineering Advisor: David Needham, PhD Thesis: Materials engineering of hydrogels. Current Position Title: Assistant Professor, Bioengineering Institution: Universityof Utah Role: Committee Member Name: Shekar Kurpad, MD, PhD Program: Pathology Duke University Medical Center Advisor: Darell Bigner, MD, PhD Thesis: Novel approaches for the selective adjuvant therapy of malignant human gliomas. Current Position Title: Assistant Professor, Department of Neurosurgery Institution: Medical College of Wisconsin Role: Committee Member Name: Zhizhong Li, PhD Date: 2008
75
Advisor: Jeremy Rich, MD Program: Molecular Cancer Biology Thesis: Differential antiogenic capability and hypoxia responses in glioma stem cells. Current Position Title: Postdoctoral Fellow Institution: Duke University Medical Center Role: Committee Member Name: Anna P. Lillis, PhD Date: 2007-2008 Program: Medical Scientist Training Program (MSTP) Advisor: Salvatore Pizzo, MD, PhD Thesis: Targeted deletion of macrophage low-density lipoprotein receptor-related protein: Roles in lipoprotein homeostasis and phagocytosis. Current Position Title: Resident, Brigman and Women Hospital, Radiology Institution: Duke University Medical Center Role: Committee Member Name: John Mavropoulos, MD, PhD Date: 2008 Advisor: Salvatore Pizzo, MD, PhD Program: Medicine/Pathology Thesis: Dietary carbohydrate restriction slows prostate tumor growth. Current Position: Resident - Dermatology Institution: Johns Hopkins Role: Committee Member Name: Janet Melonakos (Hart), PhD Date: 2008 Program: Molecular Cancer Biology/Biology Advisor: Christopher Kontos, MD Thesis: A paradoxical role for PTEN in the cellular response to hypoxia. Current Position: Instructor in Biology Institution: Lenoir Rhyne University Role: Committee Member Name: Daniel Meyer, PhD Date: 2002 Mentor: Ashutosh Chilkoti, PhD Program: Biomedical Engineering
Thesis: Genetically engineered elastin-like polypeptide carriers for thermally targeted delivery of therapeutics to solid tumors
Current Position: Staff Scientist Institution: GE Life Sciences Role: Committee Member Name: Jeffrey Mills, PhD, JD Date: 2002 Program: Mechanical Engineering and Materials Science Mentor: David Needham, PhD
Thesis: Triggered release of liposome contents: mechanisms involved in membrane permeability and compromise
76
Current Position Title: Associate Institution: Sterne, Kessler, Goldstein and Fox P.L.L.C Role: Committee Member Name: Balint Otvos Date: 2008 Program: Pathology Research Advisor: Christopher Kontos, PhD Thesis: The role of angiopoietin-2 in signaling through the endothelial receptor tyrosine. Current Position: Medical Student Institution: Case Western Reserve Medical School Role: Committee Member Name: Christine Padgett, PhD Date: 1992-1996 Program: Pharmacology/Toxicology Thesis: Mechanism of inhibition of glyceraldehyde-3-phosphate dehydrogenase by nitric oxide and its regulation by the glutathione redox cycle. Current Position: Clinical Research Scientist Institution: NOBEX Corporation Role: Committee Member Name: Deborah M. Prescott, DVM, PhD Date: 1986-1990 Mentor: Donald E. Thrall, DVM, PhD Program: Pathology College of Veterinary Medicine, NC State Univ.
Thesis: Modification of radiation damage in the canine kidney by hyperthermia
Current Position Title: Director, Radiation Oncology Center Institution: MedVet Associates Worthington, Ohio Role: Committee Member Name: Sylvester Price, DVM, PhD Date: 1989-1993 Mentor: Donald E. Thrall, DVM, PhD Program: Pharmacology/Toxicology, College of Vet. Medicine North Carolina State University
Thesis: Effect of whole body hyperthermia on the pharmacokinetics and toxicity of lonidamine +/- doxorubicin in normal dogs
Current Position Title: Senior Scientist Institution: Proctor and Gamble, Cincinatti, OH Role: Committee Member Name: Amy Pruitt, DVM, PhD Date: 2007 Program: College of Vet. Medicine North Carolina State University Advisor: Marlene Hauck, DVM, PhD Thesis: Heat induced transgene therapy Current Position: Assistant Professor
77
Institution: NC State University Role: Committee Member Name: Quinones, Quintin Jose, MD, Ph.D. Date: 2003-2008 Program: Medical Scientist Training Program Advisor: Salvatore Pizzo, MD, PhD Thesis: Metabolic targeting of cancer cells: Two molecular mechanisms involving glucose metabolism. Current Position Title: Resident (Anesthesiology) Institution: Duke University Medical Center Role: Committee Member Name: Gustaaf De Ridder, MD, PhD Date: 2008 Advisor: Salvatore Pizzo, MD, PhD Program: Pathology/Medicine Current Position Title: Resident, Anesthesiology Institution: Duke University Medical Center Role: Committee Member Name: James Schuster, MD, PhD Date: 1986-1994 Program: Pathology Advisor: Darell Bigner, MD, PhD Thesis: Strategies for overcoming biological heterogeneity in the treatment of central nervous system malignancies. Current Position Title: Assistant Professor in Neurosurgery Institution: University of Pennsylvania, Philadelphia, PA
Role: Committee Member Name: Farzan Siddiqui, MD, PhD Date: 2002-2005 Mentor: Robert Ullrich, PhD Program: Radiological Health Sciences, Colorado State University, Fort Collins, CO Title: Hyperthermia induced interleukin-12 gene therapy Current Position Title: Associate Professor
Department of Radiation Oncology Institution: Henry Ford Hospital, Detroit, MI Role: Committee Member Name: Andrew Simnick, PhD Date: 2010 Mentor: Ashutosh Chilkoti, PhD Program: Biomedical Engineering Duke University
Title: Affinity-modulation drug delivery using thermosensitive elastin-like polypeptide block copolymers
Current Position Title: Associate Institution: McKinsey & Company Role: Committee Member Name: Melissa Skala, Ph.D. Date: 2006-2007
78
Program: Biomedical Engineering Advisor: Nimmi Ramanujam, PhD Thesis: Multiphoton microscopy, fluorescence lifetime imaging and optical spectroscopy for the diagnosis of neoplasia. Current Position Title: Assistant Professor of Biomedical Engineering Institution: Vanderbilt University Role: Committee Member Name: Stacey Snyder, PhD Date: 2005 - Present Program: Molecular Biomedical Sciences (Comparative Biomedical Sciences Advisor: Marlene Hauck, DVM, PhD
Thesis: Characterization of Chronic and Intermittent Hypoxia in Canine Soft Tissue Sarcomas.
Current Position Title: Postdoctoral Fellow Institution: VA Medical Center, Durham, NC Role: Committee Member Name: Rebecca Stein, MD, PhD Date: 2007 Program: MSTP
Advisor: Donald McDonnell, PhD Thesis: Defining the functional significance of estrogen-related
receptor alpha in breast cancer Current Position: Resident in Pediatrics Institution: Stanford University Role: Committee Member Name: Joseph Byron Ventimiglia, MD, PhD Program Pathology Duke University Medical Center Advisor: Darell Bigner, MD, PhD Thesis: Optimization of tenascin-directed immunolocalization of human tumor. Current Position Title: Private Practice Institution: Irving, Texas Role: Committee Member Name: Alex Wright, PhD Program Materials Science Duke University Advisor: David Needham, PhD
Thesis: Drug loading and release from a thermally sensitive liposome
Current Position Title: Staff Scientist Institution: Amgen Corporation Role: Committee Member Name: Bin Yan, MD, PhD Date: 2005 Program: Pathology Duke University Medical Center Thesis: A novel role of DNA fragmentation factor as tumor
79
suppressor through maintenance of genomic stability. Current Position: Resident in Radiation Oncology Institution: New York University Role: Committee Member Name: Gunay Yurtserver Date: 2007 Program: Biomedical Engineering Current Position: Ph.D. student, Electrical Engeering Institution: Gent University, Belgium Role: Committee Member Name: Nicole Zandy, PhD Date: 2004 -2008 Program: Molecular Cancer Biology Thesis: Abl tyrosine kinases mediate intercellular adhesion. Current Position Title: Proposal Developer - Quintiles Institution: Duke University Medical Center Role: Committee Member Name: David Zaharoff, PhD Date: 1999-2002 Mentor: Fan Yuan, PhD Program: Biomedical Engineering
Thesis: Characterization of interstitial transport of plasmid DNA during electric field-mediated gene delivery
Current Position Title: 21st Century Assistant Professor Biomedical Engineering Program
Institution: University of Arkansas Role: Committee Member External Examiner for PhD Candidates Name: Robert Cairns, PhD Date: 2004 Mentor: Richard Hill, PhD Ontario Cancer Institute Thesis: Hypoxia in solid tumors and its impact on metastasis Current Position Title: Assistant Professor University of Toronto Name: Saske Hoving, PhD Date: 2005 Mentor: Prof.dr. A.M.M. Eggermont Erasmus Medical Center Rotterdam, The Netherlands
Thesis: Improvement of solid tumor therapy by changing the tumor pathophysiology
Current Position Title: Staff Scientist The Netherlands Cancer Institute Post Doctoral Fellows/Associates: Name: Cary Bassett, DVM, PhD
80
Position: Postdoctoral Fellow Current Position Title: Veterinarian Institution: Greensboro, NC Name: Bruce Bondurant, PhD Position: Postdoctoral Fellow Current Position Title: Professor Institution: Hillsborough Community College Tampa Bay, Florida Name: Rodney Braun, PhD Position: Postdoctoral Fellow Current Position Title: Associate Professor, with tenure, Anatomy Institution: Wayne State University, Detroit, MI Name: Yiting Cao, MD, PhD Date: 2005 Position: Post doctoral Fellow Current Position Title: Post Doctoral Fellow, Neuro-oncology Institution: Duke University Medical Center Name: Mingnan Chen, PhD Position: Postdoctoral fellow – K99 grant recipient
Current Position Title: Assistant Professor, College of Engineering Institution: University of Utah, Salt Lake City, UT Name: Diane Fels, Ph.D. Position: Postdoctoral Fellow Current Position Title: Clinical Trials Manager Institution: MedPace, Inc. , Cincinatti, OH Name: Gabi Hanna, MD Position: Postdoctoral fellow Current Position Title: Postdoctoral fellow- Radiation Oncology Institution: Duke Univ. Medical Center Name: Katherine Hansen, DVM Position: Postdoctoral fellow Current Postion Title: Radiation Oncologist
Institution: College of Veterinary Medicine, University of California, Davis, Davis, CA
Name: Michael Lora-Michiels, DVM, MS Position: Postdoctoral fellow Current Position Title: Private Practice in Veterinary Radiology Institution: New York City Name: Edgardo T. Ong, MD Position: Postdoctoral Fellow Current Position Title: Physicians Assistant Institution: Federal Prison System, PA Name: Greg Palmer, PhD Position: Postdoctoral Fellow - DOD grant recipient Current Position Title: Associate Professor – Radiation Oncology
81
Institution: Duke University Medical Center Name: Ji-Young Park, Ph.D. Position: Postdoctoral Fellow Current Position Title: Staff Scientist, FDA Institution: Rockville, MD Name: Jeanne M. Poulson, DVM, PhD Position: Postdoctoral fellow Current Position Title: Associate Professor Institution: Purdue University, College of Veterinary Medicine Name: Deborah M. Prescott, DVM, PhD Position: Postdoctoral Fellow Current Position Title: Director, Radiation Oncology Center Institution: MedVet Associates, Worthington, OH Name: Thies Schroeder, PhD Position: Postdoctoral Fellow Current Position Title: Assistant Professor Institution: University of Mainz, Mainz, Germany Name: Melissa Skala, PhD Position: Postdoctoral fellow – K99 grant recipient Current Position Title: Assistant Professor, Biomedical Engineering Institution: Vanderbilt University Name: Brian Sorg, PhD Position: Postdoctoral fellow Current Position Title: Program Director Institution: National Cancer Institute, Rockville, MD Name: Benjamin Viglianti, PhD Date: 2004 Position: Postdoctoral Fellow Current Position Title: Fellow, Radiology Institution: University of Michigan Name: Ning Z. Wu, PhD, MD Position: Postdoctoral fellow Current Position Title: Private Practice -Urology Institution: Chicago, Ill Name: Hong Yuan, PhD Position: Postdoctoral fellow - DOD grant recipient Current Position Title: Assistant Professor- Radiology Institution: University of North Carolina Name: Karthik Vishwanath, PhD Position: Postdoctoral fellow – K99 grant recipient Current Position Title: Senior Scientist, Institution: Radiation Monitoring Devices, Inc., Boston, MA
82
Residents and Clinical Fellows Name: Susan Ettinger, DVM Position: Postdoctoral fellow Current Position Title: Medical Oncologist Institution: South Bay Veterinary Specialists, San Jose, CA Name: Richard M. Foltz, MD Position: Research Fellow Current Position Title: Private Practice Neurosurgeon Institution: Medical Pracactice Carol Springs, FL Name: Amanda Gaskin, DVM Position: Postdoctoral Fellow Current Position Title: Private Practice Institution: Adavanced Critical Care & I.M., Tustin, CA Name: Brian Kavanagh, MD Position: Resident Research Trainee Current Position Title: Vice Chairman, Radiation Oncology Institution: University of Colorado, Denver, CO Name: Mary Kay Klein, DVM, MS Position: Postdoctoral fellow Current Position Title: Veterinary Radiation Oncologist Institution: Tucson, AZ Name: Craig Lockhart, MD Position: Clinical Research Fellow Current Position Title: Associate Professor, Medicine Institution: Washington University
Name: Jose Trani, MD Position: Clinical Research Fellow Current Position Title: Vascular Surgeon
Institution: Cooper University Hospital South Jersey, NJ
Name: John Kirkpatrick, PhD, MD Position: Radiation Oncology Research Fellow Current Position Title: Associate Professor, Radiation Oncology
Institution: Duke University Medical Center
Name: Junzo Chino, MD Position: Radiation Oncology Research Fellow Current Position Title: Assistant Professor, Radiation Oncology
Institution: Duke University Medical Center
Faculty: Name: Kimberly Blackwell, MD
Position: Assistant Professor, Medical Oncology – KO8 grant recipient
83
Current Position Title: Professor, Medical Oncology Institution: Duke University Medical Center Role: Mentor Name: Gordana Vlahovic, MD, MHS
Position: Assistant Professor, Medical Oncology - K12 grant recipient
Current Position Title: Associate Professor, Medical Oncology Institution: Duke University Medical Center Role: Mentor
Name: Herbert Hurwitz, MD Position: Assistant Professor, Medical Oncology- K23 grant
recipient Current Position Title: Professor, Medical Oncology
Institution: Duke University Medical Center Role: Mentor
Name: Janet Horton, MD Position: Assistant Professor, Radiation Oncology - BIRCWH Scholar Current Position Title: Assistant Professor, Radation Oncology
Institution: Duke University Medical Center Role: Mentor
Name: David M. Brizel, MD Position: Assistant Professor, Radiation Oncology Current Position Title: Leonard Prosnitz Professor, Radation Oncology
Institution: Duke University Medical Center Role: Mentor
Name: Jen Tsan Chi, MD, PhD Position: Assistant Professor, G-MGM Current Position Title: Associate Professor (with tenure) G-MGM
Institution: Duke University Medical Center Role: Faculty Mentoring Committee
Other Support: ACTIVE RSG-12045-01-CDD-03 (Hong) 01/01/12 – 12/31/15 0.12 calendar American Cancer Society $151,549 Hypoxia-Inducible Factor-1 Inhibitors as Potential Cancer Therapeutics The goal is to show that manassantins exert their antitumor activity by HIF-1 inhibition, thereby selectively inhibiting tumor growth, and could be effective tools to systemically explore the cellular components and molecular events that embody the HIF-1 signaling pathway. NA (Dewhirst) 10/01/11 – 09/30/14 0.12 calendar Celsion $31,847 Biodistribution and efficacy of cis- and carboplatin thermosensitive liposomes +/- copper chelation
84
The main goal of this project is to demonstrate that LTSL and hyperthermia administration will delay tumor growth in a xenograft mouse model alone and more significantly when combined with the copper chelator treatment. W81XWH-12-1-0148/BC111548 (Chi)06/01/12-05/31/14 0.12 calendar DoD $250,000 Genetic and Chemical Screen of Synthetic Lethality with Tumor Microenvironmental Stresses to Identify Novel Therapeutic Together, these experiments will identify kinases that are required during hypoxia or lactic acidosis and also critical for the in vivo growth of tumors. N/A (Dewhirst) 12/01/13-11/30/14 0.12 calendar Inflammatory Breast Cancer Research Foundation $45,454 HIF-1 Driven Therapeutic Resistance Mechanisms in Chest Wall Recurrences of Inflammatory Breast Cancer (IBC) The goal of this grant is generate preliminary data in pre-clinical models to show that lymphangiogenesis and tumor cell interactions with dermal lymphatics are increased with RT/CT and that we can inhibit these effects by inhibiting post-treatment oxidative stress. 5R01-CA040355-29 (Dewhirst) 06/12/09 - 03/31/14 1.2 calendar NIH $216,445 Heat and Radiation Effects on Tumor Microcirculation The overall hypothesis of this project is that successful amelioration of hypoxia will require a multifaceted approach that blocks fluctuant pO2 improves O2 delivery and reduces O2 consumption. 5U19-AI067798-09 (Chao) 08/01/10 - 07/31/15 0.6 calendar NIH $236,591 Pilot Projects/Administration Administration will be responsible for the overall management of the “Centers for Medical Countermeasures Against Radiation” program. 5P30-CA14236-40 (Kastan) 09/03/10-12/31/14 1.2 calendar NIH $189,426 Duke Comp. Cancer Inst. Core Support Grant – Senior Leaders The DCCI oversees all cancer related philanthropy at Duke, and these funds have been used to support recruitment of new members, innovative pilot projects, support of multidisciplinary research, and new laboratory and administrative space. This application for ongoing support of the DCC articulates the principles, goals and strategies for propelling the DCCI to fully leverage the enormous advances in biomedical research at Duke and beyond, to improve and extend the lives of cancer patients with cancer and at risk for cancer, and delivering these to society. 5P30-CA14236-40 (Kastan) 09/03/10-12/31/14-12/31/14 0.12 calendar NIH $23,289 Optical Molecular Imaging and Analysis This project will use multiple views to study optical molecular imaging and analysis in cancer research. 5R01-CA155664-04 (Seewaldt) 01/06/11-12/31/15 0.36 calendar NIH $185,750 KCNK9 Imprinting in Breast Cancer Progression and Metastasis The goal of this project is to investigate a novel signaling pathway that holds promise for early detection of triple-negative breast cancer. 9R01-CA174643-07 (McDonnell) 04/01/06-01/31/18 0.24 calendar
85
NIH $180,120 The Role of ERRalpha/PGC-1 in Disease Pathogenesis The goal of this project is to define the role(s) of Erralpha in the pathophysiology or ERalpa-negative breast tumors, evaluate the impact of ERRalpha on tumor responses to estrogens and antiestrogens in models of ERalpha-positive breast tumors, define the functionality of ERRalpha-regulated metabolic pathways in breast cancer. 2013-MRG-1111 (Palmer) 02/01/13-01/31/15 0.12 calendar NC Biotechnology Center $300,000 Imaging, Modeling and Modulating Stromal Cell Roles in Tumor Growth and Therapy The overall objevtive of this project is to determine the role played by CXCR4-mediated stromal cells in tumor antiogenesis and growth. W81XWH-09-0410 (Ramanujam) 09/18/09 – 10/17/14 0.12 calendar USAMRMC $401,410 Harnessing the Power of Light to see and Treat Breast Cancer This project will establish the role of optically based morphological imaging as a tool to guide surgical resection intra-operatively and pathologic assessment post-operatively. 1R01-CA-167250-02 (Dewhirst) 09/25/12-06/30/14 0.24 calendar University of VA-Charlottesville $105,678 Luminescent Oxygen Nanosensors for Tumor Hypoxia Imaging The goal of this project is to enhance preclinical studies to understand cancer biology and aid in diagnosis, treatment, and surgery. R41-CA156901 (Dewhirst) 01/01/13-02/28/14 1.2 calendar Zenalux Biomedical, Inc. $45,265 A Quantitative Optical Sensor to Monitor Tumor Vascular Physiology Goal: to develop a portable, quantitative optical spectroscopy device that can be used to obtain accurate and precise analysis of tissue absorption and scattering with applications related to head and neck cancers as the initial market. 2R01-EB007205-05A1 (Chilkoti) 07/01/12 – 06/30/16 0.6 calendar NIH $225,000 Thermally Triggered Multivalent Targeting of Tumors The overall goal of this competing NIH R01 renewal application is to create a tumor-targeted cell-penetrating peptide (CPP) nanoscale drug delivery system to target therapeutic payloads to a wide range of solid tumors. 2R01EB000188-09 (Chilkoti) 07/01/12-04/30/16 0.6 calendar NIH $225,000 Thermally Targeted Drug Delivery by Elastin Biopolymers This study will examine elastin biopolymers in patients using thermally targeted drug delivery. The overall objective of this competing R01 renewal is to exploit a newly discovered, general mechanism of attachment-triggered self-assembly of hydrophobic drugs to create thermally responsive nanoparticles for the treatment of primary and metastatic cancer. PENDING N/A (Ilyasova) 07/01/13-06/30/15 0.24 calendar Avon Foundation, Inc. $136,364 Individual Response to Low-Dose Ionizing Radiation and Breast Cancer Risk The main question of this research is whether the risk of breast cancer is associated with ECFC response to LDIR.
86
N/A (Dewhirst) 07/01/14-03/31/15 0.12 calendar BioMimetix Pharmaceutical, Inc. $41,007 BMX-001 as a Radio-Protector in Head and Neck Cancer Therapy The goal of this proposal is to get BMX-001 in clinical trials as a head and neck radio-protector. However, we need to complete some key studies before BMX-001 can be safely started in clinical trials. BC123063 (Ilyasova) 10/01/13-09/30/16 0.24 calendar DoD $125,015 Individual Response to Low-Dose Ionizing Radiation and Breast Cancer Risk The main question of this research is whether the risk of breast cancer is associated with ECFC response to LDIR. 1R01-NS087169-01 (Lo) 04/01/14-03/31/09 0.12 calendar NIH $250,000 Truncated GLI1 In Glioblastoma N/A (Chi) 07/01/14-06/30/17 0.24 calendar DoD $229,524 Targeting the Cysteine/Cystine Addiction of Triple Negative Breast Cancers by Novel Compounds N/A (Dewhirst) 03/01/14-02/28/17 1.2 calendar NASA $1,538,215 Center for Research on Acute and Degenerative Effects of Space Radiation The goal of this project is to examine degenerative effects of radiation on the cardiovascular system. 1R21-ES022738-01 (Ilyasova) 4/1/13-3/31/15 0.24 calendar NIH– NIEHS $175,000 Individual Response to Low Dose Ionizing Radiation The goal of this project is to develop a biomarker of response to LDIR that can be used to identify the most vulnerable subgroups. 1R01-NS087169-01 (Lo) 04/01/14-03/31/19 0.12 calendar National Institutes of Health $250,000 Truncated GLI1 In Glioblastoma The goals of this project are to test this hypothesis. Determine whether tGLI1 mediates malignant phenotypes of GBM; Elucidate the mechanisms by which tGLI1 regulates gene expression in GBM. tGLI1 has gained the ability to enhance expression of several genes; however, the underlying mechanisms for this unique ability is currently unknown and investigate alternative splicing process that leads to tGLI1 mRNA synthesis in GBM. N/A (Lo) 07/01/14-06/30/19 0.6 calendar NIH $250,000 Novel Mechanisms Regulating Breast Cancer Epithelial-Mesenchymal Transition The goal of the proposal is, therefore, to gain novel insights into the molecular mechanisms for breast cancer EMT. N/A (Dewhirst) 08/01/14-07/31/17 0.12 calendar NC State University $16,671 Tumor Microenvironmental Responses to Radiation Marginal Miss
87
Goal and Specific Aims: 1) Define the role of oxidative stress in radiation-induced EMT, invasion, and migration; 2) Define the role of HIF-1 in radiation-induced EMT, invasion, and migration; 3) Determine how tumor marginal miss affects the development of distant metastasis. Completion of these studies will define the mechanisms (SA1, 2) and will identify the impact (SA3) of marginal miss, and determine whether targeted inhibition of oxidative stress will alleviate the associated aggressive tumor changes. N/A (Dewhirst) 07/01/14-06/30/15 0.12 calendar RSNA Research and Education Fund $30,000 Detection of Novel Alternative Splicing Biomarkers of Hypoxia in Breast and Lung Tumor R41-CA156901 (Dewhirst) 07/01/14-06/30/16 1.2 calendar Zenalux Biomedical, Inc. $148,623 A Quantitative Optical Sensor to Monitor Tumor Vascular Physiology The goal of this project is to develop a portable, quantitative optical spectroscopy device that can be used to obtain accurate and precise analysis of tissue absorption and scattering with applications related to head and neck cancers as the initial market. OVERLAP STATEMENT The proposal “Individual Response to Low-Dose Ionizing Radiation and Breast Cancer Risk” has been submitted to both the Avon Foundation, Inc. and DoD (BC123063). If both are awarded either 1) only one award will be accepted or 2) both sponsors will be notified for approval to receive both awards. If pending grants are funded Dr. Dewhirst will review all his active effort and reduce as necessary to accommodate the pending awards that this other support is for. This will include reducing his grant funding as well as potentially reducing his administrative duties.